Document:

EX-10.2

 Exhibit 10.2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED 

BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

STRATEGIC COLLABORATION AND LICENSE AGREEMENT 

BETWEEN 
 VERTEX
PHARMACEUTICALS INCORPORATED 
 AND 

AFFINIA THERAPEUTICS INC. 

 STRATEGIC COLLABORATION AND LICENSE AGREEMENT 

This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of April 14, 2020 (the
“Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”), and Affinia Therapeutics Inc., a corporation organized
under the laws of Delaware with a place of business at 100 Beaver Street, Waltham, MA 02453 (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the
“Parties.” 
 RECITALS 

WHEREAS, Company owns or controls certain Patents and Know-How relating to the discovery of
adeno-associated virus (“AAV”) capsids; 
 WHEREAS, Vertex is a biopharmaceutical company that possesses expertise
in developing and commercializing human therapeutics; 
 WHEREAS, Vertex and Company desire to enter into this Agreement, pursuant to
which the Parties will collaborate in the discovery and characterization of novel AAV Capsids for certain diseases (as specified herein); and 

WHEREAS, Vertex desires to obtain from Company, and Company desires to grant to Vertex, an exclusive license to certain AAV Capsids
Controlled by Company for use in DMD and DM1 (each as defined below), and exclusive licenses to certain other AAV Capsids Controlled by Company for use in Cystic Fibrosis and [***], which licenses with respect to Cystic Fibrosis and [***] may not be
practiced by Vertex until the exercise of the relevant Option and the payment of the relevant Option fee (as set forth below). 
 NOW,
THEREFORE, in consideration of the respective covenants, representations, warranties and agreements set forth herein, the Parties hereto agree as follows: 

ARTICLE 1. 
 DEFINITIONS

 For purposes of this Agreement, the following capitalized terms will have the following meanings: 

 

	 	1.1.	 “AAA” has the meaning set forth in Section 11.12.2. 

 

	 	1.2.	 “AAV” has the meaning set forth in the preamble hereto. 

 

	 	1.3.	 “AAV [***] Capsids” means any Capsid that is Covered by the AAV [***] Patent.

  

	 	1.4.	 “AAV [***] Patent” means the PCT Patent [***]. 

 

	 	1.5.	 “Acquisition Transaction” has the meaning set forth in Section 4.8.

  
 1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.6. “Adverse Event” has the meaning set forth in the Applicable Law for
such term (or comparable term), and will generally mean any untoward medical occurrence in a subject in any Clinical Trial or patient who has received a Product, medical device or placebo, and which does not necessarily have a causal relationship
with such Product, medical device or placebo, including any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the applicable Product, medical device or placebo
whether or not related to such Product, medical device or placebo. 
 1.7. “Affiliate” means, as of any point in time and
for so long as such relationship continues to exist with respect to any Person, any other Person that controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another Person if it
(a) owns or controls, directly or indirectly, more than 50% of the equity securities of the subject Person entitled to vote in the election of directors (or, in the case of a Person that is not a corporation, for the election of the
corresponding managing authority), or (b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such Person (whether through ownership of securities or other ownership interests, by
contract or otherwise). 
 1.8. “Agreement” has the meaning set forth in the Preamble. 

1.9. “Agreement Know-How” means any Know-How
discovered, developed, invented or created solely by a Party or jointly by the Parties (or its or their Affiliates or Third Parties acting on its or their behalf), in each case, in the performance of activities under the Research Programs. 

1.10. “Alliance Manager” has the meaning set forth in Section 3.3.1. 

1.11. “Amended and Restated Lonza-MEE Agreement” means that certain License,
Collaboration and Commercialization Agreement, originally entered into as of [***] and amended and restated as of September 9, 2019, by and between MEE, Lonza and The Schepens Eye Research Institute, Inc. 

1.12. “Ancestral Libraries” means, collectively, all AAV capsid compositions of matter that are Covered by the
“Ancestral Technology Patent Rights” as such term is defined in the MEE/Lonza 3-Way Agreement. 

1.13. “Applicable Law” means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of
law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or other requirements of the Regulatory
Authorities that may be in effect from time to time. 
 1.14. “Approval Application” means a BLA or similar application or
submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries. 

1.15. “Arbitration Notice” has the meaning set forth in Section 11.12.2. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.16. “BLA” means a Biological License Application that is submitted to the
FDA for marketing approval for a Product pursuant to 21 C.F.R. § 601.2. 
 1.17. “Blocking Third Party Intellectual
Property” means, with respect to a Capsid or Product in any country, [***] in such country owned or controlled by a Third Party that Cover [***] the composition of matter, method of treatment or use (as set forth in the applicable
Regulatory Authority-approved labeling) or Manufacture of such Product or Capsid that [***] for the [***] Manufacture or Commercialization of such Product or Capsid within the Field in such country. 

1.18. “Blocking Third Party Intellectual Property Costs” means Out-of-Pocket Costs, comprising [***] payments arising out of the [***] Manufacture or Commercialization of a Capsid or Product within the Field, in each case solely to the extent attributable to the [***]
Manufacture or Commercialization of such Capsid or Product within the Field, and paid by Vertex or one of its Affiliates to a Third Party ([***]) who owns or controls Blocking Third Party Intellectual Property to license or acquire rights to the
relevant Patents or Know-How; provided that, [***]. In the event that a license agreement for Blocking Third Party Intellectual Property includes rights to one of more Vertex Diseases included in the
Field and a specified number of additional disease fields, then the attributable portion of any payment included in Blocking Third Party Intellectual Property Costs under such license agreement would be [***]. In the event that a license agreement
for Blocking Third Party Intellectual Property does not specify [***] in the scope of rights granted, then the Parties would mutually agree upon a [***]. 

1.19. “Breaching Party” means the Party that the other Party believes is in material breach of this Agreement. 

1.20. “Business Day” means a Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which banking institutions
in Boston, Massachusetts are authorized or obligated to close. 
 1.21. “Calendar Quarter” means the respective periods of
three consecutive calendar months ending on March 31, June 30, September 30 or December 31, during the Term, or the applicable part thereof during the first or last calendar quarter of the Term. 

1.22. “Calendar Year” means any calendar year ending on December 31, or the applicable part thereof during the first or
last year of the Term. 
 1.23. “Capsid” means (a) any AAV capsid Controlled by Company on the Effective Date or at
any time prior to the [***]), and (b) all improvements to the foregoing Controlled by Company or created by or on behalf of Vertex and its Affiliates or Sublicensees at any time during the Term; provided that, solely with respect to the
foregoing (b), any improvements arising after the [***] shall be included hereunder as a “Capsid” solely to the extent that [***]. For the avoidance of doubt, Capsid includes all AAV [***] Capsids and any other AAV capsid described in the
AAV [***] Patent. For all purposes under this Agreement, the determination of whether an AAV capsid is an “improvement” to an existing Capsid that is included under sub-part (a) of this
Section 1.21 will be made on a capsid-by-capsid basis, based on an assessment of whether such existing Capsid included under
sub-part (a) was used or modified to identify the improved capsid qualifying as a Capsid under sub-part (b) of this Section 1.21. 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.24. “CDA” has the meaning set forth in Section 1.45. 

1.25. “CF Option Exercise Period” has the meaning set forth in Section 4.2.1. 

1.26. “CF Option Fee” has the meaning set forth in Section 4.2.1. 

1.27. “Change of Control” means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party
that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than 50% of the combined voting power of the
surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of
more than 50% of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business to which the subject matter of this Agreement
relates. Notwithstanding the foregoing, with respect to Company, the term “Change of Control” [***]. 
 1.28. “Clinical
Trial” means a study in humans that is required to be conducted in accordance with GCP and is designed to generate data in support of an Approval Application. 

1.29. “Combination Product” has the meaning set forth in Section 1.108. 

1.30. “Commercialize” or “Commercializing” means to (a) market, promote, distribute, offer for sale,
sell, have sold, import, export or otherwise commercialize a Product, (b) conduct activities, other than Research, Development and Manufacturing, in preparation for the foregoing activities, including obtaining Price Approval or
(c) conduct post-Marketing Approval studies (including Clinical Trials). When used as a noun, “Commercialization” means any activities involved in Commercializing. 

1.31. “Commercially Reasonable Efforts” means with respect to the efforts to be expended by any Person, with respect to any
objective, reasonable, diligent and good faith efforts to accomplish such objective. With respect to any objective relating to the Research, Development, Manufacture or Commercialization of a Capsid or Product by Vertex hereunder, “Commercially
Reasonable Efforts” (a) means that level, caliber and quality of efforts and resources reasonably and normally used by [***], as to a potential or actual product that is important to such [***] overall strategy or objectives, taking into
account, with respect to each Capsid or Product, [***], and (b) will be determined on a country-by-country basis and [***]. 

1.32. “Common Ownership Legislation” means the legislation on Conditions for patentability; novelty, as codified at 35 U.S.C.
§ 102(c) (Common Ownership Under Joint Research Agreements). 
 1.33. “Company” has the meaning set forth in the
Preamble. 
 1.34. “Company Agreement Know-How” has the meaning set forth in
Section 6.1.1. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.35. “Company Agreement Patents” has the meaning set forth in
Section 6.1.1. 
 1.36. “Company Agreement Technology” has the meaning set forth in Section 6.1.1. 

1.37. “Company Breach Event” has the meaning set forth in Section 9.2.2(a). 

1.38. “Company Indemnified Party” has the meaning set forth in Section 8.1. 

1.39. “Company In-License Agreements” means (i) any agreements between Company
and Third Party licensors or sellers pursuant to which Company has acquired or in-licensed any rights in the Licensed Technology as of the Effective Date, and (ii) any New Company Agreements. The Company In-License Agreements existing as of the Effective Date are set forth on Schedule 1.39 hereto. 

1.40. “Company Inventions” has the meaning set forth in the MTA. 

1.41. “Company Platform” means, collectively, the proprietary technology platform Controlled by Company at any time during
the Term for use in [***], in each case ((i) – (iii)) that does not [***] a Vertex Disease and was not generated by Vertex. For clarity, Company Platform will not include [***]. 

1.42. “Comparator Study” means a non-human primate study meeting the criteria set
forth on Schedule 1.42. 
 1.43. “Competitive Infringement” has the meaning set forth in Section 6.4.1. 

1.44. “Competitive Product” means, with respect to a particular Product in a particular country, a product on the market in
such country commercialized by any Third Party that is not a Sublicensee and that did not purchase such product in a chain of distribution that included any of Vertex or its Affiliates or Sublicensees, that (a) is [***], or (b) is [***].

 1.45. “Confidential Information” means, with respect to each Party, all Know-How
or other information, including proprietary information (whether or not patentable) regarding or embodying such Party’s technology, products, business information or objectives, that is communicated in any way or form by or on behalf of the
Disclosing Party to the Receiving Party or its permitted recipients, pursuant to this Agreement or that certain Confidentiality Agreement between Vertex and Company dated [***] (the “CDA”), whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms of this Agreement will be considered Confidential Information of both Parties, with both Parties deemed to be the
Receiving Party of such Confidential Information. All information and data regarding Products generated after the Effective Date pursuant to activities contemplated by this Agreement, excluding any information and data that is specific to any of the
Capsids (which information and data will be deemed the Confidential Information of Company), will be deemed to be Vertex’s Confidential Information, and the exceptions set forth in clauses (a), (d) and (e) below will not apply to such
information and data. Notwithstanding any provision of this Section 1.45 to the contrary, Confidential Information does not include any Know-How or information that: (a) was already known by the
Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party; (b) was generally available to the public or otherwise part of the public domain at
the time of its disclosure to the Receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in
breach of its obligations under this Agreement or the CDA; (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such
information to the Receiving Party; or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of or reference to any Confidential Information belonging to the Disclosing Party. Confidential
Information disclosed to the Receiving Party hereunder will not be deemed to fall within the foregoing exceptions merely because broader or related information falls within such exceptions, nor will combinations of elements or principles be
considered to fall within the foregoing exceptions merely because individual elements of such combinations fall within such exceptions. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.46. “Control” or “Controlled” means, with respect to a
Party and to any Know-How, Patent, Regulatory Filings or Materials, possession of the ability by such Party or its Affiliate (whether by sole or joint ownership, license or otherwise) on the Effective Date or
at any time during the Term, other than pursuant to this Agreement, to grant, without violating the terms of any agreement with a Third Party, a license, access or other right in, to or under such Know-How,
Patent or Materials. Notwithstanding anything in this Agreement to the contrary, (a) any Know-How, Patent or Materials deemed “Controlled” by a Party on the Effective Date or at any time during
the Term will continue to be deemed “Controlled” by such Party for the remainder of the Term of this Agreement, and (b) a Party and its Affiliates will be deemed not to Control any Patents or
Know-How that are owned or controlled by a Third Party described in the definition of “Change of Control,” or such Third Party’s Affiliates (other than an Affiliate of such Party prior to the
Change of Control), (i) prior to the closing of such Change of Control, except to the extent that any such Patents or Know-How were developed by such Third Party prior to such Change of Control using or
incorporating such Party’s or its pre-existing Affiliate’s Know-How or Patents, or (ii) after such Change of Control to the extent that such Patents or Know-How are developed or conceived by such Third Party or its Affiliates (other than such Party) after such Change of Control without using or incorporating such Party’s or its
pre-existing Affiliate’s Know-How or Patents and are not developed or conceived by personnel who were employees or consultants of such Party or its pre-existing Affiliates. 
 1.47. “Cover,” “Covering” or
“Covers” means, as to a compound, composition, product or activity and Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, keeping, selling, offering for sale or importation of
such compound, composition or product or the conduct of such activity would infringe such Patent or, as to a pending claim included in such Patent, the making, using, keeping, selling, offering for sale or importation of such compound, composition
or product or the conduct of such activity would infringe such Patent if such pending claim were to issue in an issued patent without modification. 

1.48. “Development” means, with respect to a Capsid or Product, all clinical and
non-clinical research and development activities conducted after filing of an IND for such Capsid or Product, including [***]. When used as a verb, “Develop” or “Developing”
means to engage in Development. 
 1.49. “Disclosing Party” has the meaning set forth in Section 10.1. 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.50. “Dispute” has the meaning set forth in Section 11.12. 

1.51. “Distracting Product” means any product that is intended to treat, diagnose or prevent a Vertex Disease. 

1.52. “Distributor” means a Third Party to whom Vertex or its Affiliates or Sublicensees grant a right to sell or distribute
a Product, that purchases its requirements for such Product from Vertex or its Affiliates or Sublicensees, has no significant responsibility for marketing and promotion of the Product, and does not otherwise make any royalty or other payments to
Vertex or its Affiliates or Sublicensees with respect to its intellectual property rights or Products, including any payments that are calculated on the basis of a percentage of, or profit share on, such Third Party’s sale of Products. 

1.53. “Divest” means, with respect to a Distracting Product, the sale, exclusive license or other transfer by the applicable
Party and its Affiliates of all of their development and commercialization rights with respect to such Distracting Product to a Third Party without the retention or reservation of any development or commercialization obligation, interest or
participation rights (other than solely an economic interest or the right to enforce customary terms contained in the relevant agreements effectuating such transaction). 

1.54. “DM1” means Myotonic Dystrophy Type 1. 

1.55. “DMD” means Duchenne Muscular Dystrophy. 

1.56. “Effective Date” has the meaning set forth in the preamble. 

1.57. “EMA” means the European Medicines Agency and any successor entity thereto. 

1.58. “European Commission” means the European Commission or any successor entity that is responsible for granting marketing
approvals authorizing the sale of pharmaceuticals in the European Union. 
 1.59. “European Union” or “EU”
means (a) the economic, scientific and political organization of member states as it may be constituted from time to time, which as of the Effective Date consists of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and that certain portion of Cyprus included in such organization,
(b) any member country of the European Economic Area that is not otherwise a member of the European Union, and (c) any country not otherwise included in clauses (a) or (b) that participates in the unified filing system under the
auspices of the EMA. For purposes of this Agreement only, the United Kingdom shall be included in the “European Union” or “EU”. Further, for clarity, European Union will at all times be deemed to include each of
Italy, Germany, France and Spain. 
 1.60. “Executive Officers” means the [***] of Company, [***], and the [***] of Vertex,
[***]. 
 1.61. “Existing Third Party Option” has the meaning set forth in Section 2.1.2. 

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.62. “FDA” means the United States Food and Drug Administration and any
successor entity thereto. 
 1.63. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended,
and the rules and regulations promulgated thereunder. 
 1.64. “Field” means, separately and collectively, the diagnosis,
treatment or prevention of DMD, DM1, and, subject to the terms and conditions of Section 4.2, Cystic Fibrosis and [***]. 
 1.65.
“First Commercial Sale” means with respect to a Product, the first sale of such Product by Vertex, its Affiliate or its Sublicensee to a Third Party resulting in Net Sales in a particular country; provided that the following will
not constitute a First Commercial Sale: [***]. 
 1.66. “Force Majeure” means a condition, the occurrence and continuation
of which is beyond the reasonable control of a Party, including an act of God, governmental acts or restrictions, pandemic, war, civil commotion, labor strike or lock-out, epidemic, flood, failure or default
of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

1.67. “[***] Option Fee” has the meaning set forth in Section 4.2.2. 

1.68. “FTE” means [***] hours of work per annum devoted to or in support of the Research Activities that are carried out by
one or more qualified scientific or technical employees ([***]) of Company or its Affiliates. 
 1.69. “FTE Rate” means,
[***]; provided that such rates will increase or decrease on January 1 of each Calendar Year (starting with January 1, 2021) in accordance with [***]. 

1.70. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.71. “GCP” means good clinical practices, which are the then-current standards for Clinical Trials for pharmaceuticals, as
set forth in the FD&C Act or other Applicable Law, and such standards of good clinical practice as are required by the Regulatory Authorities of the European Union and other organizations and governmental authorities in countries for which the
applicable Capsid or Product is intended to be Developed, to the extent such standards are not less stringent than United States standards. 

1.72. “Gene Augmentation Modality” means the [***]. 

1.73. “Gene Editing Modality” means the [***]. 

1.74. “Gene Silencing/Other Modality” means [***]. 

1.75. “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21
C.F.R. Part 58, or comparable regulatory standards in jurisdictions outside of the United States, to the extent such standards are not less stringent than United States standards. 

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.76. “GMP” means the then-current Good Manufacturing Practices as
specified in the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules or regulations of an applicable Regulatory Authority at the time of manufacture. 

1.77. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national,
state, county, city or other political subdivision. 
 1.78. “Grantor” has the meaning set forth in Section 5.5.1.

 1.79. “IND” means any Investigational New Drug application filed with the FDA pursuant to Part 312 of Title 21 of the
U.S. Code of Federal Regulations or a similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries. 

1.80. “IND Acceptance Date” means, after filing an IND for a Product with a Regulatory Authority, the 31st consecutive day on
which there is no clinical hold or similar adverse regulatory action with respect to such IND. 
 1.81. “Indemnified Party”
has the meaning set forth in Section 8.1.3. 
 1.82. “Indemnifying Party” has the meaning set forth in
Section 8.1.3. 
 1.83. “Initiation” or “Initiate” means, with respect to any Clinical Trial, dosing
of the first human subject in such Clinical Trial. 
 1.84. “Insolvency Event” has the meaning set forth in
Section 9.2.4. 
 1.85. “Joint Agreement Know-How” has the meaning set forth
in Section 6.1.3. 
 1.86. “Joint Agreement Patents” has the meaning set forth in Section 6.1.3. 

1.87. “Joint Agreement Technology” has the meaning set forth in Section 6.1.3. 

1.88. “JRC” has the meaning set forth in Section 3.1.1. 

1.89. “Know-How” means intellectual property, data, results, pre-clinical and clinical protocols and data from studies and Clinical Trials, chemical structures, chemical sequences, materials, information, inventions, know-how, formulas,
trade secrets, techniques, methods, processes, procedures and developments, whether or not patentable; provided that Know-How does not include Patents. 

1.90. “Knowledge” means, with respect to Company, the actual knowledge of [***] after having consulted with Company’s
external patent counsel. For clarity, [***]. 
 1.91. “Liability” has the meaning set forth in Section 8.1. 

1.92. “Library Expansion Election” has the meaning set forth in Section 2.1.2. 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.93. “Licensed Know-How” means any
Know-How Controlled by Company or its Affiliates (a) on the Effective Date, (b) that is related to a Capsid and arises after the Effective Date but before the [***], or (c) that is related to a
Capsid and arises after the [***], solely to the extent that the practice of such Know-How is Covered by the Licensed Patents (as such Licensed Patents exist immediately prior to such Know-How arising) [***], provided that such Licensed Patents or other Patents are Controlled by Company prior to the [***], in each case ((a)—(c)), that is necessary [***] to Research, Develop, Manufacture or
Commercialize Products in the Field, and with respect to the foregoing (b) and (c), to the extent that any such Know-How is Controlled by Company by virtue of a license from a Third Party, solely to the
extent that Vertex has elected to include such license as a New Company Agreement in accordance with Section 5.5. For the avoidance of doubt, the Licensed Know-How shall exclude the Reserved Library with
respect to DMD unless and until Vertex exercises the Library Expansion Election. 
 1.94. “Licensed Patents” means any
Patents, including Company Agreement Patents and Joint Agreement Patents, Controlled by Company or its Affiliates on or after the Effective Date that Cover the Licensed Know-How. A list of Licensed Patents as
of the Effective Date is set forth in Schedule 1.94. 
 1.95. “Licensed Technology” means the Licensed Patents and
Licensed Know-How. 
 1.96. “Licensed Trademarks” has the meaning set forth in
Section 2.5.2. 
 1.97. “Licensee” has the meaning set forth in Section 5.5.2. 

1.98. “Lonza” has the meaning set forth in Section 1.105. 

1.99. “Major EU Markets” means [***]. 

1.100. “Major Market Countries” means [***]. 

1.101. “Manufacture” or “Manufactured” or “Manufacturing” means activities directed to
making, having made, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality control testing and quality assurance release, shipping or storage of a Capsid or Product. 

1.102. “Marketing Approval” means, with respect to a Product in a particular jurisdiction, all approvals ([***]), licenses,
registrations or authorizations necessary for the Commercialization of such Product in such jurisdiction, including, with respect to the United States, approval of an Approval Application for such Product by the FDA and with respect to the European
Union, approval of an Approval Application for such Product by the European Commission or the applicable Regulatory Authority in any particular country in the EU. 

1.103. “Materials” means all biological materials, chemical compounds and other materials arising out of a Party’s
activities under the Research Programs and provided by such Party to the other Party for use by the other Party or otherwise provided by a Party for use by the other Party, in each case, to conduct activities pursuant to the Research Programs,
including [***]. 
 1.104. “MEE” has the meaning set forth in Section 1.105. 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.105. “MEE/Lonza 3-Way Agreement”
means that certain Exclusive License Agreement entered into on September 9, 2019, by and between Company, Massachusetts Eye and Ear Infirmary (“MEE”) and Lonza Houston, Inc. (“Lonza”). 

1.106. “Modality” means a therapeutic method, consisting of the Gene Augmentation Modality, the Gene Editing Modality, or the
Gene Silencing/Other Modality. 
 1.107. “MTA” means the Material Transfer Agreement entered into by Company and Vertex on
[***] pursuant to which Company has provided to Vertex certain Materials (as defined therein) for Vertex to perform certain specified and limited Research and Manufacturing activities related thereto as expressly stated within such Material Transfer
Agreement, which activities shall be deemed conducted under the Research Programs hereunder. 
 1.108. “Net Sales” means
the gross invoiced price for Products sold by Vertex (including sales generated from named patient programs and excluding sales deferred for GAAP accounting purposes until such sales are recognized), its Affiliates or Sublicensees (the
“Selling Party”) to Third Parties, less the following deductions from such gross amounts: 
 (a) credits or allowances on
account of price adjustments, recalls, claims, damaged goods, rejections or returns of items previously sold (including Product returned in connection with recalls or withdrawals) and [***]; 

(b) import taxes, export taxes, excise taxes (including [***]), but only such portion [***], or government invoiced fees, sales taxes,
value-added taxes, consumption taxes, duties or other taxes levied on, absorbed, determined or imposed with respect to such sales (excluding income or net profit taxes or franchise taxes of any kind), [***]; 

(c) insurance, customs charges, freight, shipping and other transportation costs incurred in shipping Product to such non-related parties, to the extent [***]; 
 (d) discounts (including trade, quantity, cash discounts and
fees for services), cash and non-cash coupons, co-payment support programs, retroactive price reductions, and charge back payments and rebates granted to any non-related party (including [***]); 
 (e) rebates (or their equivalent), [***], chargebacks and
retroactive price adjustments [***]; and 
 (f) compulsory payments [***], provided that any such deduction [***]. 

Only items that are deducted from the Selling Party’s gross sales of Product(s), as included in the Selling Party’s published financial statements
and that are in accordance with GAAP, applied on a consistent basis, will be deducted from such gross sales for purposes of the calculation of Net Sales. Notwithstanding the foregoing, [***]. 

A qualifying amount may be deducted only once regardless of the number of the preceding categories that describes such amount. If a Selling Party makes any
adjustment to such deductions after the associated Net Sales have been reported pursuant to this Agreement, the adjustments and payment of any royalties due will be reported with a subsequent quarterly report. Sales between or among Vertex, its
Affiliates and Sublicensees will be excluded from the computation of Net Sales if such sales are not intended for end use, but Net Sales will include the subsequent final sales to Third Parties by Vertex or any such Affiliates or Sublicensees. A
Product will not be deemed to be sold if [***]. For clarity, Net Sales include [***]. 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 If a sale, transfer or other disposition with respect to a Product involves consideration other than cash or
is not at arm’s length, the Net Sales from such sale, transfer or other disposition will be [***]. 
 Solely for purposes of calculating Net Sales, if
Vertex or its Affiliates or any permitted Sublicensee sells a Product in the form of a combination product containing a Product and [***] that is not a Product (“Other Product”) ([***]) (such combination product, a
“Combination Product”), Net Sales of such Combination Product for the purpose of determining the payments due to Company pursuant to this Agreement will be calculated by [***]. If the gross selling price of a Product in such country
when sold separately in finished form (i.e., without the other active ingredients or delivery device) can be determined but the gross selling price of the Other Product in such country cannot be determined, Net Sales in such country for
purposes of determining royalty payments will be calculated by [***]. If such separate sales are not made in a country, Net Sales will be calculated by [***]. For the avoidance of doubt, [***]. 

1.109. “New Company Agreement” has the meaning set forth in Section 5.5.2. 

1.110. “New Technology” means (a) any Know-How that is Controlled by Company or
its Affiliates on the Effective Date or during [***] that is necessary [***] to Research, Develop, Manufacture or Commercialize Products in the Field, and (b) any Patents Covering the Know-How in the foregoing clause (a), in each case ((a) and
(b)), to the extent not included in the Licensed Technology. For clarity, [***]. 
 1.111.
“Non-Breaching Party” means the Party that believes the other Party is in material breach of this Agreement. 

1.112. “Option” has the meaning set forth in Section 4.2. 

1.113. “Option Exercise Data Package” has the meaning set forth in Section 4.2.2. 

1.114. “Other Product” has the meaning set forth in Section 1.108. 

1.115. “Out-of-Pocket Costs” means, with
respect to a Party, costs and expenses paid by such Party or its Affiliates to Third Parties ([***]), other than employees of such Party or its Affiliates. 

1.116. “Party” or “Parties” has the meaning set forth in the Preamble. 

1.117. “Patents” means the rights and interests in and to issued patents and pending patent applications in any country,
jurisdiction or region (including inventor’s certificates and utility models), including all provisionals, non-provisionals, substitutions, continuations, continuations-in-part, divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations and patents of addition thereof,
including patent term extensions and supplementary protection certificates, international patent applications filed under the Patent Cooperation Treaty (PCT) and any foreign equivalents to any of the foregoing. 

  
 12 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.118. “Person” means an individual, sole proprietorship, partnership,
limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political
subdivision or department or agency of a government. 
 1.119. “Phase 3 Clinical Trial” means any Clinical Trial as
described in 21 C.F.R. §312.21(c) (as amended from time to time), or, with respect to a jurisdiction other than the United States, a similar Clinical Trial. 

1.120. “Pivotal Clinical Trial” means (a) a Phase 3 Clinical Trial, or (b) any other Clinical Trial that is
determined by the applicable Regulatory Authority (as evidenced by written correspondence from such Regulatory Authority) prior to the Initiation of such Clinical Trial to be sufficient to form the basis for Regulatory Approval of the applicable
Product. 
 1.121. “Price Approval” means, in any country where a Governmental Authority authorizes reimbursement for, or
approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination. 

1.122. “Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or
before any Governmental Authority. 
 1.123. “Product” means any pharmaceutical or biopharmaceutical product, medical
therapy, preparation, substance, or formulation comprising or employing, in whole or in part, (a) a Capsid or (b) any AAV capsid that is [***] and that incorporates the Licensed Technology. 

1.124. “Proposed New Company Agreement” has the meaning set forth in Section 5.5.1. 

1.125. “Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to a Patent, the
preparing, filing, prosecuting and maintenance of such Patent, as well as handling re-examinations and reissues with respect to such Patent, together with the conduct of interferences, derivation proceedings,
the defense of oppositions, post-grant patent proceedings (such as inter partes review and post grant review) and other similar proceedings with respect to the particular Patent. For clarification, “Prosecution and Maintenance” or
“Prosecute and Maintain” will not include any other enforcement actions taken with respect to a Patent. 
 1.126.
“Receiving Party” has the meaning set forth in Section 10.1. 

  
 13 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.127. “Regulatory Approval” means the technical, medical and scientific
licenses, registrations, authorizations and approvals (including approvals of Approval Applications, supplements and amendments, pre- and post- approvals, and labeling approvals) of any Regulatory Authority,
necessary for the research, development, clinical testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of a pharmaceutical product in a regulatory jurisdiction, including Marketing Approval
but excluding Price Approval. 
 1.128. “Regulatory Authority” means, with respect to a country in the Territory, any
national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in
the granting of Regulatory Approvals or Price Approvals for pharmaceutical products in such country or countries. 
 1.129.
“Regulatory Filings” means, collectively: (a) all INDs, Approval Applications, establishment license applications, Drug Master Files, applications for designation as an “Orphan Product(s)” under the Orphan Drug Act,
for “Fast Track” status under Section 506 of the FD&C Act (21 U.S.C. § 356) or for a Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FD&C Act (21 U.S.C. § 355(b)(4)(B)) and all other
similar filings (including counterparts of any of the foregoing in any country or region in the Territory); (b) any applications for Regulatory Approval or Price Approval and other applications, filings, dossiers or similar documents submitted to a
Regulatory Authority in any country for the purpose of obtaining Regulatory Approval or Price Approval from that Regulatory Authority; (c) any Patent-related filings with any Regulatory Authority; (d) all supplements and amendments to any
of the foregoing; and (e) all data and other information contained in, and correspondence with any Regulatory Authority relating to, any of the foregoing. 

1.130. “Remainder” has the meaning set forth in Section 5.1.2. 

1.131. “Research” means conducting research activities to discover, design, optimize, deliver and advance Capsids and
Products, including pre-clinical studies and optimization, but specifically excluding Development, Manufacture and Commercialization. When used as a verb, “Researching” means to engage in
Research. 
 1.132. “Research Activities” means the activities with respect to the Research of Capsids to be conducted by
either Party or jointly by the Parties for each of Cystic Fibrosis, DMD and DM1 during the Research Term. 
 1.133. “Research
Extension” has the meaning set forth in Section 2.1.1. 
 1.134. “Research Program” means the program of
Research Activities for each of (a) Cystic Fibrosis and (b) DMD and DM1 (each of (a) and (b), a separate Research Program). 

1.135. “Research Term” means the period of time commencing upon the Research Term Effective Date and continuing until the
fifth anniversary thereof. 
 1.136. “Research Term Effective Date” has the meaning set forth in Section 5.1.2. 

1.137. “Reserved Library” has the meaning set forth in Section 2.1.2. 

1.138. “Residual Knowledge” means knowledge, techniques, experience and Know-How that
[***] by the Disclosing Party. 

  
 14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.139. ”Results” has the meaning set forth in the MTA. 

1.140. “ROFN Notice” has the meaning set forth in Section 4.4. 

1.141. “Royalty Term” means, with respect to a Product in a country, the period commencing on the first sale of such Product
giving rise to Net Sales in such country and ending upon the later of: (a) the expiration of the last Valid Claim of a Licensed Patent that Covers such Product in such country; (b) 10 years after the First Commercial Sale of such Product in
such country; or (c) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such Product. 

1.142. “Rules” has the meaning set forth in Section 11.12.2(a). 

1.143. “Safety Data Exchange Agreement” has the meaning set forth in Section 2.8. 

1.144. “Selling Party” has the meaning set forth in Section 1.108. 

1.145. “Subcontractor” has the meaning set forth in Section 2.1.4. 

1.146. “Sublicense” means, directly or indirectly, to sublicense, grant any other right with respect to, or agree not to
assert, the rights granted to Vertex hereunder. When used as a noun, “Sublicense” means any agreement to Sublicense. 

1.147. “Sublicensee” means an Affiliate or Third Party, other than a Distributor, to whom Vertex (or a Sublicensee or
Affiliate) sublicenses any of the rights granted to Vertex hereunder during the Term. 
 1.148. “Term” has the meaning set
forth in Section 9.1. 
 1.149. “Territory” means worldwide. 

1.150. “Third Party” means any Person other than Vertex, Company or their respective Affiliates. 

1.151. “Third Party Infringement Claim” has the meaning set forth in Section 6.3. 

1.152. “Third Party Optionee” means that certain Third Party to whom [***]. 

1.153. “United Kingdom” means the United Kingdom of Great Britain and Northern Ireland. 

1.154. “United States” or “U.S.” means the United States of America and all of its districts, territories
and possessions. 
 1.155. “Upfront Fee” means an amount equal to Twenty Five Million US Dollars ($25,000,000). 

  
 15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.156. “Valid Claim” means a claim (a) of any issued, unexpired United
States or foreign Patent, which has not, in the country of issuance, been donated to the public, disclaimed, held invalid or unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision, or (b) of any United
States or foreign patent application, which has not, in the country in question, been cancelled, withdrawn, or abandoned. Notwithstanding the foregoing, on a
country-by-country basis, a patent application pending for more than [***] will not be considered to have any Valid Claim for purposes of this Agreement unless and until
a patent that meets the criteria set forth in clause (a) above with respect to such application issues. 
 1.157.
“Vertex” has the meaning set forth in the Preamble. 
 1.158. “Vertex Agreement
Know-How” has the meaning set forth in Section 6.1.2. 
 1.159. “Vertex
Agreement Patents” has the meaning set forth in Section 6.1.2. 
 1.160. “Vertex Agreement Technology” has
the meaning set forth in Section 6.1.2. 
 1.161. “Vertex Background Know-How”
means any and all Know-How Controlled by Vertex or its Affiliates (a) prior to the Effective Date, or (b) during the Term, to the extent invented, developed, acquired or created independently of the
activities performed under this Agreement. 
 1.162. “Vertex Background Patents” means any Patents Controlled by Vertex or
its Affiliates that Cover the Vertex Background Know-How. 
 1.163. “Vertex Background
Technology” means the Vertex Background Know-How and the Vertex Background Patents. 

1.164. “Vertex Diseases” means Cystic Fibrosis, DMD, DM1 and [***]; provided that if Vertex does not make a timely exercise
of the Option with respect to Cystic Fibrosis or with respect to [***] with respect to at least one Modality, then Cystic Fibrosis or [***], as applicable, will cease to be a Vertex Disease as of the date that each such Option expires pursuant to
Section 4.2. 
 1.165. “Vertex Indemnified Party” has the meaning set forth in Section 8.1.2. 

1.166. “Vertex Inventions” has the meaning set forth in the MTA. 

1.167. “VXc Nomination” means a determination by Vertex, in accordance with its internal policies and procedures consistently
applied, that [***]. 

  
 16 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 2. 

RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION 

2.1. Research. 

2.1.1. Research Activities. During the first two years of the Research Term, Company shall perform the Research Activities under
each Research Program in accordance with Section 2.1.3 and the other terms of this Agreement. Following the first two years of the Research Term, Vertex will have the right, in its sole discretion, to extend Company’s obligation to perform
Research Activities on a Research Program-by-Research Program basis for additional one-year periods at a cost of [***] per year
per Research Program, up to a total of three additional years for each Research Program (each, a “Research Extension”), by providing notice to Company no later than [***] before the expiration of the [***] year of the Research Term,
and thereafter, no later than [***] before the conclusion of each additional year for which Vertex has elected to extend Company’s obligations (as applicable); provided that, for any Research Extension, Vertex will have the right to
update the Capsid criteria set forth on Schedule 2.1.3 for the applicable Research Program, which update will be provided with the applicable notice of a Research Extension. Vertex will have the right to perform Research Activities for each
Research Program at any time during the Research Term, regardless of whether Company is also performing Research Activities pursuant to this Section 2.1.1; provided that, prior to Vertex’s exercise of the Option for Cystic Fibrosis,
Vertex’s activities with respect to the Research of Capsids for Cystic Fibrosis shall be limited to the evaluation of Capsids as set forth in Section 4.2.1, and any other activities agreed to by the Parties. 

2.1.2. Existing Third Party Option. The Parties acknowledge that, as of the Effective Date, Lonza Houston, Inc. has granted to
the Third Party Optionee an option to obtain an exclusive right and license to the Licensed Patents existing as of the Effective Date with respect to [***] (the “Reserved Library”) for the exploitation of products for the treatment,
diagnosis and prevention of DMD, which option expires on [***] (the “Existing Third Party Option”). In the event that the Existing Third Party Option expires or otherwise terminates with respect to all or a portion of the Reserved
Library, such that Company’s rights to Capsids included in the Reserved Library can be licensed to Vertex for DMD (in whole or in part), then Company shall promptly notify Vertex and Vertex will have [***] from such notice to determine whether
it wishes to include the Reserved Library within the scope of the Research Activities for DMD in the Research Program for DMD and DM1 (as being within the Capsid libraries Controlled by Company) (in whole or in part). Company shall provide to Vertex
any and all information in Company’s possession as Vertex may reasonably request during such [***] notice period to assist Vertex in determining whether to exercise the Library Expansion Election. In the event that Vertex elects during the Term
to include (a) such capsids in the Reserved Library and (b) all Know-How and Patents Controlled by Company related to such capsids, in each case, in the Licensed Technology, then Vertex shall notify
Company within such [***] period and together with such notice shall pay to Company a one-time, non-refundable, non-creditable
payment of Two Million Dollars ($2,000,000) (the “Library Expansion Election”); provided that, if Vertex provides notice to Company of such election during the Research Term and the Existing Third Party Option has only
terminated with respect to a portion of the Reserved Library at such time, no further payment shall be owed by Vertex if it subsequently provides an additional notice to Company of such election in the event that the Existing Third Party Option
subsequently terminates with respect to an additional portion of the Reserved Library; and provided further that, if Vertex provides notice to Company of such election after the conclusion of the Company’s Research Activities during the
Research Term for DMD and DM1, then the foregoing fee shall not be payable by Vertex but clauses (ii) and (iii) of the following sentence shall apply. In the event that Vertex makes the Library Expansion Election, (i) solely in the event
that the Library Expansion Election occurs after the conclusion of the Company’s Research Activities during the Research Term for DMD and DM1, then such Capsids shall be automatically included in the Capsids being Researched pursuant to
Company’s Research Activities for DMD, (ii) the capsids in the Reserved Library for which Vertex has made such election shall be deemed Controlled by Company and included in the Capsids hereunder for DMD, and (iii) the Patents and Know-How Controlled by Company related to the Reserved Library that would otherwise be included in the Licensed Technology for DMD but for the Existing Third Party Option shall be deemed to be included in the
Licensed Technology for DMD to the extent of Vertex’s election. 

  
 17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.1.3. Conduct of the Research. 

(a) Research Efforts. On a Research
Program-by-Research Program basis, during the first two years of the Research Term, and continuing during any applicable Research Extension for such Research Program,
Company shall use Commercially Reasonable Efforts to Research and deliver Capsids to Vertex that meet the criteria set forth on Schedule 2.1.3 hereto (as such criteria may be amended by Vertex pursuant to Section 2.1.1) for such Research
Program, which Commercially Reasonable Efforts shall include [***]. Each Party, directly or through its Affiliates or permitted Subcontractors, will use Commercially Reasonable Efforts to conduct its Research Activities in a professional and timely
manner, and will, and will require its Affiliates and Subcontractors to, perform such Research Activities in compliance with all Applicable Laws. 

(b) Non-Human Primate Studies Research Costs. During the first two years of the
Research Term, if Company intends to initiate a Comparator Study in the Research Programs, then, subject to Vertex’s agreement to fund such study, Vertex and Company shall together design such Comparator Study, [***]. In the event that Vertex
declines to fund such study, then Company shall have no obligation to conduct such study as part of the applicable Research Program. Vertex shall reimburse Company on a Calendar Quarter basis for (i) the reasonable Out-of-Pocket Costs incurred by Company or Company’s Subcontractors, subject to Section 2.1.4 below, and (ii) Company’s approved internal costs at the FTE
Rate, in each case ((i) and (ii)) solely to the extent such costs are in accordance with the approved budget for such Comparator Study. Within [***] following the end of each Calendar Quarter, Company shall provide an invoice to Vertex for the costs
and expenses set forth in, and subject to, the foregoing clauses (i) and (ii), and Vertex shall pay any undisputed amounts set forth in such invoices within [***] of receipt. 

2.1.4. Subcontracting. Each Party may engage consultants, subcontractors, academic researchers or other vendors (each, a
“Subcontractor”) to perform Research Activities; provided that Company shall not engage any Subcontractor without Vertex’s written consent, which consent shall not be unreasonably withheld or delayed; provided,
that no such consent shall be required for any Third Party listed on Schedule 2.1.4 to perform the activities specified for such Third Party on Schedule 2.1.4, as such schedule may be updated at any time during the Research Term by approval of the
JRC, subject to the right of Vertex to have final decision-making authority with respect thereto in its sole discretion, notwithstanding anything in Section 3.1.4 to the contrary; and provided further, that Vertex shall have the right to
withhold its consent, in its sole discretion, with respect to any proposed Subcontractor [***]. Notwithstanding the foregoing, the consent of Vertex shall not be required with respect to any subcontractor if [***]. Each contract between a Party and
a Subcontractor shall be consistent with the provisions of this Agreement and shall include confidentiality provisions that are at least as restrictive as those described in ARTICLE 10. Each Party shall be responsible for the effective and timely
management of and payment of its Subcontractors. The engagement of any Subcontractor in compliance with this Section 2.1.4 shall not relieve the applicable Party of its obligations under this Agreement. 

  
 18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.1.5. Records. Each Party shall maintain, and cause its Affiliates and
Subcontractors to maintain, records of its Research Activities in sufficient detail and in good scientific manner appropriate for scientific, patent and regulatory purposes, which shall be complete and accurate in all material respects and shall
fully and properly reflect all work done, data and developments made, and results achieved. 
 2.1.6. Progress Reports. During
the Research Term, each Party shall furnish to the JRC, within [***] after the end of each Calendar Quarter an update on such Party’s progress under the Research Programs with respect to the performance of the Research Activities during the
relevant Calendar Quarter, including a [***]. 
 2.2. Development. 

2.2.1. Generally. Vertex will have sole and exclusive control over all matters relating to the Development of Capsids and
Products in the Field. 
 2.2.2. Reporting. Beginning in the first Calendar Year in which Vertex is conducting Development
activities, Vertex will provide Company with a high-level report regarding the status of Vertex’s Development of Products no less than [***] per Calendar Year, which reports will include [***]. Such reports may be provided to Company in
conjunction with meetings and other communications between the representatives of Vertex and Company. 
 2.3. Regulatory
Matters. 
 2.3.1. Responsibilities. Vertex or its designated Affiliates and Sublicensees will have the sole authority
to (a) prepare and file Regulatory Filings, each in its own name, and applications for Regulatory Approval and Price Approval for all Capsids and Products in the Field in the Territory, and (b) communicate with Regulatory Authorities with
respect to Capsids and Products in the Field in the Territory, both prior to and following Regulatory Approval and Price Approval, including all communications and decisions with respect to [***]. 

2.3.2. Ownership. Ownership of all rights in and to all Regulatory Filings, Regulatory Approvals and Price Approvals directed to
any Capsids or Product in the Field in each country of the Territory will be held in the name of Vertex, its Affiliate, designee or Sublicensee. 

2.3.3. Cooperation. Company will, and will cause its Affiliates to, cooperate with Vertex with respect to all regulatory matters
relating to any Product. Without limiting the foregoing, as requested by Vertex, Company will reasonably assist Vertex in preparing Regulatory Filings for Products and make information Controlled by Company or its Affiliates available to Vertex to
the extent necessary or useful in connection with such Regulatory Filings. Vertex will provide Company with copies of all material correspondence between Vertex and a Regulatory Authority. Upon Vertex’s reasonable request and at Vertex’s
sole expense, Company will support the Development of Capsids and Products by providing Regulatory Authorities with access to, and the right to audit, any data or other Know-How and associated documents that
are in Company’s Control and are relied on by Vertex in its Regulatory Filings for Products. For as long as the exclusive license granted to Vertex under this Agreement is in force with respect to the applicable Vertex Disease, Company will not
make any submission to any Regulatory Authority related to any Product for such Vertex Disease in the Field without first obtaining Vertex’s prior written consent. 

  
 19 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.3.4. Right of Reference. Company hereby grants Vertex, its Affiliates and
Sublicensees a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings Controlled by Company or its Affiliates to the extent necessary or
useful to Research, Develop, Manufacture or Commercialize Capsids or Products in the Field in the Territory. If requested by Vertex, Company will provide a signed statement to this effect in accordance with 21 C.F.R. §314.50(g)(3) or any
foreign counterpart to such regulation. In the event of a termination of this Agreement in its entirety or with respect to a Vertex Disease, except in the event of any such termination by Vertex pursuant to Section 9.2.2(a) or
Section 9.2.4, Vertex will grant to Company, its Affiliates and Sublicensees a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings
Controlled by Vertex or its Affiliates to the extent necessary or useful to Research, Develop, Manufacture or Commercialize Capsids or Products for the applicable terminated Vertex Disease(s), provided that [***]. If requested by Company,
Vertex will provide a signed statement to this effect in accordance with 21 C.F.R. §314.50(g)(3) or any foreign counterpart to such regulation. 

2.4. Manufacturing. Vertex will have the exclusive right to Manufacture and supply Products itself or through one or more
Affiliates or Third Parties selected by Vertex in its sole discretion for Research, Development and Commercialization in the Field in the Territory. Company shall Manufacture Capsids as necessary for use in the Research Activities and, subject to
Section 4.7.1, may Manufacture Capsids for the research, development and manufacture of products outside of the Field. 
 2.5.
Commercialization. 
 2.5.1. General. Vertex will have sole and exclusive control over all matters relating to
the Commercialization of Products in the Field in the Territory. 
 2.5.2. Branding. Vertex or its designated Affiliates or
Sublicensees will select and own all trademarks used in connection with the Commercialization of any Product in the Field in the Territory, except with respect to any trademarks specifically related to a Capsid, for which Company will have the right
to select and own such trademarks and will license such trademarks to Vertex pursuant to Section 4.1.3 (such trademarks, the “Licensed Trademarks”). Company will not use nor seek to register, anywhere in the Territory, any
trademark that is confusingly similar to any trademark used by or on behalf of Vertex, its Affiliates or Sublicensees in connection with any Product. 

2.6. Diligence. 

2.6.1. Generally. 

(a) Commencing as of the Research Term Effective Date, for each of DMD and, in the event that Vertex exercises the applicable Option, Cystic
Fibrosis (commencing on the date that such Option is exercised), Vertex (acting directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and Commercialize [***] Product for such
Vertex Disease in [***] Modality in each of the Major Market Countries; provided that if, (i) with respect to DMD, [***] for [***] Modality, or (ii) with respect to Cystic Fibrosis, [***] for [***] Modality, then Vertex (acting
directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and Commercialize [***] Product for DMD or Cystic Fibrosis (as applicable) in [***]. 

  
 20 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) Commencing as of the Research Term Effective Date, for each of DM1 and, in the event
that Vertex exercises the applicable Option, [***] (commencing on the date that such Option is exercised), Vertex (acting directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and
Commercialize [***] Product for such Vertex Disease in [***] Modality in each of the Major Market Countries. 
 2.6.2. Consequence of
Diligence Failure. In the event that Company believes in good faith that Vertex has failed to satisfy the diligence obligations set forth in Sections 2.6.1(a) or 2.6.1(b) with respect to a Vertex Disease, Company shall promptly notify
Vertex, which notice shall include a reasonably detailed description of the basis for such belief, and Vertex shall have [***] from receipt of such notice to cure such breach. Vertex may challenge the occurrence of such breach in good faith through
the dispute resolution process set forth in Section 11.12. Unless it is determined through such dispute resolution process that no breach occurred, if Vertex fails to cure such breach within such [***] period, which [***] period may be tolled
during the pendency of any dispute resolution proceedings provided for herein and [***], then the license granted to Vertex in Section 4.1 with respect to such Vertex Disease shall, upon notice by Company to Vertex, be terminated (i) in
the case of Cystic Fibrosis or DMD, on a [***] and (ii) in the case of DM1 or [***], with respect to all Modalities for such Vertex Disease. Following any such termination, the exclusivity obligations of Company set forth in Section 4.7.1
with respect to such Modality for such Vertex Disease shall no longer apply. Notwithstanding anything in this Agreement to the contrary, Company’s sole and exclusive remedy for Vertex’s failure to satisfy its diligence obligations set
forth in Sections 2.6.1(a) and 2.6.1(b) shall be limited to the remedy set forth in this Section 2.6.2. 
 2.7. Applicable
Laws. Vertex will, and will require its Affiliates and Sublicensees to, comply with all Applicable Law in its and their Research, Development, Manufacture and Commercialization of Capsids and Products, including where appropriate GMP, GCP
and GLP (or similar standards). 
 2.8. Safety Data Exchange. Upon Vertex’s request, the Parties will negotiate and enter
into a separate safety data exchange agreement (a “Safety Data Exchange Agreement”). The Safety Data Exchange Agreement will set forth guidelines and procedures for the receipt, investigation, recording, review, communication,
reporting and exchange between the Parties of Adverse Event reports, that, for purposes of information exchange between the Parties, will include Adverse Events and serious Adverse Events, and any other information concerning the safety of any
Product or Capsid. Without limiting the foregoing, the Parties will meet to establish a safety oversight working group comprised of members of both Parties, which, except as otherwise provided in the Safety Data Exchange Agreement, will discuss
processes and procedures for sharing information needed to support each Party’s regulatory responsibilities and to comply with applicable regulatory pharmacovigilance requirements. Any such procedures will not be construed to restrict either
Party’s ability to take any action that it deems to be appropriate or required of it under the applicable regulatory requirements, if permitted by Applicable Laws. Without limiting the foregoing, Company will promptly disclose to Vertex in
writing any information in Company’s possession regarding the occurrence of any Adverse Event that may reasonably relate to the safety of a Capsid. In addition, Vertex will (a) maintain a unified worldwide Adverse Event database for
Products, and be responsible for reporting Adverse Events and serious Adverse Events to the applicable Regulatory Authorities and (b) be responsible for all signal detection and risk management activities with respect to Products and will
develop and approve the contents of all safety communications to Regulatory Authorities, including but not limited to expedited non-clinical and clinical safety reports and aggregate reports to health
authorities, institutional review boards and ethics committees. 

  
 21 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 3. 

GOVERNANCE 
 3.1.
Joint Research Committee. 
 3.1.1. Formation. Within [***] after the Effective Date, the Parties will establish
a joint research committee (the “JRC”) to oversee and coordinate the Research Programs under this Agreement. The JRC will be comprised of three representatives from each Party. Each Party’s representatives on the JRC shall be
[***]. In addition, each Party may invite a reasonable number of additional representatives to participate in discussions and meetings of the JRC. Each Party’s representatives on the JRC and all other individuals participating in discussions
and meetings of the JRC on behalf of a Party will be subject to confidentiality and non-use obligations with respect to information disclosed at such meeting that are no less restrictive than the provision of
ARTICLE 10. The JRC will designate a chairperson at its first meeting. The chairperson of the JRC will be responsible for setting the agenda for meetings of the JRC with input from the other members, and for conducting the meetings of the JRC. The
JRC will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. 
 3.1.2.
Responsibilities. The JRC will oversee and coordinate the Research Programs under this Agreement. Without limiting the foregoing, the JRC will: 

(a) review all material Research Activities undertaken by or on behalf of the Parties, including the exchange and review of data and
information generated pursuant to the Research Activities; 
 (b) discuss Company’s plans for Research Activities and [***]; 

(c) prioritize the performance of Research Activities; 

(d) oversee and coordinate the transfer of Licensed Technology to Vertex in accordance with Section 4.3; and 

(e) perform such other duties as are specifically assigned to the JRC under this Agreement. 

  
 22 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.1.3. Meetings; Minutes. 

(a) The JRC will meet in person or by teleconference at least [***] on such dates and at such times and places as agreed to by the members of
the JRC; provided that at least [***] such meeting per [***] shall be in person unless the Parties agree otherwise. Each Party will be responsible for its own expenses relating to attendance at, or participation in, JRC meetings. 

(b) The Alliance Managers will provide the members of the JRC with draft written minutes for approval from each meeting within [***] after
each such meeting. The responsibility for preparing the minutes will alternate between the Alliance Managers on a meeting-by-meeting basis. If the minutes of any meeting
of the JRC are not approved by the JRC ([***]) within [***] after the meeting, the objecting Party will append a notice of objection with the specific details of the objection to the proposed minutes. 

3.1.4. Decision-Making. Each Party’s representatives on the JRC will [***] on all matters within the scope of the
JRC’s responsibilities. The JRC members will use reasonable efforts to reach agreement on all JRC matters. If the JRC is unable to reach consensus with respect to a particular matter for which it is responsible within [***] after the matter is
first presented to the JRC, the matter will be referred to the Executive Officers, who will use reasonable efforts to reach agreement on such matters. If such Executive Officers are unable to reach consensus with respect to a particular matter
within [***] after the matter is first referred to such Executive Officers, [***]; provided that, [***] will not have the right to: (i) amend, modify or waive compliance with any term or condition of this Agreement; (ii) make any
decision that is expressly stated to require the mutual agreement of the Parties; (iii) resolve any claim or dispute regarding whether or in what amount a payment is owed under this Agreement; (iv) exercise its final decision-making
authority in a manner that would require [***] to perform any act that [***] reasonably believes would violate Applicable Law; or (v) make a determination that a Party is in material breach of any obligation under this Agreement. 

3.1.5. Discontinuation of the JRC. The JRC’s authority will continue to exist until the first to occur of (a) the
Parties mutually agreeing to disband the JRC and (b) the conclusion of the Research Term. 
 3.2. Other Committees. The
Parties may, by mutual agreement, form such other committees or working groups as may be necessary or desirable to facilitate activities under this Agreement. Any dispute arising from such committees or working groups will be escalated to the JRC
for resolution; provided that, following discontinuation of the JRC pursuant to Section 3.1.5, any such disputes will be resolved in the manner mutually agreed to by the Parties at the time of the formation of such committee or working
group. 
 3.3. Alliance Managers. 

3.3.1. Appointment. Each Party will appoint a representative of such Party to act as its alliance manager under this Agreement
(each, an “Alliance Manager”). Each Party may replace its Alliance Manager at any time upon notice to the other Party. The initial Alliance Managers will be: 

[***] 

  
 23 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.3.2. Specific Responsibilities. The Alliance Managers may attend meetings of
the JRC but may not be members of the JRC. The Alliance Managers will serve as the primary contact point between the Parties for the purpose of providing each Party with information regarding the other Parties’ activities pursuant to this
Agreement and will have the following responsibilities: 
 (a) schedule meetings of the JRC and circulate draft written minutes as provided
in Section 3.1.3(b); 
 (b) facilitate the flow of information and otherwise promote communication, coordination and collaboration
between the Parties; 
 (c) provide a single point of communication for seeking consensus both internally within the respective
Party’s organization and between the Parties regarding key strategy and planning issues; and 
 (d) perform such other functions as
requested by the JRC. 
 ARTICLE 4. 

LICENSE GRANTS; OPTIONS; EXCLUSIVITY 

4.1. License Grants to Vertex. 

4.1.1. License. Subject to the terms of this Agreement, including Section 4.7.2, Company grants to Vertex and its
Affiliates an exclusive, royalty-bearing license, including the right to grant and authorize Sublicenses in accordance with Section 4.1.2, under Company’s and its Affiliates’ interest in the Licensed Technology to Research, Develop,
Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Capsids and Products in the Field in the Territory. 

4.1.2. Sublicensing. Vertex and its Affiliates may grant Sublicenses of any rights granted to Vertex by Company under this
Agreement through multiple tiers of Sublicenses to one or more Sublicensees. Each such Sublicense will be consistent with the terms of this Agreement and will require such Sublicensee to comply with all applicable terms of this Agreement. Vertex
will remain responsible for each Sublicensee’s compliance with the applicable terms of this Agreement. 
 4.1.3. Trademark
License. Subject to the terms and conditions of this Agreement, including Section 2.5.2, Company hereby grants to Vertex an exclusive right and license to use the Licensed Trademarks in the Territory during the Term in connection with
the exploitation, including Commercialization, of Products in the Field hereunder. Vertex shall mark all Products in accordance with applicable trademark laws, and shall require all of its Affiliates and Sublicensees to do the same. 

4.1.4. Limitations. Notwithstanding the license granted to Vertex pursuant to Section 4.1.1, subject to the terms of this
Agreement, Company will retain rights under the Licensed Technology in the Field for the sole purpose of performing Research Activities or, with respect to [***], pursuant to Research activities conducted outside of the Research Programs in
accordance with Sections 4.2.2 and 4.7.1 below. 

  
 24 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.1.5. Retained Rights of MEE. The license grant set forth in
Section 4.1.1 shall be subject to: 
 (a) the retained right of MEE and MEE’s Affiliates and academic, government and not-for-profit institutions to make and to use the subject matter described or claimed in the Licensed Technology that has been
in-licensed by Company under the MEE/Lonza 3-Way Agreement; provided, however, that such making and using shall not include the production, Commercialization or
Manufacture of Products for sale and only to the extent that such making and using by academic, government and not-for-profit institutions does not conflict with any of
the provisions of this Agreement or the MEE/Lonza 3-Way Agreement; and 
 (b) certain effects
resulting from the fact that the Licensed Technology that has been in-licensed by Company under the MEE/Lonza 3-Way Agreement that is supported by federal funding, the
rights, conditions and limitations imposed by 35 U.S.C. Section 202 et seq. (and regulations pertaining thereto), including without limitation: 

(i) the royalty-free, non-exclusive license granted to the U.S. government; and 

(ii) the requirement that any Products used or sold in the United States shall be manufactured substantially in the United States. 

4.2. Cystic Fibrosis and [***] Option. Subject to the terms and conditions of this Agreement, Company hereby
grants to Vertex and its Affiliates the option and right to terminate the covenant set forth in Section 4.7.2 with respect to Cystic Fibrosis and [***] (the “Option”) in accordance with the following: 

4.2.1. Cystic Fibrosis. Vertex’s Option with respect to Cystic Fibrosis may be exercised at any time prior to the date that
is [***] following the later of (a) the conclusion of the first two years of the Research Term or (b) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable); provided that, prior to
the exercise of the Option for Cystic Fibrosis, Vertex shall have the right to evaluate the Capsids in [***], and provided further, that if Vertex is so evaluating a Capsid(s) for Cystic Fibrosis on the date that is [***] following the later
of (a) or (b) above, or is scheduled to commence such evaluation within [***] thereafter, then the Option will expire upon the earlier of (i) [***] after Vertex’s receipt of the final data from such evaluation, or (ii) [***] following the
later of (A) the conclusion of the first two years of the Research Term or (B) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable) (such period, the “CF Option Exercise
Period”). Upon timely notice to Company during the CF Option Exercise Period that Vertex wishes to exercise the Option for Cystic Fibrosis and payment to Company of a one-time, non-refundable, non-creditable option exercise fee of [***] (the “CF Option Fee”), the covenant set forth in Section 4.7.2 with respect to Cystic
Fibrosis shall expire. For the avoidance of doubt, Vertex’s exercise of the Option for Cystic Fibrosis shall not affect Company’s obligation to conduct Research Activities with respect to Cystic Fibrosis in accordance with Section 2.1
during the first two years of the Research Term and during any applicable Research Extension for the Cystic Fibrosis Research Program, as applicable. If Vertex does not make a timely exercise of the Option for Cystic Fibrosis during the CF Option
Exercise Period, the Option for Cystic Fibrosis will lapse and the diagnosis, treatment and prevention of Cystic Fibrosis shall no longer be included in the Field, effective as of the conclusion of the CF Option Exercise Period, and any and all
rights granted hereunder by Company to Vertex with respect to Cystic Fibrosis as a Vertex Disease will revert automatically to Company, and all exclusivity obligations of Company and its Affiliates and successors under Section 4.7.1 with
respect to Cystic Fibrosis shall automatically terminate. 

  
 25 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.2.2. [***]. If at any time during the Research Term Company identifies a Capsid through
its Research activities ([***]) that meets the criteria for [***] set forth on Schedule 4.2.2(a), Company shall promptly (a) notify Vertex of such Capsid, (b) provide Vertex with a data package that contains, at a minimum, data
showing that such Capsid has satisfied the requirements set forth on Schedule 4.2.2(a) and the additional information set forth in Schedule 4.2.2(b) (an “Option Exercise Data Package”), and any other information
reasonably requested by Vertex with respect to such Capsid, and (c) allow Vertex to evaluate the Capsid for up to [***] in [***] in accordance with a study design and analysis plan selected by Vertex in its discretion. In addition, unless and
until Company identifies a Capsid that meets the criteria for [***] set forth on Schedule 4.2.2(a) and provides to Vertex an Option Exercise Data Package for such Capsid in accordance with the foregoing (a) and (b), Vertex shall have the
right to request an Option Exercise Data Package at any time during the Research Term with respect to any Capsid that [***], and to perform the evaluation activities set forth in the foregoing clause (c) with respect to such Capsid.
Vertex’s Option with respect to [***] may be exercised at any time after the Effective Date until the date that is [***] following the later of (i) delivery to Vertex of the complete Option Exercise Data Package with respect to a Capsid
that meets the criteria for [***] set forth on Schedule 4.2.2(a), or (ii) if Vertex elects to conduct an evaluation of a Capsid that meets the criteria for [***] set forth on Schedule 4.2.2(a), Vertex’s receipt of the final
data from such evaluation confirming [***] and satisfaction of such criteria as determined in accordance with Vertex’s study design and analysis plan. If Company does not identify a Capsid that meets the criteria for [***] set forth on
Schedule 4.2.2(a) prior to the conclusion of the Research Term and Vertex does not otherwise exercise its Option for [***] after receipt of an Option Exercise Data Package with respect to any other Capsid disclosed to Vertex pursuant to
Section 3.1.2(b), then Vertex’s Option with respect to [***] shall expire on the date that is [***] following the conclusion of the Research Term. Further, Vertex shall have the right to exercise the Option for [***] with respect to [***].
Upon timely notice to the Company that Vertex wishes to exercise the Option for [***]([***]) and payment to Company of a one-time, non-refundable, non-creditable option exercise fee of [***] ([***] Option Fee”), the covenant set forth in Section 4.7.2 with respect to [***] shall expire, either for all Modalities or the Modality selected by
Vertex pursuant to this Section 4.2.2, as applicable. If Vertex does not make a timely exercise of the Option for [***] with respect to one Modality, multiple Modalities or all Modalities, then the Option for [***] will lapse with respect to
such Modalities for which Vertex has not exercised its Option, and the diagnosis, treatment and prevention of [***] in such Modalities shall no longer be included in the Field, effective as of the date that the Option for [***] lapses, and any and
all rights granted hereunder by Company to Vertex with respect to [***] as a Vertex Disease will revert automatically to Company, and all exclusivity obligations of Company and its Affiliates and successors under Section 4.7.1 with respect to
[***] shall automatically terminate. 

  
 26 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.3. License Grant for Research Activities. Subject to the terms and
conditions of this Agreement, during the Research Term, (a) Vertex hereby grants to Company and its Affiliates a non-exclusive license in the Territory, with no right to grant sublicenses except to
permitted Subcontractors, (i) under any Vertex Background Technology or Vertex Agreement Technology necessary or useful to perform the Research Activities, to the extent actually disclosed by Vertex to Company, and (ii) under its and its
Affiliates’ interest in the Joint Agreement Technology, in each case, solely to perform any Research Activities under this Agreement, and (b) Company hereby grants to Vertex and its Affiliates a
non-exclusive license in the Territory, with no right to grant sublicenses except to permitted Subcontractors, (i) under any Licensed Technology or Company Agreement Technology necessary or useful to
perform the Research Activities, and (ii) under its and its Affiliates’ interest in the Joint Agreement Technology, in each case, solely to perform any Research Activities. 

4.4. Right of First Negotiation. In the event that any New Technology arises during [***], Vertex will have an exclusive right
of first negotiation for such New Technology in accordance with this Section 4.4, such right to be exercised on a New Technology-by-New Technology basis and on a
Vertex Disease-by-Vertex Disease basis. Company will provide written notice to Vertex of New Technology, which notice shall include a reasonably detailed description of
such New Technology, within [***] after (a) with respect to internally-developed New Technology, the earlier of [***], and (b) with respect to New Technology for which rights are acquired or licensed from a Third Party, [***] (a
“ROFN Notice”). Vertex will have a period of [***] from the date of receipt of such ROFN Notice (or, [***]) to notify Company in writing that Vertex desires to enter into negotiations with Company for the New Technology identified
in the applicable ROFN Notice. If Vertex so notifies Company during such [***], then, for the period commencing upon Company’s receipt of such notice from Vertex and continuing until [***] thereafter, such [***] period to be extendable by
mutual written agreement, the Parties will negotiate exclusively in good faith the terms (including financial terms) on which Company would grant a license to such New Technology to Vertex. If Company and Vertex agree on such terms within such
[***]-period, then such New Technology will be included as Licensed Technology hereunder, and subject to the terms and conditions of this Agreement and a written agreement (which may be in the form of an amendment to this Agreement) with respect to
the new financial terms and any other additional terms negotiated between Company and Vertex which will be applicable to the license of such New Technology to Vertex by Company. If Company and Vertex are unable to agree on such terms within such
[***]-period (as extended, as applicable), then Company will be free to continue the internal development of such New Technology, or to enter into negotiations with a Third Party with respect to such new Technology (as applicable), provided
that [***]. For the avoidance of doubt, Vertex shall have a right of first negotiation, as set forth in this Section 4.4, with respect to any New Technology that arises during the Term, regardless of [***]. For the avoidance of doubt, nothing
in this Section 4.4 shall limit the restrictions set forth in Section 4.7.1. Further, unless otherwise agreed to in writing by the Parties, any new agreement (or amendment to this Agreement) entered into with respect to the license of New
Technology pursuant to this Section 4.4 shall be limited to the Field. 

  
 27 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.5. Technology Transfer. 

4.5.1. Initial Transfers. Company will transfer to Vertex a copy of all Licensed
Know-How in its possession or Control as of the Effective Date pertaining to the AAV [***] Capsids and any other Capsid that is necessary or reasonably likely to be useful for the Research, Development,
Manufacture and Commercialization of Capsids and Products for DMD or DM1 including, for the avoidance of doubt, any and all relevant materials ([***]), and any documentation ([***]) or similar removable media ([***]), but excluding any Licensed Know-How comprising the Company Platform. Company will provide such Licensed Know-How to Vertex within [***] after the Effective Date; provided that, in accordance with
Section 11.3 (but without the need to provide notice required by such Section 11.3) such time period may be tolled if Company is unable to transfer such Licensed Know-How as a result of any Force
Majeure. Company will transfer to Vertex a copy of all Licensed Know-How in its possession or Control as of the date of the exercise of the Option with respect to Cystic Fibrosis or [***] (as applicable)
pertaining to any Capsid that is necessary or reasonably likely to be useful for the Research, Development, Manufacture and Commercialization of Capsids and Products for Cystic Fibrosis or [***] (as applicable) including, for the avoidance of doubt,
any and all relevant materials (e.g., [***]), and any documentation ([***]) or similar removable media ([***]), but in each case excluding any Licensed Know-How comprising the Company Platform. Company will
provide such Licensed Know-How to Vertex within [***] after the applicable Option exercise. 

4.5.2. Additional Transfers. Following the initial transfer described in Section 4.5.1, no more than [***], Company will
provide updates to Vertex regarding any newly acquired or generated Licensed Know-How pertaining specifically to the AAV [***] Capsids and [***] that are necessary or reasonably likely to be useful for the
Research, Development, Manufacture and Commercialization of DMD and DM1, and following the date on which Vertex exercises the Option for Cystic Fibrosis or [***], Cystic Fibrosis and [***] (as applicable) (but in each case excluding any Licensed Know-How comprising the Company Platform), and improved procedures for synthesis or manufacture of Capsids or Products. During the Term, as reasonably requested by Vertex, Company will promptly provide Vertex with
any specific information included in the Licensed Technology that is necessary or [***] for Vertex to Research, Develop, Manufacture or Commercialize Capsids or Products in the Field. 

4.5.3. Assistance by Company Personnel. To assist with the transfer of Licensed Know-How
under this Section 4.2 and Vertex’s exploitation thereof in accordance with the terms of this Agreement, Company will make its personnel reasonably available to Vertex during normal business hours to transfer such Licensed Know-How to Vertex and respond to Vertex’s inquiries with respect thereto. 
 4.6. No Implied
Licenses. Except as expressly provided in this Agreement, no Party will be deemed by estoppel or implication to have granted the other Party any licenses or other right with respect to any intellectual property. 

  
 28 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.7. Covenants. 

4.7.1. Exclusivity. Except in the performance of its obligations or exercise of its rights under this Agreement, neither Company
nor any of its Affiliates will work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to the discovery, research, development, manufacture or commercialization of any product using a
Modality for use in the treatment, prevention or diagnosis of a Vertex Disease; provided that the foregoing restrictions shall not apply with respect to (a) rights granted by Company as of the Effective Date pursuant to the Existing
Third Party Option, and (b) Company’s internal Research ([***]) and Manufacture of Capsids or Products for [***], unless and until Vertex exercises the Option for [***], in which case the foregoing restrictions on Company would be deemed
to apply to any Modalities for which Vertex has exercised such Options for [***]. The covenants set forth in this Section 4.7.1 shall expire with respect to all Vertex Diseases on [***], provided that such covenants may sooner expire
(i) with respect to Cystic Fibrosis and [***], if Vertex does not timely exercise the applicable Option, on the date that such Option expires pursuant to Section 4.2, and (ii) with respect to DMD and DM1 (and, following Option
exercise, Cystic Fibrosis and [***] (as applicable)), on a Vertex Disease-by-Vertex Disease [***] basis, upon the termination of the license granted to Vertex in
Section 4.1 with respect to such Vertex Disease and [***] as set forth in Section 2.6.2 or under the termination provisions of Article 9 of this Agreement. 

4.7.2. Cystic Fibrosis and [***]. Until such time as Vertex has paid to Company (a) with respect to Cystic Fibrosis, the CF
Option Fee, and (b) with respect to [***], the [***] Option Fee, Vertex shall not practice the Licensed Technology in the Territory to Research, Develop, Manufacture or Commercialize any Capsids or Products for Cystic Fibrosis or [***] (as
applicable), but shall, notwithstanding the foregoing, be permitted to practice the Licensed Technology solely for the limited purposes of (i) performing non-clinical, internal Research evaluation of
Capsids for Cystic Fibrosis and [***] pursuant to Sections 4.2.1 and 4.2.2, and (ii) conducting the Research Activities that are allocated to Vertex under the Research Program. The covenant as described herein shall apply to Vertex and its
Affiliates and shall be binding upon its and their respective successors and assigns until such time as the terms and conditions of this Section 4.7.2 are satisfied by the payment of the CF Option Fee or the [***] Option Fee, each as
applicable. 
 4.8. Acquisition of Distracting Product. Notwithstanding the provisions of Section 4.7, if Company or any
of its Affiliates acquires rights to research, develop or commercialize a Distracting Product in the Field as the result of a merger, acquisition or combination with or of a Third Party other than a Change of Control (each, an “Acquisition
Transaction”) and, on the date of the closing of such Acquisition Transaction, such Distracting Product is being researched, developed or commercialized and such activities would, but for the provisions of this Section 4.8, constitute
a breach of Section 4.7, Company or its Affiliate will, within [***] after the closing of such Acquisition Transaction notify Vertex in writing of such acquisition and either: 

(a) request that such Distracting Product be [***], in which case, the Parties will [***]; 

(b) notify Vertex in writing that Company or its Affiliate will Divest its rights to such Distracting Product, in which case, within [***],
Company or its Affiliate will Divest such Distracting Product; or 
 (c) notify Vertex in writing that it is ceasing all such research,
development and commercialization activities with respect to the Distracting Product, in which case, within [***], Company and its Affiliates will cease all such activities. 

  
 29 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 During the discussion period under clause (a), prior to the time of divestiture pursuant to clause
(b) or prior to the termination of activities pursuant to clause (c), as applicable, Company and its Affiliates will use Commercially Reasonable Efforts to segregate all research, development or commercialization activities relating to the
Distracting Product from Research, Development and Commercialization with respect to Capsids or Products under this Agreement, including Commercially Reasonable Efforts to ensure that (i) [***] and (ii) [***]. 

4.9. Change of Control. If there is a Change of Control involving Company (where Company is the acquired entity), the
obligations of Sections 4.7 will not apply to any Distracting Product that is controlled by the relevant acquirer or its Affiliates and that exists prior to the closing of such Change of Control; provided that [***]. 

ARTICLE 5. 
 FINANCIAL
PROVISIONS 
 5.1. Up-Front Fee. 

5.1.1. Initial Payment. Within [***] Business Days following the Effective Date, Vertex will pay to Company one half of the
Upfront Fee (equal to Twelve-Million, Five-Hundred Thousand US Dollars ($12,500,000)) payable by wire transfer of immediately available funds. 

5.1.2. Remainder. Company shall provide notice to Vertex promptly following Company’s determination in good faith that
Company’s employees have generally resumed on-site activities at Company’s facilities, which notice shall include a reasonably detailed description of the FTEs available to conduct Research
Activities under the Research Programs in accordance with this Agreement. Following Vertex’s receipt of such notice or any time after Company’s employees have generally resumed on-site activities at
Company’s facilities, Vertex shall notify Company after Vertex has substantially resumed its normal business operations, provided, however, [***]. Vertex shall pay the remaining one half of the Upfront Fee (equal to
Twelve-Million, Five-Hundred Thousand US Dollars ($12,500,000)) (the “Remainder”) within [***] Business Days after the earlier of Vertex providing notice to Company of its resumption of its operations as described in the preceding
sentence or Company providing notice of [***] as described in the preceding sentence by wire transfer of immediately available funds (the date of either such notice, the “Research Term Effective Date”). In the event that the
Research Term Effective Date [***], then Vertex shall [***]. 
 5.2. Milestone Payments. 

5.2.1. Research Milestones. Vertex will pay Company the milestone payments set forth in this Section 5.2.1 in accordance
with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event by Company in the case of milestone events 1, 2 or 3, or by Vertex (at Vertex’s sole cost) in the case of milestone event 4, in each case,
regardless of whether such milestone event is achieved during or after the Research Term or within or outside the Research Program, and regardless of whether achieved by a Capsid identified within or outside of the Research Program. [***] 

 

					
	 	 	 Milestone Event
	  	 Milestone Payment

	1	 	[***]	  	[***]
	2	 	[***]	  	[***]
	3	 	[***]	  	[***]
	4	 	[***]	  	[***]

  
 30 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.2.2. Development & Regulatory
Milestones. Vertex will pay Company the milestone payments set forth in this Section 5.2.2 in accordance with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event with respect to a Product
by Vertex or its Affiliates or any Sublicensees. Each milestone payment set forth below shall be payable [***] for the [***] Product for each Modality to achieve the relevant milestone event for each Vertex Disease (i.e., each milestone may be
achieved no more than [***] for each Vertex Disease). 
  

							
	 	  	 Milestone Event
	  	 Milestone Payment for each

of Cystic Fibrosis
 and
[***]
	  	 Milestone Payment for

each of DM1 and DMD
[***]

	5	  	[***]	  	[***]	  	[***]
	6	  	[***]	  	[***]	  	[***]
	7	  	[***]	  	[***]	  	[***]
	8	  	[***]	  	[***]	  	[***]
	9	  	[***]	  	[***]	  	[***]
	10	  	[***]	  	[***]	  	[***]

 5.2.3. Commercial Milestones. Vertex will pay Company the milestone payments set forth in this
Section 5.2.3 in accordance with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event by Vertex or its Affiliates or any Sublicensees whether such milestone event is achieved by Vertex or its
Affiliates or any of their Sublicensees. Each milestone payment set forth below shall be [***] (i.e., each milestone may be achieved no more than [***] for each Vertex Disease). 

 

					
	 Milestone Event
	  	 Milestone Payment for each

of Cystic Fibrosis and [***]
	  	 Milestone Payment for each

of DM1 and DMD [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 5.2.4. Notice; Payment; Skipped Milestones. Company will provide Vertex with written notice upon
the achievement of each of the milestone events 1-3 set forth in Section 5.2.1, and Vertex will provide Company with written notice upon the achievement of each of the milestone event 4 set forth in
Section 5.2.1 and the milestone events set forth in Section 5.2.2 and Section 5.2.3, such written notice, by each of Company and Vertex, to be provided (a) with respect to any milestone event under Section 5.2.1 or
Section 5.2.2, within [***] after such achievement and (b) with respect to any milestone event under Section 5.2.3, [***] to the date of delivery of the royalty report under Section 5.3.6 for the Calendar Quarter in which such
milestone event is first achieved. Following delivery of such written notice by Company with respect to milestone events 1-3 set forth in Section 5.2.1, or receipt of such written notice by Company with
respect to the milestone event 4 set forth in Section 5.2.1 or the milestone events set forth in Section 5.2.2 and Section 5.2.3, Company will promptly invoice Vertex for the applicable milestone and Vertex will make the appropriate
milestone payment within [***] after receipt of such invoice. Milestone payments corresponding with the milestones events [***] as set forth in Section 5.2.2 are intended to be successive; if a Product is not required to undergo an applicable
event associated with any such milestone event, such skipped milestone will be deemed to have been achieved [***]; provided that, the first achievement of any of milestone events [***] shall be deemed to trigger payment for milestones [***]
that have not, as of the date of such achievement with respect [***], been paid. Payment for any such skipped milestone that is owed in accordance with the provisions of the foregoing sentence with respect to [***] will be due [***]. 

  
 31 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.3. Royalties. 

5.3.1. Royalty Rates. Subject to Sections 5.3.2, 5.3.3, 5.3.4 and 5.3.5, on a Product-by-Product and country-by-country basis, Vertex will pay Company royalties based on the aggregate Net Sales of each
Product sold by Vertex, its Affiliates or Sublicensees in the Field in the Territory during a Calendar Year at the rates set forth in the table below. The obligation to pay royalties will be imposed only once with respect to the same unit of a
Product. 
  

			
	 Calendar Year Net Sales (in Dollars)

for such Product in the Territory
	  	 Royalty Rates as a Percentage

(%) of Net Sales

	Portion of Calendar Year Net Sales [***]	  	[***]
	Portion of Calendar Year Net Sales [***]	  	[***]
	Portion of Calendar Year Net Sales [***]	  	[***]

 5.3.2. Royalty Term. Vertex will pay royalties to Company under this Section 5.3 on a Product-by-Product and a country-by-country basis during the Royalty Term. Upon the expiration
of the Royalty Term for a given Product in a given country, the license granted to Vertex under Section 4.1.1 will become fully-paid, perpetual and irrevocable with respect to such Product. 

5.3.3. Reduction for Lack of Patent Coverage. If during any period within the applicable Royalty Term for a country, no Valid
Claim of a Licensed Patent exists that would, but for the licenses granted herein, be infringed by the [***] in such country, Net Sales of such Product in such country will be reduced [***] for purposes of calculating the royalty owed under
Section 5.3.1. 
 5.3.4. Reduction for Competition. If during any Calendar Quarter during the Royalty Term for a Product
in a given country, the aggregate number of units of Competitive Products with respect to such Product sold during such Calendar Quarter in such country [***] of the aggregate units of the sum of all such Competitive Products and such Product sold
in such Calendar Quarter in such country, then Net Sales of such Product in such country (after any applicable reduction pursuant to Section 5.3.3) will be reduced by [***] for purposes of calculating the royalty owed under Section 5.3.1.

  
 32 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.3.5. Third Party Licenses. In the event that, with respect to a Product in a
country, [***], then Vertex may deduct from the royalties payable to Company under this Section 5.3, [***] of all such Blocking Third Party Intellectual Property Costs paid by Vertex; provided, however, that in no event will the
royalties that would otherwise be payable to Company with respect to Net Sales of Products, after any applicable reduction to such Net Sales under Sections 5.3.3 and 5.3.4, be reduced [***] in any given Calendar Quarter as a result of any deduction
under this Section 5.3.5; and provided further, that Vertex will be entitled to carry forward to subsequent Calendar Quarters any amounts with respect to which Vertex would have been entitled to make a deduction pursuant to this
Section 5.3.5 but is unable to take such deduction pursuant to the first proviso in this Section 5.3.5. 
 5.3.6. Aggregate
Limitation on Deductions. Notwithstanding Sections 5.3.3, 5.3.4, and 5.3.5, in no event will the combined effect of all reductions to the royalties payable to Company under Sections 5.3.3, 5.3.4 and 5.3.5 reduce the royalty payable by Vertex
to Company under this Section 5.3 for any Product in any country during a Calendar Quarter to [***] of the amount that would otherwise be due under Section 5.3.1, but for such deductions; provided that, if in a particular Calendar
Quarter, Vertex is entitled to a royalty reduction under both Sections 5.3.3 and 5.3.4, then the royalty payable by Vertex to Company under this Section 5.3 for any Product in any country for such Calendar Quarter may be reduced [***] of the
amount that would otherwise be due under Section 5.3.1; and provided further, that Vertex shall have the right to apply any uncredited reduction in royalties to any subsequent Calendar Quarter until such reduction is fully realized. 

5.3.7. Royalty Reports. Following the first sale of a Product giving rise to Net Sales and continuing for the remainder of the
Royalty Term for such Product, within [***] after the end of each Calendar Quarter, Vertex will deliver a report to Company specifying on a Product-by-Product and country-by-country basis: (a) Net Sales in the relevant Calendar Quarter; (b) to the extent such Net Sales include sales not denoted in US Dollars, a summary of the
then-current exchange rate methodology then in use by Vertex, and (c) royalties payable on such Net Sales. All royalty payments due under Section 5.3 for each Calendar Quarter will be due and payable within [***] after the end of each
Calendar Quarter. 
 5.4. Payments Owed Under Company In-License Agreements. Except as
set forth in Section 5.5, any payment obligations arising under the Company In-License Agreements as a result of the Research, Development, Manufacture and Commercialization of a Product by or on behalf
of Vertex under this Agreement will be paid solely by Company. In the event that Vertex enters into a direct license with the licensor under any Company In-License Agreement following a termination of such
Company In-License Agreement, then Vertex may deduct [***] due to such licensor under any such direct license from any payments owed to Company hereunder ([***]), provided that, such deductions shall be
subject to the limitation on aggregate deductions set forth in Section 5.3.6, except with respect to [***], for which no such limitation on aggregate deductions shall apply. 

  
 33 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.5. New Company Agreements. 

5.5.1. Company may, during the Term, acquire or in-license rights to additional intellectual property
that is related to a Capsid and is necessary [***] to Research, Develop, Manufacture or Commercialize Products in the Field and that, if solely owned by Company, without any encumbrance or restriction on licensing, [***] (such agreements, the
“Proposed New Company Agreements”), provided that, [***], and provided further that, the Agreement has not been terminated with respect to the applicable Vertex Disease. In the event that [***], Company [***] a Proposed New
Company Agreement, Company shall so notify Vertex [***] with respect to the applicable Vertex Disease(s) within the Field pursuant to such Proposed New Company Agreement, and the terms that would be applicable to Vertex, [***], if the intellectual
property rights to be acquired or in-licensed within the Field pursuant to such Proposed New Company Agreement [***]. Company shall use [***] to include in any such Proposed New Company Agreement a provision
[***]. Company shall provide Vertex with [***] such Proposed New Company Agreement, [***], sufficiently [***]. Vertex may [***], and Company shall [***] the Proposed New Company Agreement. For the avoidance of doubt, Company will control the
negotiations with the Grantor with respect to the Proposed New Company Agreement. Any Proposed New Company Agreement shall be [***] under this Agreement. 

5.5.2. Promptly following execution of a Proposed New Company Agreement, Company shall provide to Vertex [***] of such Proposed New Company
Agreement with [***] thereunder (a “Licensee”) and [***] subject to the applicable Proposed New Company Agreement. Company and Vertex will discuss in good faith to determine whether Vertex will take a license or sublicense (as the case may
be) under all or a portion of the intellectual property rights that are the subject of such Proposed New Company Agreement and if so, Company and Vertex will enter into a written agreement setting forth the terms under which Vertex will take such
license or sublicense. Following such written agreement, subject to the terms of such Proposed New Company Agreement that are applicable to a Licensee thereunder, such intellectual property rights described in such notice shall [***] (any such
Proposed New Company Agreement with respect to intellectual property rights that are [***] pursuant to this sentence, a “New Company Agreement”). Any payment obligations arising under the New Company Agreements directly as a result
of the Research, Development, Manufacture or Commercialization of a Product in the Field by or on behalf of Company, Vertex, or any of their respective Affiliates or Vertex’s Sublicensees, after application of all available reductions to and
deductions from such payment obligations under the applicable New Company Agreement (but, for the avoidance of doubt, [***]), will be paid by Company and reimbursed by Vertex in accordance with this Section 5.5 and the written agreement
described above, and Company shall be responsible for all other payment obligations under such agreements ([***]). Company shall provide Vertex with a reasonably detailed invoice for any reimbursable payments made by Company pursuant to this
Section 5.5.2 within [***] of the end of each Calendar Quarter in which any such payments were made by Company, and Vertex shall pay the undisputed portion of such invoices within [***] of receipt thereof. For clarity, Vertex and its Affiliates
will be obligated to reimburse a given amount owed under a New Company Agreement one time only. Notwithstanding the foregoing, Vertex may, at its sole discretion, notify Company that it elects to abandon its payment obligations under this
Section 5.5.2 with respect to a New Company Agreement, whereupon such New Company Agreement, as applicable, shall be deemed not to be a New Company Agreement, as applicable, under this Agreement. Except as otherwise provided in this Agreement,
as between the Parties, Company shall be responsible for all payments in connection with this Agreement, including with respect to the Research, Development, Manufacture and Commercialization of Products, that arise under any license or other
agreement to which Company or its Affiliate is a party, including any New Company Agreement. The provisions of Section 5.6 shall apply to such amounts paid or payable by Vertex, mutatis mutandis. 

  
 34 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.6. Payment Terms. 

5.6.1. Currency; Payment Method. All payments under this Agreement are expressed in U.S. Dollars and will be paid in U.S.
Dollars, by wire transfer or Automated Clearing House (ACH) payment to an account designated by Company (which account Company may update from time to time in writing). 

5.6.2. Exchange. If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any
calculations to be performed under this Agreement are denoted in a currency other than U.S. Dollars, such amounts will be converted to their U.S. Dollar equivalent using [***], including [***] or, in the case of Sublicensees, such similar
methodology, consistently applied. Calculation of Net Sales will exclude [***]. 
 5.7. Withholding Tax. Where any sum due to
be paid to Company hereunder is subject to any withholding or similar tax, Vertex will pay such withholding or similar tax to the appropriate Governmental Authority and deduct the amount paid from the amount then due to Company. Vertex will timely
transmit to Company an official tax certificate or other evidence of such withholding sufficient to enable Company to claim such payment of taxes. The Parties will cooperate with one another and use reasonable efforts to reduce or eliminate tax
withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Vertex to Company under this Agreement. Company will provide Vertex any tax forms that may be reasonably necessary in order for Vertex not to
withhold tax or to withhold tax at a reduced rate under an applicable income tax treaty. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes,
or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. 

5.8. Records; Audits. Vertex will keep and maintain accurate and complete records regarding Net Sales during the [***] preceding
Calendar Years. Upon [***] prior written notice from Company, Vertex will permit an independent certified public accounting firm of internationally recognized standing, selected by Company and reasonably acceptable to Vertex, to examine the relevant
books and records of Vertex and its Affiliates, as may be reasonably necessary to verify the royalty reports submitted by Vertex in accordance with Section 5.3.7. An examination by Company under this Section 5.8 will occur not more than
[***] in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm will be provided access to such books and records at Vertex’s
facility or facilities where such books and records are normally kept and such examination will be conducted during Vertex’s normal business hours. Vertex may require the accounting firm to sign a customary
non-disclosure agreement before providing the accounting firm access to its facilities or records. Upon completion of the audit, the accounting firm will provide to both Parties a written report disclosing
whether the reports submitted by Vertex are correct or incorrect and the specific details concerning any discrepancies. No other information will be provided to Company. If the report or information submitted by Vertex results in an underpayment or
overpayment, the Party owing the underpaid or overpaid amount will promptly pay such amount to the other Party. The costs and fees of any audit conducted by Company under this Section 5.8 will be borne by Company, unless such audit reveals an
underpayment of amounts owed to Company of more than [***] of the amount that was owed by Vertex with respect to the relevant period, in which case, Vertex will reimburse Company for the reasonable expense incurred by Company in connection with the
audit. 

  
 35 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY 
BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 5.9. Late Payment. Any payments or portions thereof due hereunder that are not
paid when due will accrue interest from the date due until paid at [***]. 
 ARTICLE 6. 

INTELLECTUAL PROPERTY 

6.1. Ownership of Agreement Technology. For purposes of determining ownership under this Section 6.1, except as expressly
set forth in this Section 6.1, ownership will be determined in accordance with inventorship, and inventorship will be determined in accordance with United States patent laws (regardless of where the applicable activities occurred). 

6.1.1. Company Agreement Technology. As between the Parties, Company will be the sole owner of any and all Agreement Know-How, whether created solely by a Party or jointly by the Parties, (a) that is not included in the Vertex Agreement Know-How, and (b) to the extent specifically
relating to (i) any Capsid or (ii) the Company Platform (“Company Agreement Know-How”) and any Patents that Cover such Know-How
(“Company Agreement Patents” and together with the Company Agreement Know-How, the “Company Agreement Technology”), and will retain all of its rights thereto, subject to any
rights or licenses expressly granted by Company to Vertex under this Agreement. For the avoidance of doubt, Company Inventions arising out of the MTA shall be deemed Company Agreement Know-How hereunder.
Company will promptly disclose to Vertex in writing, and will cause its Affiliates to so disclose, the discovery, development, invention or creation of any Company Agreement Know-How or Company Agreement
Patent under this Agreement, excluding any Company Agreement Know-How or Company Agreement Patents that comprise the Company Platform. 

6.1.2. Vertex Agreement Technology. As between the Parties, Vertex will be the sole owner of any and all Agreement Know-How, whether created solely by a Party or jointly by the Parties, (a) that is specific to a Vertex Disease, or (b) to the extent specifically relating to an improvement to the Vertex Background
Technology, in each case ((a) and (b)), to the extent that such Know-How is not an improvement to or a further development or modification of the Company Platform (the “Vertex Agreement Know-How”) and any Patents that Cover Vertex Agreement Know-How (“Vertex Agreement Patents” and together with the Vertex Agreement Know-How, the “Vertex Agreement Technology”), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Vertex to Company under this Agreement. For the
avoidance of doubt, Vertex Inventions arising out of the MTA shall be deemed Vertex Agreement Know-How hereunder. Vertex hereby grants to Company a worldwide,
non-exclusive, fully paid-up, sublicenseable (through multiple tiers) royalty-free license under the Vertex Agreement Technology that relates to any Capsid for use in
any and all diseases that are not Vertex Diseases for which Vertex continues to maintain exclusive license rights in force under this Agreement. 

  
 36 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.1.3. Joint Agreement Technology. Any and all Agreement Know-How developed, invented or created jointly by (a) Vertex, its Affiliates or Third Parties acting on its or their behalf and (b) Company, its Affiliates or Third Parties acting on its or their behalf,
in each case ((a) and (b)), (i) in the performance of activities under this Agreement (including in any meeting of the JRC) and (ii) to the extent not included in the Company Agreement Know-How or the
Vertex Agreement Know-How (such Know-How, “Joint Agreement Know-How”), and any Patents that claim or cover such
Joint Agreement Know-How (“Joint Agreement Patents,” and together with the Joint Agreement Know-How, the “Joint Agreement Technology”),
will be owned jointly by Vertex and Company on an equal and undivided basis, including all rights thereto, subject to any rights or licenses expressly granted by one Party to the other Party under this Agreement. For the avoidance of doubt, the
Results arising from the MTA shall be deemed Joint Agreement Know-How hereunder. Except as expressly provided in this Agreement, neither Party will have any obligation to account to the other for profits with
respect to, or to obtain any consent of the other Party to license or exploit, Joint Agreement Technology by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such
consent or accounting. 
 6.2. Prosecution and Maintenance of Patents. 

6.2.1. Company Agreement Patents; Company Platform. As between the Parties, and subject to the expressly stated rights of Lonza
or MEE under the Lonza/MEE 3-Way Agreement as applicable, Company will have the sole right, at Company’s expense, to control the Prosecution and Maintenance of the Patents (a) within the Company
Agreement Patents, other than those Company Agreement Patents that are included within the Licensed Patents for which Vertex has the first right to Prosecute and Maintain pursuant to Section 6.2.3, and (b) that claim the Company Platform.

 6.2.2. Vertex Agreement Patents. As between the Parties, Vertex will have the sole right, at Vertex’s expense, to
control the Prosecution and Maintenance of the Vertex Agreement Patents. 
 6.2.3. Licensed Patents and Joint Agreement
Patents. As between the Parties, Vertex will have the first right, at Vertex’s expense, to control the Prosecution and Maintenance of the Licensed Patents (other than any Licensed Patents that claim the Company Platform) and Joint
Agreement Patents, using counsel reasonably acceptable to Company (and to MEE as applicable with respect to the Licensed Patents); provided that, the Parties acknowledge [***]. Vertex agrees to keep Company reasonably informed with respect to
such Prosecution and Maintenance and consult in good faith with Company regarding such matters. If Vertex decides to abandon a Licensed Patent or Joint Agreement Patent, Vertex will provide Company with notice at least [***] prior to the date such
abandonment would become effective. Following such notice, Company may elect, upon written notice to Vertex, to control the Prosecution and Maintenance of such Patent at its own expense in Company’s name. Upon such election, Vertex will
cooperate and assist in transitioning the Prosecution and Maintenance of such Patent to Company, Company agrees to keep Vertex reasonably informed with respect to such Prosecution and Maintenance and consult in good faith with Vertex regarding such
matters. 

  
 37 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.2.4. Cooperation. Vertex and Company will obtain the cooperation of their
respective employees or obligated Third Parties that are inventors in the Prosecution and Maintenance directed to any inventions that may arise hereunder. 

6.3. Defense of Claims Brought by Third Parties. If any Third Party brings a claim or otherwise asserts that a Product or Capsid
infringes such Third Party’s Patent or misappropriates such Third Party’s Know-How (each, a “Third-Party Infringement Claim”), the Party first having notice of the claim or assertion
will promptly notify the other Party in writing. Subject to Section 8.1.2, and subject to the expressly stated rights of Lonza or MEE under the Lonza/MEE 3-Way Agreement as applicable with respect to any
Third Party Infringement Claim brought against Company, Vertex will have the sole right to undertake and control the defense or settlement of any Third-Party Infringement Claim using counsel of its choice, at its cost and expense. If Company is
named as a defendant in such suit, Company will have the right to participate in such defense and settlement with its own counsel, at its cost. Vertex will not enter into any settlement of any Third-Party Infringement Claim that is instituted or
threatened to be instituted against Company without Company’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; except that, such consent will not be required if such settlement includes a release of
all liability in favor of Company or an assumption of any unreleased liability by Vertex. As requested by Vertex, Company will provide reasonable cooperation and assistance to Vertex in connection with Vertex’s control of the defense or
settlement of a Third-Party Infringement Claim. Such cooperation and assistance will include executing all necessary and proper documents and taking such actions as will be appropriate to allow Vertex to control the defense and settlement of such
Third-Party Infringement Claim. Vertex will reimburse Company for the reasonable Out-of-Pocket Costs incurred by Company in providing such assistance and cooperation;
except that Vertex will have no obligation to reimburse Company for any costs or expenses incurred if Company exercises its right to participate in the defense and settlement of a Third-Party Infringement Claim with its own counsel. Vertex
will keep Company reasonably informed of the progress of any Third Party Infringement Claim. To the extent reasonable, both Parties will cooperate in good faith to (a) ensure that Vertex has the ability to continue to commercialize Products and
(b) avoid or minimize any additional royalties on Products. 
 6.4. Enforcement of Patents Against Competitive
Infringement. 
 6.4.1. Duty to Notify of Competitive Infringement. If either Party learns of an infringement,
unauthorized use, misappropriation or threatened infringement by a Third Party with respect to any Licensed Technology by reason of the making, using, offering to sell, selling or importing of a compound or product that would be competitive with a
Capsid or Product in the Field in the Territory (a “Competitive Infringement”), such Party will promptly notify the other Party in writing and will provide such other Party with available information regarding such Competitive
Infringement. 

  
 38 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.4.2. Enforcement. Subject to the expressly stated rights of Lonza or MEE
under the Lonza/MEE 3-Way Agreement as applicable, Vertex will have the first right, but not the obligation, to institute, prosecute, and control a Proceeding to enforce the Licensed Technology (excluding any
Patents that are included in the Company Platform, for which Company will have the sole enforcement right) with respect to any Competitive Infringement by counsel of its own choice, at its own expense. If Vertex fails to initiate a Proceeding within
[***] after written notice of such Competitive Infringement is first provided by a Party under Section 6.4.1, Company will have the right to initiate and control a Proceeding with respect to such Competitive Infringement by counsel of its own
choice, at its own expense and Vertex will have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, that if Vertex notifies Company during such [***] period that it is electing in good
faith not to institute any Proceeding against such Competitive Infringement for strategic reasons, Company will not have the right to initiate and control any Proceeding with respect to such Competitive Infringement. The Party prosecuting and
controlling any such Proceeding will (a) keep the other Party reasonably apprised of the progress of such Proceeding, (b) reasonably consider the other Party’s comments with respect to the conduct of such Proceeding and (c) not
enter into a settlement, consent judgment or other voluntary final disposition of a Proceeding that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue, or similar immunity that has
an adverse effect on the other Party’s rights hereunder without the other Party’s prior written consent, not to be unreasonably withheld. 

6.4.3. Joinder. 

(a) If a Party initiates a Proceeding in accordance with this Section 6.4, the other Party agrees to be joined as a party plaintiff
where necessary and to give the first Party reasonable assistance and authority to file and prosecute the Proceeding. Subject to Section 6.4.4, the costs and expenses of each Party incurred pursuant to this Section 6.4.3(a) will be borne
by the Party initiating such Proceeding. 
 (b) If one Party initiates a Proceeding in accordance with this Section 6.4, the other
Party may join such Proceeding as a party plaintiff where necessary for such other Party to seek lost profits with respect to such infringement. 

6.4.4. Share of Recoveries. Any damages or other monetary awards recovered with respect to a Proceeding brought pursuant to this
Section 6.4 will be shared as follows: 
 (a) the amount of such recovery will first be applied to the Parties’ reasonable Out-of-Pocket Costs incurred in connection with such Proceeding (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses); then

 (b) any remaining proceeds [***] will be [***]; provided that [***]; and 

(c) any remaining proceeds [***] will be [***]. 

6.4.5. Settlement. Notwithstanding anything to the contrary under this ARTICLE 6, neither Party may enter a settlement, consent
judgment or other voluntary final disposition of a suit under this ARTICLE 6 that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue or similar immunity under a Patent Controlled by
the other Party or its Affiliates without first obtaining the written consent of the Party that Controls the relevant Patent; provided, that the foregoing restriction will not apply with respect to any Sublicense granted by Vertex. 

  
 39 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.5. Other Infringement. 

6.5.1. Joint Agreement Patents. With respect to the infringement of a Joint Agreement Patent that is not a Competitive
Infringement, neither Party shall enforce any Joint Agreement Patent unless mutually agreed by the Parties, provided that the Parties will cooperate in good faith to bring suit together against such infringing party or the Parties may decide to
permit one Party to solely bring suit. Any damages or other monetary awards recovered with respect to a Proceeding brought pursuant to this Section 6.5.1 will be shared as follows: [***]. 

6.5.2. Patents Solely Owned by Company. Subject to the expressly stated rights of Lonza or MEE under the Lonza/MEE 3-Way Agreement as applicable, Company will retain all rights to pursue an infringement of any Patent solely owned by Company that is not a Competitive Infringement and Company will retain all recoveries with
respect thereto. 
 6.5.3. Patents Solely Owned by Vertex. Vertex will retain all rights to pursue an infringement of any
Patent solely owned by Vertex and Vertex will retain all recoveries with respect thereto. 
 6.6. Patent Listing. Vertex will
have the sole right, but not the obligation, to submit to all applicable Regulatory Authorities patent information pertaining to each applicable Product pursuant to 21 U.S.C. § 355(b)(1)(G), any similar statutory or regulatory requirement
enacted in the future regarding biologic products, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction. Vertex shall consult with Company reasonably in
advance of any such submission, and shall reasonably consider Company’s and Licensors’ (as defined in the MEE/Lonza 3-Way Agreement) comments with respect thereto (it being understood that Company
may disclose to Licensors Vertex’s intention regarding such submission for purposes of obtaining Licensors’ comments, if any, with respect thereto). 

6.7. Common Ownership Legislation. Notwithstanding anything to the contrary in this ARTICLE 6, neither Party will have the right
to make an election under the Common Ownership Legislation when exercising its rights under this ARTICLE 6 without the prior written consent of the other Party, which will not be unreasonably withheld, conditioned or delayed. With respect to any
such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a
“joint research agreement” as defined in the Common Ownership Legislation. Notwithstanding the foregoing, the other Party’s consent under this Section 6.7 will not be required in connection with an obviousness-type double
patenting rejection in any patent application claiming a Capsid, Product, or uses thereof. 
 6.8. Patent Term Extension.
Vertex will be solely responsible for obtaining patent term restoration in any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. § 156, where applicable to a Product. Vertex will determine which
relevant patents will be extended (including, without limitation, by filing supplementary protection certificates and any other extensions that are now or in the future become available). Company will abide by Vertex’s determination and
cooperate, as reasonably requested by Vertex, in connection with the foregoing (including by providing appropriate information and executing appropriate documents). Vertex shall consult with Company reasonably in advance of making any such patent
term extension determination, and shall reasonably consider Company’s and Licensors’ (as defined in the MEE/Lonza 3-Way Agreement) comments with respect thereto (it being understood that Company may
disclose to Licensors Vertex’s intention regarding such determination for purposes of obtaining Licensors’ comments, if any, with respect thereto). 

  
 40 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.9. Recording. If Vertex deems it necessary or desirable to register or
record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, Company will reasonably cooperate to execute and deliver to Vertex any documents
accurately reflecting or evidencing this Agreement that are necessary or desirable, in Vertex’s reasonable judgment, to complete such registration or recordation. Vertex will reimburse Company for all reasonable
Out-of-Pocket Costs, including attorneys’ fees, incurred by Company in complying with the provisions of this Section 6.9. 

6.10. Unitary Patent System. Vertex will have the exclusive right to opt-in or opt-out of the EU Unitary Patent System for all Licensed Patents, Joint Agreement Patents and Vertex Agreement Patents. For clarity, “to opt-in or opt-out” refers to both the right to have or have not a European patent application or an issued European patent registered to have unitary effect within the meaning of Regulation (EU) No 1257/2012 of
December 17, 2012 as well as the Agreement on a Unified Patent Court as of February 19, 2013; and to the right to opt-in or opt-out from the exclusive
competence of the Unified Patent Court in accordance with Article 83(3) of that Agreement on a Unified Patent Court. Without limiting the generality of the foregoing, unless a Party or its Affiliate has expressly opted in to the EU Unitary Patent
System with respect to a given Patent, the other Party will not initiate any action under the EU Unitary Patent System without such Party’s prior written approval, such approval to be granted or withheld in such Party’s sole discretion.

 6.11. Trademarks. As between the Parties, all trademarks and trade dress rights used in connection with the
Commercialization of the Products in the Field in the Territory will be owned exclusively by Vertex. 
 ARTICLE 7. 

REPRESENTATIONS AND WARRANTIES 

7.1. Representations and Warranties of Vertex. Vertex hereby represents and warrants to Company, as of the Effective Date, that:

 (a) Vertex is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization; 
 (b) Vertex (i) has the requisite power and authority and the legal right to enter into this Agreement and to perform
its obligations hereunder, and (ii) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

(c) this Agreement has been duly executed and delivered on behalf of Vertex, and constitutes a legal, valid and binding obligation,
enforceable against Vertex in accordance with the terms hereof; 

  
 41 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) the execution, delivery and performance of this Agreement by Vertex will not constitute
a default under or conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over Vertex; and 
 (e) Vertex has obtained all necessary consents, approvals and authorizations of all Governmental
Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement. 

7.2. Representations and Warranties of Company. Company hereby represents and warrants to Vertex, as of the Effective Date,
that: 
 (a) it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization; 
 (b) it (i) has the requisite power and authority and the legal right to enter into this Agreement and to perform its
obligations hereunder, including the right to grant a sublicense to Vertex under the Licensed Technology pursuant to the Company In-License Agreements existing as of the Effective Date, and (ii) has taken
all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

(c) this Agreement has been duly executed and delivered on behalf of Company, and constitutes a legal, valid and binding obligation,
enforceable against it in accordance with the terms hereof; 
 (d) the execution, delivery and performance of this Agreement by Company
will not constitute a default under or conflict with any agreement (including any Company In-License Agreement existing as of the Effective Date), instrument or understanding, oral or written, to which it is a
party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 

(e) it has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities
required to be obtained by it in connection with the execution and delivery of this Agreement; 
 (f) the Licensed Technology constitutes
all of the Patents and Know-How owned by or licensed to Company or its Affiliates that are necessary or useful to Research, Develop, Manufacture or Commercialize Capsids and Products in the Field, and as of
the Effective Date, Company has provided to Vertex all material information and data concerning the Licensed Technology; 
 (g) Company is
the exclusive licensee or sublicensee of the Licensed Technology within the Field, all of which are free and clear of any liens, charges and encumbrances, and, as of the Effective Date, neither any license granted by Company or its Affiliates to any
Third Party, nor any agreement between any Third Party and Company or its Affiliates conflicts with the license grants to Vertex hereunder and Company is entitled to grant all rights and licenses (or sublicenses, as the case may be) under the
Licensed Technology within the Field that it purports to grant to Vertex under this Agreement; 

  
 42 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (h) (i) Company Controls the AAV [***] Capsids to the extent necessary to grant the
licenses to Vertex hereunder for the diagnosis, treatment or prevention of DMD, DM1, Cystic Fibrosis and [***], and the Ancestral Libraries for the diagnosis, treatment or prevention of Cystic Fibrosis, DM1 and [***], and (ii) neither Company
nor Lonza nor MEE has granted any right or license, or option to acquire any right or license, to the Third Party Optionee under the AAV [***] Capsids for the diagnosis, treatment or prevention of DMD, DM1, Cystic Fibrosis or [***]; 

(i) Schedule 1.94 sets forth a true, correct and complete list of all Licensed Patents as of the Effective Date and indicates whether
each such Patent is owned by Company or licensed by Company from a Third Party and if so, identifies the licensor or sublicensor from which the Patent is licensed; 

(j) the Licensed Know-How is free and clear of liens, charges or encumbrances other than licenses
granted to Third Parties that are not inconsistent with the rights and licenses granted to Vertex hereunder; 
 (k) to its Knowledge, the
Licensed Patents, are, or, upon issuance, will be, valid and enforceable patents and no Third Party (i) is infringing any such Patents or (ii) has challenged the extent, validity or enforceability of such Patents (including by way of
example through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

(l) to its Knowledge, [***] with respect to any such Patents for which it controls Prosecution and Maintenance; 

(m) it has obtained assignments from the inventors of all inventorship rights relating to the Licensed Patents, and all such assignments of
inventorship rights relating to such Patents are valid and enforceable; 
 (n) except for the Company
In-License Agreements, there are no agreements between Company or any of its Affiliates and any Third Party pursuant to which Company or its Affiliate has acquired Control of any of the Licensed Technology,
and no Third Party has any right, title or interest in or to, or any license under, any of the Licensed Technology within the Field. All Company In-License Agreements are in full force and effect and have not
been modified or amended. Neither Company nor its Affiliates nor, to the best of its Knowledge, the Third Party licensor in an Company In-License Agreement is in default with respect to a material obligation
under such Company In-License Agreement in connection with this Agreement, and neither such party has claimed or has grounds upon which to claim that the other party is in default with respect to a material
obligation under, any Company In-License Agreement in connection with this Agreement; 
 (o) this
Agreement [***]; 

  
 43 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (p) Company and its Affiliates have [***]; 

(q) no Licensed Technology is subject to any funding agreement with any government or governmental agency; 

(r) to its Knowledge, [***]; 

(s) there are no judgments or settlements against or owed by Company or its Affiliates or, to its Knowledge, pending or threatened claims or
litigation, in either case relating to the Licensed Technology; 
 (t) there is no action, claim, demand, suit, proceeding, arbitration,
grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the best of its Knowledge, threatened against Company, any of its Affiliates or any Third
Party, in each case in connection with the Licensed Technology or relating to the transactions contemplated by this Agreement; and 
 (u)
Company has not employed (and, to the best of its Knowledge, has not used a contractor or consultant that has employed) any Person debarred by the FDA (or subject to a similar sanction of EMA or foreign equivalent), or any Person that is the subject
of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent), in any capacity in connection with this Agreement. 

7.3. Company Covenants. Company hereby covenants to Vertex that, except as expressly permitted under this Agreement: 

(a) Company will, and will require its Affiliates and Subcontractors to, comply with all Applicable Law in its and their conduct of the
Research Activities, including where appropriate GMP, GCP and GLP (or similar standards); 
 (b) Company will maintain and not breach, and
will cause its Affiliates to maintain and not breach, any Company In-License Agreements in connection with this Agreement; 

(c) Company will promptly notify Vertex in writing of any material breach by Company or its Affiliate or a Third Party of any Company In-License Agreements, and in the event of a breach by Company or its Affiliate, will permit Vertex to cure such breach on Company’s or its Affiliate’s behalf upon Vertex’s request; 

(d) Company will not, and will cause its Affiliates not to, amend, modify or terminate any Company
In-License Agreement in a manner that would adversely affect Vertex’s rights hereunder within the Field without first obtaining Vertex’s written consent, which consent may be withheld in
Vertex’s sole discretion; 
 (e) neither Company nor any of its Affiliates will effect any corporate restructuring or enter into any
new agreement or otherwise obligate itself to any Third Party, or amend an existing agreement with a Third Party, in each case, in a manner that restricts, limits, or encumbers the rights granted to Vertex under this Agreement; 

  
 44 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (f) Company will have, as of the Research Term Effective Date, and will maintain for the
duration of the Term, the requisite resources and expertise to perform its obligations hereunder with respect to the Research Programs; 

(g) Company will not, and will cause its Affiliates not to (i) license, sell, assign or otherwise transfer to any Person any Licensed
Technology (or agree to do any of the foregoing), or (ii) incur or permit to exist, with respect to any Licensed Technology, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other
restriction (including in connection with any indebtedness), in each case, that would conflict with, limit, [***] the rights and licenses granted to Vertex hereunder; 

(h) all employees and Subcontractors of Company performing Research Activities hereunder on behalf of Company will be [***], to Company as
the sole owner thereof; 
 (i) in the event of a termination of the Amended and Restated Lonza-MEE
Agreement during the Term, Company will timely request that MEE enter into a direct license with Company in accordance with Section 11.5.6 of the Lonza/MEE 3-Way Agreement; 

(j) Company will not engage directly or indirectly, in any capacity in connection with this Agreement any Person who either has been debarred
by the FDA, is the subject of a conviction described in Section 306 of the FD&C Act or is subject to any such similar sanction; and 

(k) Company will inform Vertex in writing promptly if it or any Person engaged by Company or any of its Affiliates who is performing services
under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FD&C Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to
Company’s knowledge, is threatened, relating to the debarment or conviction of Company, any of its Affiliates or any such Person performing services hereunder or thereunder. 

7.4. Disclaimer. 

7.4.1. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. VERTEX AND COMPANY UNDERSTAND THAT EACH CAPSID AND PRODUCT IS THE SUBJECT OF ONGOING RESEARCH AND DEVELOPMENT AND THAT
NEITHER PARTY CAN ASSURE THE SAFETY, USEFULNESS OR COMMERCIAL OR TECHNICAL VIABILITY OF ANY CAPSID OR PRODUCT. 
 7.4.2. Vertex acknowledges
that the licensed technology in-licensed by company under the Lonza/MEE 3-way agreement is subject to certain disclaimers by Lonza and MEE as set forth in
Section 12.3 of the Lonza/MEE 3-Way Agreement. 

  
 45 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 8. 

INDEMNIFICATION; INSURANCE; LIMITATIONS 

8.1. Indemnification. 

8.1.1. Indemnification by Vertex. Vertex will indemnify Company, its Affiliates, and its and its Affiliates’ employees,
officers and directors (each, a “Company Indemnified Party”) from and against any liability, loss, damage or expense (including reasonable attorneys’ fees and expenses) (collectively, “Liability”) that the
Company Indemnified Party may incur or otherwise be required to pay to one or more Third Parties in connection with any Third Party suit, investigation, claim or demand to the extent attributable to, resulting from or arising out of: 

(a) any claims arising out of the Research, Development, Manufacture, Commercialization or use of any Capsid or Product by, on behalf of, or
under the authority of, Vertex (other than by any Company Indemnified Party) or any of its Affiliates or any of its or their Sublicensees, other than (i) claims by one or more Third Parties relating to Patent infringement arising out of the
practice of the Licensed Patents within the Field in accordance with the license rights as expressly granted under and in accordance with the terms and conditions of this Agreement, or (ii) claims by Third Parties relating to misappropriation
of trade secrets or other intellectual property rights arising out of the practice of the Licensed Know-How within the Field in accordance with the license rights as expressly granted under and in accordance
with the terms and conditions of this Agreement; 
 (b) the material breach by Vertex of any of its representations, warranties or
covenants set forth in this Agreement; or 
 (c) the negligence or intentional acts of Vertex or any Vertex Indemnified Party; 

and except, in each case ((a)-(c)), to the extent such claims fall within the scope of Company’s indemnification obligations under Section 8.1.2.

 8.1.2. Indemnification by Company. Company will indemnify Vertex, its Affiliates and its and its Affiliates’
employees, officers and directors, Sublicensees and Distributors (each, a “Vertex Indemnified Party”) from and against any Liability that the Vertex Indemnified Party may incur or otherwise be required to pay to one or more Third
Parties in connection with any Third Party suit, investigation, claim or demand to the extent attributable to, resulting from or arising out of: 

(a) any claim that [***]; 

(b) any claims of any nature arising out of Company’s practice of the Licensed Technology prior to the Effective Date; 

(c) the material breach by Company of any of its representations, warranties or covenants set forth in this Agreement; or 

(d) the negligence or intentional acts of Company or any Company Indemnified Party; 

  
 46 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 and except, in each case ((a)-(d)), to the extent such claims fall within the scope of Vertex’s
indemnification obligations under Section 8.1.1. 
 8.1.3. Procedure. Each Party will notify the other Party in writing
if it becomes aware of a claim for which such Party may seek indemnification hereunder. If any Procedure is instituted against a Party with respect to which indemnity may be sought pursuant to Section 8.1.1 or 8.1.2, as applicable, such Party
(the “Indemnified Party”) will give prompt written notice of the indemnity claim to the other Party (the “Indemnifying Party”) and provide the Indemnifying Party with a copy of any complaint, summons or other
written notice that the Indemnified Party receives in connection with any such claim. An Indemnified Party’s failure to deliver such written notice will relieve the Indemnifying Party of liability to the Indemnified Party under
Section 8.1.1 or 8.1.2, as applicable, only to the extent such delay is prejudicial to the Indemnifying Party’s ability to defend such claim. Provided that the Indemnifying Party is not contesting the indemnity obligation, the
Indemnified Party will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise (subject to this Section 8.1) and any failure to contest such
obligation prior to assuming control will be deemed to be an admission of the obligation to indemnify. The Indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim and will not settle or otherwise
resolve such claim without the Indemnified Party’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; provided that such consent will not be required with respect to any settlement involving only the
payment of monetary awards for which the Indemnifying Party will be fully-responsible. The Indemnified Party will cooperate with the Indemnifying Party in the Indemnifying Party’s defense of any claim for which indemnity is sought under this
Agreement, at the Indemnifying Party’s cost and expense. 
 8.2. Insurance. The Parties hereby acknowledge and agree that
the requirements set forth in Section 12.2 of the Lonza/MEE 3-Way Agreement with respect to insurance coverage and requirements shall apply to the Parties hereunder during the Term for so long as such
Lonza/MEE 3-Way Agreement remains in effect. Further, throughout the Term, each Party will respectively, at its cost, obtain and maintain the insurance coverage listed on Schedule 8.2 from insurance carriers
licensed to do business under the laws of the country, state, commonwealth, province or territory in which such Parry’s obligations are provided, with insurers that carry a rating of [***]. Each Party will furnish to the other Party evidence of
such insurance upon request. Notwithstanding the foregoing, Vertex may self-insure to the extent that it self-insures for its other activities. 

8.3. Limitation of Consequential Damages. Except for (a) claims of a Third Party that are subject to indemnification under
this ARTICLE 8, (b) claims arising out of a Party’s willful misconduct or (c) a Party’s breach of Section 4.7 or ARTICLE 10, neither Party nor any of its Affiliates will be liable to the other Party or its Affiliates for any
incidental, consequential, special, punitive or other indirect damages or lost or imputed profits or royalties, whether liability is asserted in contract, tort (including negligence and strict product liability), indemnity or contribution, and
irrespective of whether that Party or any representative of that Party has been advised of, or otherwise might have anticipated the possibility of, any such loss or damage. 

  
 47 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 9. 

TERM; TERMINATION 
 9.1.
Term; Expiration. Except as expressly set forth herein, this Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 9, will expire as follows (such period, the
“Term”): 
 (a) on a country-by-country
and Product-by-Product basis, on the date of expiration of all payment obligations under this Agreement with respect to such Product in such country; and 

(b) in its entirety upon the expiration of all payment obligations under this Agreement with respect to all Products in all countries
pursuant to Section 9.1(a). 
 9.2. Termination of the Agreement. 

9.2.1. Vertex’s Termination for Convenience. Vertex may terminate this Agreement ([***]), for convenience by providing
written notice of its intent to terminate to Company, in which case, such termination will be effective [***] after Company’s receipt of such written notice; except, that if any termination under this Section 9.2.1 applies to
a Product in a country in which Vertex has received Marketing Approval, such termination will be effective [***] after Company’s receipt of such written notice. 

9.2.2. Termination for Material Breach. 

(a) Vertex’s Right to Terminate. If Vertex believes that Company is in material breach of this Agreement, Vertex may deliver
written notice of such material breach to Company. If the breach is curable, Company will have [***] following its receipt of such written notice to cure such breach. If Company fails to cure such breach within such [***] period or the breach is not
subject to cure (a “Company Breach Event”), (i) Vertex may terminate this Agreement by providing written notice to Company, in which case, this Agreement will terminate on the date on which Company receives such written notice or
(ii) Vertex may [***]; provided, however, that if (A) the relevant breach is curable, but not reasonably curable within [***], and (B) Company is making a bona fide effort to cure such breach, Vertex’s right
to terminate this Agreement or elect to exercise the alternate remedy provisions set forth in Section 9.3 on account of such breach will be suspended [***] and if such breach is successfully cured, Vertex will no longer have the right to
terminate this Agreement or elect to exercise the alternate remedy provisions set forth in Section 9.3 on account of such breach. 

(b) Company’s Right to Terminate. If Company believes that Vertex is in material breach of this Agreement (other than a breach of
the confidentiality and non-use obligations set forth in ARTICLE 10), Company may deliver written notice of such material breach to Vertex. If the breach is curable, Vertex will have [***] following its
receipt of such written notice to cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [***] following its receipt of such written notice). If Vertex fails to cure such
breach within the [***] period, as applicable, or the breach is not subject to cure, then, other than for a material breach of the Confidentiality and non-use obligations set forth in ARTICLE 10, Company may
terminate this Agreement by providing written notice to Vertex, in which case, this Agreement will terminate on the date on which Vertex receives such written notice; provided, however, that if (i) the relevant breach
(A) does not involve Vertex’s failure to make a payment when due, and (B) is curable, but not reasonably curable within [***], and (ii) Vertex is making a bona fide effort to cure such breach, Company’s right to
terminate this Agreement on account of such breach will be suspended [***] and if such breach is successfully cured, Company will no longer have the right to terminate this Agreement on account of such breach and provided, further, that if
any such material breach of this Agreement relates to one or more, but not all, Vertex Diseases, then Company shall only have the right to terminate this Agreement in accordance with this 9.2.2(b) with respect to such Vertex Disease(s). 

  
 48 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.2.3. Disputes Regarding Material Breach. Notwithstanding the foregoing, if
the Breaching Party in Section 9.2.2 disputes in good faith the existence, materiality, or failure to cure of any breach, and provides written notice to the Non-Breaching Party of such dispute within the
relevant cure period, the Non-Breaching Party will not have the right to terminate this Agreement in accordance with Section 9.2.2, or the right to exercise the alternative remedy provisions of 9.3, as
applicable, unless and until the relevant dispute has been resolved. During the pendency of such dispute, all the terms of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder.

 9.2.4. Termination for Insolvency. If Company makes an assignment for the benefit of creditors, appoints or suffers
appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within [***] after the filing thereof (each,
an “Insolvency Event”), Vertex may terminate this Agreement in its entirety by providing written notice of its intent to terminate this Agreement to Company, in which case, this Agreement will terminate on the date on which Company
receives such written notice. In addition: 
 (a) All rights and licenses now or hereafter granted by Company to Vertex under or pursuant
to this Agreement are, for all purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined in the U.S. Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to
Company, Company agrees that Vertex, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Company will, during the Term, create and maintain current
copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all intellectual property licensed under this Agreement. Each Party acknowledges and agrees that “embodiments” of
intellectual property within the meaning of Section 365(n) include laboratory notebooks, cell lines, product samples and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of
reference therein, the Licensed Technology and all information related to the Licensed Technology. If (x) a case under the U.S. Bankruptcy Code is commenced by or against Company, (y) this Agreement is rejected as provided in the U.S.
Bankruptcy Code, and (z) Vertex elects to retain its rights hereunder as provided in Section 365(n) of the U.S. Bankruptcy Code, Company (in any capacity, including
debtor-in-possession) and its successors and assigns (including a trustee) will: 

(i) provide Vertex with all such intellectual property (including all embodiments thereof) held by Company and such successors and assigns,
or otherwise available to them, immediately upon Vertex’s written request. Whenever Company or any of its successors or assigns provides to Vertex any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this
Section 9.2.4(a)(i), Vertex will have the right to perform Company’s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by Vertex will release Company from liability resulting
from rejection of the license or the failure to perform such obligations; and 

  
 49 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (ii) not interfere with Vertex’s rights under the Agreement, or any agreement
supplemental hereto, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the U.S. Bankruptcy
Code. 
 (b) All rights, powers and remedies of Vertex provided herein are in addition to and not in substitution for any other rights,
powers and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with respect to Company. The Parties intend the following rights to
extend to the maximum extent permitted by Applicable Law, and to be enforceable under U.S. Bankruptcy Code Section 365(n): 
 (i) the
right of access to any intellectual property rights (including all embodiments thereof) of Company, or any Third Party with whom Company contracts to perform an obligation of Company under this Agreement, and, in the case of any such Third Party,
which is necessary for the Manufacture, use, sale, import or export of Capsids; and 
 (ii) the right to contract directly with any Third
Party to complete the contracted work. 
 9.3. [***]. If a [***] occurs, subject to Section 9.2.3, and if Company disputes in good
faith the existence, materiality, or failure to cure of any breach and such [***] has been finally adjudicated against Company in accordance with Section 11.12, Vertex may [***] by providing written notice of such election to Company, in which
case, this Agreement will continue in full force and effect with the following modifications, each at Vertex’s election: 
 9.3.1.
Company’s [***]; and 
 9.3.2. Solely in the event that the applicable [***] is either the uncured material breach by Company of [***],
then in [***] ((a) through (c)), the [***] and the [***]; provided that, such [***] or that is [***]. 
 9.4. Consequences of
Expiration or Termination of the Agreement. 
 9.4.1. In General. If this Agreement expires or is terminated in whole
or in part with respect to one or more countries or one or more Vertex Diseases by a Party pursuant to this ARTICLE 9, the following terms will apply to this Agreement, either in its entirety or with respect to the terminated Vertex Disease or
country that is the subject of such termination, as the case may be: 
 (a) each Party will take all action required under
Section 10.3; 

  
 50 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) termination or expiration of this Agreement for any reason will be without prejudice to
any rights or financial compensation that will have accrued to the benefit of a Party prior to such expiration or termination. Such expiration or termination will not relieve a Party from obligations that are expressly indicated to survive the
termination or expiration of this Agreement; and 
 (c) the following provisions of this Agreement will survive the expiration or
termination of this Agreement: [***]. 
 9.4.2. Early Termination. If this Agreement is terminated in its entirety or in part
by a Party pursuant to Sections 9.2.1, 9.2.2 or 9.2.4, the following terms will apply with respect to any country or Vertex Disease that is the subject of such termination (i.e., all Vertex Diseases or all countries worldwide in the case of
termination of this Agreement in its entirety or the applicable terminated Vertex Diseases or country(ies) in the case of termination of this Agreement in part, as the case may be): 

(a) except as set forth in Section 9.4.2(d), the applicable licenses granted by Company to Vertex with respect to the relevant country
or countries or with respect to the relevant Vertex Diseases under this Agreement will terminate automatically upon the effective date of any such termination; 

(b) except as set forth in this Section 9.4, as of the effective date of any such termination, Vertex will have no further rights and
Company will have no further obligations with respect to the relevant country or countries or the relevant Vertex Diseases; 
 (c) the
Territory will be automatically amended to exclude the relevant country or countries or the Field will be automatically amended to exclude the relevant Vertex Diseases, as applicable, upon the effective date of any such termination; and 

(d) any permitted Sublicense of Vertex will, at the Sublicensee’s option, survive such termination on the condition that the relevant
Sublicensee is not in material breach of any of its obligations under such Sublicense. In order to effect this provision, at the request of the Sublicensee, Company will enter into a direct license with the Sublicensee on terms that are
substantially the same terms as the applicable terms of this Agreement; provided that Company will not be required to undertake obligations in addition to those required by this Agreement, and Company’s rights under such direct license
will be consistent with its rights under this Agreement, taking into account the scope of the license granted under such direct license. 

ARTICLE 10. 

CONFIDENTIALITY 
 10.1.
Confidentiality. During the Term and for [***] thereafter, each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will:
(a) keep the Disclosing Party’s Confidential Information confidential; (b) not publish, or allow to be published, and will not otherwise disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and
(c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose, except, in each case, to the extent expressly permitted under this Agreement or otherwise agreed in writing. Without limiting the
generality of the foregoing, to the extent that either Party provides the other Party any Confidential Information owned by any Third Party, the Receiving Party will handle such Confidential Information in accordance with the terms of this ARTICLE
10 applicable to a Receiving Party. 

  
 51 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.2. Authorized Disclosure. Notwithstanding Section 10.1, each Party may
disclose the other Party’s Confidential Information to the extent such disclosure is reasonably necessary to: 
 (a) file or prosecute
patent applications as contemplated by this Agreement; 
 (b) prosecute or defend litigation; 

(c) exercise its rights and perform its obligations hereunder; provided that such disclosure is covered by terms of confidentiality
similar to those set forth herein; 
 (d) subject to the remainder of this Section 10.2, its advisors (including financial advisors,
attorneys and accountants), actual or potential acquisition partners, financing sources or investors and underwriters on a need to know basis; provided that such disclosure is covered by terms of Confidentiality similar to those set forth
herein (which may include professional ethical obligations); or 
 (e) comply with Applicable Law. 

In addition to the foregoing, Vertex may disclose Company’s Confidential Information to Third Parties in connection with the actual or potential
Research, Development, Manufacture or Commercialization of Capsids or Products; provided that such disclosure is covered by terms of Confidentiality similar to those set forth herein. 

If a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to Sections 10.2(b) or 10.2(e), the
Disclosing Party will, to the extent possible, give reasonable advance notice of such disclosure to the other Party and take reasonable measures to ensure confidential treatment of such information. 

Notwithstanding anything to the contrary contained herein, in no event may Company disclose Vertex’s Confidential Information to any Third Party [***]
engaged in [***]. 
 10.3. Expiration or Termination of this Agreement. Following the expiration or termination of this
Agreement, if requested by the Disclosing Party, at the Receiving Party’s election, the Receiving Party will return or destroy, all data, files, records and other materials containing or comprising the Disclosing Party’s Confidential
Information, except to the extent such Confidential Information is necessary or useful to conduct surviving obligations or exercise surviving rights. Notwithstanding the foregoing, (a) the Receiving Party will be permitted to retain one copy of
such data, files, records, and other materials for archival and legal compliance purposes and (b) the Receiving Party will not be required to delete or destroy any electronic back-up tapes or other
electronic back-up files that have been created solely by the Receiving Party’s automatic or routine archiving and back-up procedures, to the extent created and
retained in a manner consistent with its or their standard archiving and back-up procedures. 

  
 52 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.4. SEC Filings and Other Disclosures. Either Party may disclose the terms
of this Agreement to the extent required to comply with Applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory;
provided, that such Party will provide the other Party a reasonable opportunity to review such disclosure and reasonably consider the other Party’s comments regarding confidential treatment sought for such disclosure. 

10.5. [***]. Notwithstanding any provision of this Agreement to the contrary, Confidential Information will [***]. Any use made by the
Receiving Party of [***]. 
 10.6. Public Announcements; Publications. 

10.6.1. Announcements. On a date to be determined by the mutual agreement of the Parties (which date shall not be earlier than
[***]), the Parties will jointly issue a press release regarding the signing of this Agreement in a form to be mutually agreed to by the Parties. Except (a) as set forth in the preceding sentence and (b) as required to comply with
Applicable Law (including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory in accordance with Section 10.4), neither Party will
make any public announcement regarding this Agreement without the prior written approval of the other Party. Notwithstanding the foregoing, subject to Section 10.6.2, Vertex may make scientific publications or public announcements concerning
its Research, Development, Manufacture or Commercialization activities with respect to any Capsid or Product being Researched, Developed or Commercialized for DMD and DM1 and, following exercise of the Option with respect to Cystic Fibrosis or
[***], with respect to any Capsid or Product being Researched, Developed or Commercialized for Cystic Fibrosis or [***], as applicable, without Company’s prior written approval. 

10.6.2. Publications. 

(a) By Vertex. During the Term, Vertex and its Affiliates will submit to Company for review any proposed academic, scientific
and medical publication or academic, scientific and medical public presentation related to the use of any Capsid or Product within the Field or any activities conducted pursuant to this Agreement. Company will review such publication or presentation
for purposes of determining whether any portion of the proposed publication or presentation contains Company’s Confidential Information. Vertex and its Affiliates will submit written copies of such proposed publication or presentation to
Company no later than [***] before submission for publication or presentation (or [***] in advance in the case of an abstract). Company will provide its comments with respect to such publications and presentations within [***] after its receipt of
such written copy (or [***] in the case of an abstract). If requested by Company, Vertex and its Affiliates will (i) redact Company’s Confidential Information from any such proposed publication or presentation or (ii) delay the
proposed publication for a period of up to an additional [***] to enable Company to file a Patent with respect to the subject matter to be made public in such publication or presentation for which Company has the applicable intellectual property
rights. Vertex and its Affiliates will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication. Notwithstanding the foregoing, Vertex’s and its
Affiliates’ obligation to submit any publication to Company for review and approval under this Section 10.6.2 will not apply to any publication that does not contain Company’s Confidential Information. 

  
 53 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) By Company. (i) During the Research Term, Company and its
Affiliates will submit to Vertex for review any proposed academic, scientific and medical publication or academic, scientific and medical public presentation related to any Capsid that is reasonably likely to be useful in the Field, or any
activities conducted pursuant to this Agreement, provided that, if any such publication or presentation is related to any Product being Researched, Developed or Commercialized by Vertex in the Field or to the Field itself, then Company and
its Affiliates will not make such publication or presentation without Vertex’s prior written consent. Company and its Affiliates will submit written copies of all such proposed publication or presentation to Vertex no later than [***] before
submission for publication or presentation (or [***] in advance in the case of an abstract). Vertex will provide its comments (or consent (or notice of non-consent), as applicable) with respect to such
publications and presentations within [***] after its receipt of such written copy (or [***] in the case of an abstract). If requested by Vertex, Company and its Affiliates will (A) redact Vertex’s Confidential Information from any such
proposed publication or presentation, or (B) delay the proposed publication for a period of up to an additional [***] to enable Vertex to file a Patent with respect to the subject matter to be made public in such publication or presentation for
which Vertex has the applicable intellectual property rights. (ii) Following the conclusion of the Research Term, the review and comment rights set forth in the foregoing clause (i) shall continue to apply with respect to any proposed
publication or presentation by Company or its Affiliates that relates to the Research, Development or Commercialization of a Capsid within the Field for which Vertex is conducting Research, Development, Manufacturing or Commercialization activities
at the time of such proposed publication or presentation, regardless of whether such publication or presentation contains the Confidential Information of Vertex. In addition, Company and its Affiliates will not make any publication or presentation
related to any Product being Researched, Developed or Commercialized in the Field by Vertex or to the Field itself without Vertex’s prior written consent. At all times during the Term, Company and its Affiliates will comply with standard
academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication. 

10.7. Vertex Information Rights. 

10.7.1. If Vertex determines in good faith that Company is an entity that is subject to financial consolidation with Vertex for the purposes
of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex: 

(a) as soon as practicable, but in any event within [***] after the end of each Calendar Quarter [***]; 

(b) as soon as practicable, but in any event within [***] after the end of each Calendar Year [***]; 

(c) on or prior to December 31 of each Calendar Year, Company will perform [***] as prepared by an independent valuation expert; and

  
 54 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) any other information or agreements requested by Vertex and reasonably necessary for
the purposes of its quarterly and annual financial statements. 
 ARTICLE 11. 

MISCELLANEOUS 
 11.1.
Assignment. This Agreement will not be assignable by any Party to any Third Party without the prior written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may assign
this Agreement or its rights and obligations under this Agreement in whole, and with respect to Vertex, in part on a Vertex Disease-by-Vertex Disease basis, without any
requirement to obtain the consent of the other Party, to an Affiliate or to a Third Party that acquires all or substantially all of the business or assets of such Party to which this Agreement relates (and with respect to a partial assignment by
Vertex for a Vertex Disease, all of the business or assets of Vertex related to such Vertex Disease) (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms of this Agreement. This
Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry
out the intent of this Agreement. Any assignment not in accordance with this Section 11.1 will be void. 
 11.2. Change of
Control of Company; Notification. Company will notify Vertex in writing promptly (and in any event within [***]) following the extension of a definitive agreement by Company, its Affiliates or its equity holders that could reasonably be
expected to result in a Change of Control of Company. 
 11.3. Force Majeure. Each Party will be excused from the performance
of its obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides written notice of the Force Majeure to the other Party. Such excuse will continue for so long as
the condition constituting a Force Majeure continues, on the condition that the nonperforming Party continues to use Commercially Reasonable Efforts to resume performance of its obligations under this Agreement. 

11.4. Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection
with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, no presumption will exist or be implied against the Party that drafted such terms and
provisions. 

  
 55 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.5. Notices. All notices which are required or permitted hereunder will be
in writing and sufficient if delivered personally or sent by nationally-recognized overnight courier, or through email to the applicable email address, addressed as follows: 

If to Vertex: 
 Vertex
Pharmaceuticals Incorporated 
 Attn: Business Development 

50 Northern Avenue Boston, Massachusetts 02210 

[***] 
 with a copy to: 

Vertex Pharmaceuticals Incorporated 

Attn: Corporate Legal 
 50
Northern Avenue 
 Boston, Massachusetts 02210 

[***] and legal_notice@vrtx.com 

and 
 Ropes & Gray LLP

 Attn: Marc Rubenstein 
 800
Boylston Street 
 Boston, Massachusetts 02119 

marc.rubenstein@ropesgray.com 

and if to Company: 
 Affinia
Therapeutics Inc. 
 Attn: Robert Aboud, Chief Legal Officer 

100 Beaver Street, Suite 304 

Waltham, MA 02453 
 [***] 

or to such other address as the Party to whom written notice is to be given may have furnished to the other Party in writing in accordance
herewith. In addition, each Party will deliver a courtesy copy to the other Party’s Alliance Manager concurrently with such notice. Any such written notice will be deemed to have been given and received by the other Party: (a) when
delivered if personally delivered; or (b) on receipt if sent by overnight courier or email. 
 11.6. Amendment. No
amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each of Vertex and Company. 

11.7. Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either Party of any breach of any provision hereof by the other Party will not be construed to
be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

  
 56 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.8. Severability. If any clause or portion thereof in this Agreement is for
any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity
and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as
will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

11.9. Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or
effect in construing or interpreting any of the provisions of this Agreement. 
 11.10. Export Control. This Agreement is made
subject to any restrictions concerning the export of products or technical information from the United States of America or other countries that may be imposed upon or related to Company or Vertex from time to time. Each Party agrees that it will
not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or
other governmental approval, without first obtaining the written consent to do so from the appropriate Governmental Authority. 

11.11. Governing Law. This Agreement, and all claims arising under or in connection therewith, will be governed by and
interpreted in accordance with the substantive laws of [***], without regard to conflict of law principles thereof. 
 11.12. Dispute
Resolution. Subject to Section 11.12.3 regarding the resolution of certain Patent-related disputes, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in
connection herewith (a “Dispute”), it will be resolved pursuant to Sections 11.12.1 and 11.12.2. 
 11.12.1.
Escalation to Executive Officers. Either Party may refer any Dispute to the Executive Officers of the Parties (or their designees having sufficient authority to resolve such Dispute), who will confer in good faith on the resolution of the
issue, by delivering written notice to the other Party. 
 11.12.2. Arbitration. If the Executive Officers are unable to agree
on the resolution of any such Dispute within [***](or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then within [***] after the end of such [***] period or such other
mutually-agreed period of time, either Party may, by written notice to the other Party, elect to initiate an arbitration proceeding pursuant to the procedures set forth in this Section 11.12.2 for purposes of having the matter settled (the
“Arbitration Notice”) in accordance with the rules and regulations established and administered by the American Arbitration Association (“AAA”). 

 

  
 57 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (a) Binding Arbitration. Within [***] following a Party’s receipt of the
Arbitration Notice, the Parties will submit such Dispute to, and such Dispute will be finally resolved by, binding arbitration in accordance with the Commercial Arbitration Rules (the “Rules”) of the AAA by an arbitral tribunal
composed of three impartial arbitrators bound by The Code of Ethics for Arbitrators in Commercial Disputes, all of whom will have relevant experience in the pharmaceutical industry ([***]), one appointed by each of the Parties within [***] after the
Arbitration Notice, and the third who will chair the arbitral tribunal appointed by the Party-appointed arbitrators within [***] after the appointment of the second arbitrator, or, failing agreement by the Party-appointed arbitrators, by the AAA in
accordance with the Rules. If, at the time of the arbitration, the Parties agree in writing to submit the Dispute to a single arbitrator, said single arbitrator will (i) have relevant experience in the pharmaceutical industry ([***]) and
(ii) be appointed by agreement of the Parties within [***] after the Arbitration Notice, or, failing such agreement, by the AAA in accordance with the Rules. In no case shall any arbitrator have participated in a prior mediation involving
either Party unless explicitly agreed to by the Parties. Unless otherwise agreed by the Parties hereto, all such arbitration proceedings will be held in [***] All arbitration proceedings will be conducted in the English language. 

(b) Limited Discovery. Documentary discovery may be conducted at the discretion of the arbitrator(s), provided that any such
discovery will (i) be limited to documents directly relating to the Dispute, (ii) be conducted pursuant to document discovery procedures as set forth under the laws of the International Bar Association Rules of Evidence, and (iii) be
conducted subject to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s). At the request of a Party, the arbitrator(s) may at their discretion order the deposition of witnesses.
Depositions shall be limited to a maximum of three depositions per Party, each of a maximum of four hours duration, unless the arbitrator(s) otherwise determine. Notwithstanding any provision of this Section 11.12.2 to the contrary, all
discovery must be completed within [***] after the appointment of the arbitrator(s). 
 (c) Awards and Fees. The
arbitrator(s) may only issue awards of direct monetary damages and will not under any circumstances have the authority or power to grant (i) equitable relief, (ii) orders for specific performance, (iii) punitive damages or
(iv) to the extent set forth in Section 8.3, consequential damages. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such
determination, each Party will pay its own expenses, including attorney’s fees. 
 (d) Rulings. All arbitration
proceedings must be completed within [***] after the Arbitration Notice. The Parties hereby agree that, subject to the provisions of this Section 11.12.2, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and
evidentiary matters that the arbitrator(s) deem reasonable and necessary with or without petition therefor by the Parties as well as the final award. The final award will be issued no more than [***] after the final submissions of the Parties, or as
soon thereafter as practicable. All rulings by the arbitrator(s) will be final and binding on the Parties. The arbitrator(s) shall issue a reasoned decision that accompanies the final award. 

(e) Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s) pursuant to
Section 11.12.2(d) may be enforced, to the extent that such ruling complies with the provisions of Section 11.12.2(c), in any court having jurisdiction over any of the Parties or any of their respective assets. 

  
 58 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (f) Confidentiality. All activities undertaken by the arbitrator(s) or the
Parties pursuant to this Section 11.12.2 will be conducted subject to obligations of confidentiality no less restrictive than those set forth in ARTICLE 10. Further, the Parties acknowledge and agree that their respective conduct during the
course of the arbitration, their respective statements and all information exchanged in connection with the arbitration, and the conduct of the arbitration and any information produced thereunder is Confidential Information under this Agreement and
subject to the provisions of ARTICLE 10. 
 11.12.3. Patent Disputes. Notwithstanding the foregoing in this
Section 11.12, if a dispute arises between the Parties under this Agreement with respect to the interpretation, scope, validity, enforceability, applicability or term of any Patent, then such dispute shall not be resolved pursuant to Sections
11.12.1 and 11.12.2, but instead may be brought by either Party in the federal courts of Massachusetts. 
 11.12.4. Equitable
Relief. Notwithstanding the foregoing in this Section 11.12, nothing contained in this Agreement will in any way limit or preclude a Party from, at any time, seeking or obtaining equitable relief hereunder, whether preliminary or
permanent, including a temporary or permanent restraining order, preliminary or permanent injunction, specific performance or any other form of equitable relief, from any United States court of competent jurisdiction if necessary to protect the
interests of such Party. Each Party agrees that its unauthorized release of the other Party’s Confidential Information or its breach of Section 4.7 of this Agreement will cause irreparable damage to other Party for which recovery of
damages would be inadequate, and that such other Party will be entitled to obtain timely injunctive relief with respect to such breach, without the need to show irreparable harm or the inadequacy of monetary damages as a remedy, and without the
requirement of having to post bond or other security, as well as any further relief that may be granted by a court of competent jurisdiction. 

11.13. Entire Agreement. This Agreement, together with the MTA, constitutes and contains the complete, final and exclusive
understanding and agreement of the Parties and cancels and supersedes all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof, including the CDA, which
is hereby superseded and replaced in its entirety as of the Effective Date. For the avoidance of doubt, the MTA shall survive the Effective Date of this Agreement in accordance with the terms and conditions thereof. 

11.14. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing contained herein will be
deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the
other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

11.15. Use of Name. Neither Company nor Vertex shall use the name of Lonza or MEE or of any trustee, director, officer, staff
member, employee, student or agent of MEE or Lonza, or any logo, trade name or trademark of MEE or Lonza or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or
financing without the prior written approval of MEE or Lonza (as applicable). 

  
 59 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.16. Inerpretation. Except where the context expressly requires otherwise,
(a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include,” “includes” and
“including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference
to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein,” “hereof” and “hereunder,” and
words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Schedules or Exhibits will be construed to refer to Sections, Schedules or
Exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto, (h) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or
“approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and
instant messaging), (i) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof,
(j) any action or occurrence deemed to be effective as of a particular date will be deemed to be effective as of 11:59 PM ET on such date and (k) the term “or” will be interpreted in the inclusive sense commonly associated with
the term “and/or.” 
 11.17. Intended Third Party Beneficiaries. Except as expressly provided in this
Section 11.17, no provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement. Vertex acknowledges and agrees that for so long as any
Licensed Technology is in-licensed by Company under the MEE/Lonza 3-Way Agreement, MEE and Lonza shall each be an intended Third Party beneficiary of this Agreement for
purposes of enforcing any provision of this Agreement that may be reasonably construed in good faith as being necessary to enforce any right that is expressly granted to MEE or Lonza under the MEE/Lonza 3-Way
Agreement or any obligation of Company or any of its sublicensees to MEE or Lonza under the MEE/Lonza 3-Way Agreement. 

11.18. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.19.
Counterparts. This Agreement may be executed in two counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission
(e.g., .pdf), each of which will be binding when received by the applicable Party. 
 [Signature Page Follows] 

  
 60 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
representatives thereunto duly authorized as of the Effective Date. 
  

									
	 VERTEX PHARMACEUTICALS INCORPORATED
	 		 	 AFFINIA THERAPEUTICS INC.

					
	By:	 	/s/ [***]	 		 	By:	 	/s/ [***]
	 Name: [***]
 Title: President and
Chief Executive Officer
	 		 	 Name: [***]
 Title: Chief Executive
Officer

 [Signature Page to Strategic Collaboration and License Agreement] 

 Schedule 1.39 

[***] 

 Schedule 1.42 

[***] 
 {2 pages omitted} 

 Schedule 1.94 

[***] 
 {2 pages omitted} 

 Schedule 2.1.3 

[***] 

 Schedule 2.1.4 

[***] 

 Schedule 4.2.2 

[***] 

 Schedule 5.2.1 

[***] 
 {4 pages omitted} 

 Schedule 8.2 

[***]EX-10.7

 Exhibit 10.7 

TDTX, INC. 
 2019 EQUITY
INCENTIVE PLAN 
 ADOPTED BY THE BOARD OF DIRECTORS: November 25, 2019 

APPROVED BY THE STOCKHOLDERS: November 25, 2019 

TERMINATION DATE: November 24, 2029 

1. General. 
 (a)
Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. 
 (b)
Available Stock Awards. The Plan provides for the grant of the following types of Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock
Awards, (v) Restricted Stock Unit Awards and (vi) Other Stock Awards. 
 (c) Purpose. The Plan, through the grant of
Stock Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the
eligible recipients may benefit from increases in value of the Common Stock. 
 2. Administration. 

(a) Administration by the Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or
Committees, as provided in Section 2(c). 
 (b) Powers of the Board. The Board will have the power, subject to, and within the
limitations of, the express provisions of the Plan: 
 (i) To determine (A) who will be granted Stock Awards; (B) when and
how each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or
Common Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award. 

(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for
administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient
to make the Plan or Stock Award fully effective. 
 (iii) To settle all controversies regarding the Plan and Stock Awards granted
under it. 
 (iv) To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which
cash or shares of Common Stock may be issued in settlement thereof). 

  
 1. 

 (v) To suspend or terminate the Plan at any time. Except as otherwise provided in the
Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under the Participant’s then-outstanding Stock Award without the Participant’s written consent except as provided in
subsection (viii) below. 
 (vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without
limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Stock Awards granted under the Plan into compliance with the
requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If
required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the
number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the benefits accruing to Participants under
the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Stock Awards available for
issuance under the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Stock Award without the Participant’s written
consent. 
 (vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan
intended to satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options. 
 (viii) To approve forms of
Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement,
subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that a Participant’s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the
consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole
discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards
without the affected Participant’s consent (A) to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change
results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Stock Award
into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws. 
 (ix) Generally, to exercise
such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards. 

(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit
participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award
Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

  
 2. 

 (xi) To effect, with the consent of any adversely affected Participant, (A) the
reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award,
(3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different
number of shares of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting
principles. 
 (c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the
power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any
delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the authority to concurrently
administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 
 (d)
Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent
permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a
Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation
authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(t) below.  

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in
good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 3. Shares Subject to the Plan.

 (a) Share Reserve. 

(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be
issued pursuant to Stock Awards from and after the Effective Date will not exceed 120,000 shares (the “Share Reserve”). 

  
 3. 

 (ii) For clarity, the Share Reserve in this Section 3(a) is a limitation on the
number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). 

(b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates
without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset)
the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency
or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax
withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. 

(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three multiplied by the Share Reserve. 

(d) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including
shares repurchased by the Company on the open market or otherwise. 
 4. Eligibility. 

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent
corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;
provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the
stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the
Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards
comply with the distribution requirements of Section 409A of the Code. 
 (b) Ten Percent Stockholders. A Ten Percent
Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date
of grant. 
 (c) Consultants.    A Consultant will not be eligible for the grant of a Stock Award
if, at the time of grant, either the offer or sale of the Company’s securities to such Consultant is not exempt under Rule 701 because of the nature of the services that the Consultant is providing to the Company, because the Consultant is
not a natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as
comply with the securities laws of all other relevant jurisdictions. 

  
 4. 

 5. Provisions Relating to Options and Stock Appreciation Rights. 

Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be
separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of
Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable
rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Stock Award Agreement will conform to (through incorporation of
provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions: 

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after
the expiration of 10 years from the date of its grant or such shorter period specified in the Stock Award Agreement. 
 (b) Exercise
Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on
the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is
granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable,
Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. 
 (c) Purchase Price for
Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment
set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to
use a particular method of payment. The permitted methods of payment are as follows: 
 (i) by cash, check, bank draft, electronic
funds transfer or money order payable to the Company; 
 (ii) subject to Company and/or Board consent at the time of exercise and
provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of
cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day
sale”, or “sell to cover”; 
 (iii) subject to Company and/or Board consent at the time of exercise and provided that
at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security
interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company and/or the Board, at the time 

  
 5. 

 
Participant exercises their Option, will include delivery to the Company of Participant’s attestation of ownership of such shares of Common Stock in a form approved by the Company.
Participant may not exercise their option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock; 

(iv) subject to Company and/or Board consent at the time of exercise, and provided that the Option is a Nonstatutory Stock Option, by a
“net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate
exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that Participant must pay any remaining balance of the
aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to the extent that
(A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding
obligations; 
 (v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that
interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of
the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 
 (vi) in any other form
of legal consideration that may be acceptable to the Board. 
 (d) Exercise and Payment of a SAR. To exercise any outstanding
SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not
greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested
under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such
date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR. 

(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of
Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply: 

(i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or
pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and
securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. 

  
 6. 

 (ii) Domestic Relations Orders. Subject to the approval of the Board or a duly
authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering
written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or
other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the
Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the
provisions of applicable laws. 
 (f) Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR
may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the
satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the
minimum number of shares of Common Stock as to which an Option or SAR may be exercised. 
 (g) Termination of Continuous Service.
Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s
death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the
earlier of (i) the date three months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement, which period will not be less than
30 days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the
Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate. 

(h) Extension of Termination Date. If the exercise of an Option or SAR following the termination of the Participant’s
Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the
Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the
Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock
Award Agreement. In addition, unless otherwise provided in a Participant’s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service
(other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of the period of time (that need not be consecutive) equal to the applicable
post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading
policy, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. 

  
 7. 

 (i) Disability of Participant. Except as otherwise provided in the applicable
Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the
extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of
Continuous Service (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the
expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as
applicable) will terminate. 
 (j) Death of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other
agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award
Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of
the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only
within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to
comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised
within the applicable time frame, the Option or SAR (as applicable) will terminate. 
 (k) Termination for Cause. Except as
explicitly provided otherwise in a Participant’s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the
Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR (whether vested or unvested) from and after the date of such
termination of Continuous Service. 
 (l) Non-Exempt Employees. If an Option or SAR is granted
to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six
months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such
non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or
(iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Stock Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the
Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income
derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt 

  
 8. 

 
from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this
Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. 
 (m) Early
Exercise of Options. An Option may, but need not, include a provision whereby the Optionholder may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of
Common Stock subject to the Option prior to the full vesting of the Option. Subject to the “Repurchase Limitation” in Section 8(l), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of
the Company or to any other restriction the Board determines to be appropriate. Provided that the “Repurchase Limitation” in Section 8(l) is not violated, the Company will not be required to exercise its repurchase right until at
least six months (or such longer or shorter period of time required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically
provides in the Option Agreement. 
 (n) Right of Repurchase. Subject to the “Repurchase Limitation” in
Section 8(l), the Option or SAR may include a provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR. 

(o) Right of First Refusal. The Option or SAR may include a provision whereby the Company may elect to exercise a right of first
refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject to the
“Repurchase Limitation” in Section 8(l). Except as expressly provided in this Section 5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of
the Company. 
 6. Provisions of Stock Awards Other than Options and SARs. 

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and
conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the
Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of
Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the
provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 
 (i) Consideration.
A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration
(including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 
 (ii)
Vesting. Subject to the “Repurchase Limitation” in Section 8(l), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to
be determined by the Board. 

  
 9. 

 (iii) Termination of Participant’s Continuous Service. If a Participant’s
Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service
under the terms of the Restricted Stock Award Agreement. 
 (iv) Transferability. Rights to acquire shares of Common Stock under the
Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. 
 (v)
Dividends. A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which
they relate. 
 (b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will
contain such terms and conditions as the will Board deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements
need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to
be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may
be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or
conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 
 (iii)
Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the
Restricted Stock Unit Award Agreement. 
 (iv) Additional Restrictions. At the time of the grant of a Restricted Stock
Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such
Restricted Stock Unit Award. 
 (v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of
Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of
Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same
terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. 

  
 10. 

 (vi) Termination of Participant’s Continuous Service.
Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service. 

 (vii) Compliance with Section 409A of the Code.    Notwithstanding anything to the contrary
set forth herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code will contain such provisions so that such Restricted Stock Unit Award will comply with the
requirements of Section 409A of the Code. Such restrictions, if any, will be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may
include, without limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed
pre-determined schedule. 
 (c) Other Stock Awards. Other forms of Stock Awards valued
in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock
at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete
authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other
terms and conditions of such Other Stock Awards. 
 7. Covenants of the Company. 

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required
to satisfy then-outstanding Stock Awards. 
 (b) Securities Law Compliance. The Company will seek to obtain from each regulatory
commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking will not
require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from
any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common
Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or
issuance would be in violation of any applicable securities law. 
 (c) No Obligation to Notify or Minimize Taxes. The Company
will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending
termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. 

  
 11. 

 8. Miscellaneous. 

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will
constitute general funds of the Company. 
 (b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a
grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award
is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise
price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock Award Agreement or related grant documents, the
corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents. 

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any
shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the
issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company. 
 (d) No Employment
or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve
the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without
cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 
 (e)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an
Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its
sole discretion to (x) make a corresponding reduction in the number of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in
combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or
extended. 
 (f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of
grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit
established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such
rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 

  
 12. 

 (g) Investment Assurances. The Company may require a Participant, as a condition of
exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks
of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present
intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of
Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such
requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. 

(h) Withholding Obligations. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion,
satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of
Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash;
(iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement. 

(i) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document
delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). 

(j) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common
Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will
be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is
authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such
other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 

  
 13. 

 (k) Compliance with Section 409A of the Code. To the extent
that the Board determines that any Stock Award granted hereunder is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences
specified in Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements will be interpreted in accordance with Section 409A of the Code. Notwithstanding anything to the contrary in the Plan (and unless
the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes “deferred compensation” under Section 409A of the Code is a
“specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to
alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to
alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a
lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. 
 (l)
Repurchase Limitation. The terms of any repurchase right will be specified in the Stock Award Agreement. The repurchase price for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of
repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company will
not exercise its repurchase right until at least six months (or such longer or shorter period of time necessary to avoid classification of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of
shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. 
 9. Adjustments upon Changes in Common Stock;
Other Corporate Events. 
 (a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will
appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise
of Incentive Stock Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be
final, binding and conclusive. 
 (b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the
event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase)
will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the
Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no
longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. 

(c) Corporate Transaction. The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the
event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:

 (i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate
Transaction); 

  
 14. 

 (ii) arrange for the assignment of any reacquisition or repurchase rights held by the
Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 

(iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be
exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Corporate Transaction),
with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of
exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction; 

(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock
Award; 
 (v) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the
effective time of the Corporate Transaction, in exchange for such cash consideration (including no consideration) as the Board, in its sole discretion, may consider appropriate; and 

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property
the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity,
this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock
in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. 
 The Board need not take
the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. 

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in
Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration
will occur. 

  
 15. 

 10. Plan Term; Earlier Termination or Suspension of the Plan. 

(a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will
automatically terminate on the day before the 10th anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under
the Plan while the Plan is suspended or after it is terminated. 
 (b) No Impairment of Rights. Suspension or termination of the Plan
will not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan. 

11. Effective Date of Plan. 
 This
Plan will become effective on the Effective Date.  
 12. Choice of Law. 

The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan,
without regard to that state’s conflict of laws rules. 
 13. Definitions. As used in the Plan, the following definitions will apply to
the capitalized terms indicated below: 
 (a) “Affiliate” means, at the time of determination, any
“parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “majority-owned
subsidiary” status is determined within the foregoing definition. 
 (b) “Board” means the Board of
Directors of the Company. 
 (c) “Capitalization Adjustment” means any change that is made in, or other events
that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. 
 (d) “Cause”
will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of
the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted
commission of, or participation in, a fraud or act of dishonesty against the Company, or any of its employees or directors; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and
the Company, the Company’s employment policies, or of any statutory or other duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade

  
 16. 

 
secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made
by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon
any determination of the rights or obligations of the Company or such Participant for any other purpose. 
 (e) “Change in
Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the
acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s
securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (C) solely because the level of Ownership held by any Exchange Act
Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the
Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the
Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control will be deemed to occur;  
 (ii) there is consummated a merger,
consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the
combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such transaction; or 
 (iii) there is consummated a sale, lease, exclusive license or other disposition of all
or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more
than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition. 
 Notwithstanding the foregoing definition or any other provision of this Plan, (A) the term Change in
Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Change in Control (or any analogous term) in an individual written
agreement between the Company or any Affiliate and the Participant will supersede the 

  
 17. 

 
foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an
individual written agreement, the definition set forth herein will apply, and (C) if at any time the Company’s Certificate of Incorporation provides definitions of various analogous transactions that would be deemed a liquidation event for
the Company, then such definition will apply as if it were the definition set forth herein except as is otherwise expressly provided in an individual written agreement between the Company or any Affiliate and the Participant. 

(f) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. 
 (g) “Committee” means a committee of one or more Directors to whom authority has been
delegated by the Board in accordance with Section 2(c). 
 (h) “Common Stock” means the common stock of
the Company. 
 (i) “Company” means TDTx, Inc., a Delaware corporation. 

(j) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.  
 (k)
“Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the
Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the
Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as
determined by the Board in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the
Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may
determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or
(ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in
the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. 

(l) “Corporate Transaction” means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) a sale or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

  
 18. 

 (ii) a sale or other disposition of more than 50% of the outstanding securities of
the Company; 
 (iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 (iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of
Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. 
 (m) “Director” means a member of the Board. 

(n) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than
twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(o) “Effective Date” means the effective date of this Plan, which is the earlier of (i) the date that this
Plan is first approved by the Company’s stockholders, and (ii) the date this Plan is adopted by the Board. 
 (p)
“Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for
purposes of the Plan. 
 (q) “Entity” means a corporation, partnership, limited liability company or other
entity. 
 (r) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 (s) “Exchange Act Person” means any natural person,
Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or
(v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more
than 50% of the combined voting power of the Company’s then outstanding securities. 
 (t) “Fair Market
Value” means, as of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

  
 19. 

 (u) “Incentive Stock Option” means an option granted pursuant
to Section 5 of the Plan that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 

(v) “Nonstatutory Stock Option” means an option granted pursuant to Section 5 of the Plan that does not
qualify as an Incentive Stock Option. 
 (w) “Officer” means any person designated by the Company as an
officer. 
 (x) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of
Common Stock granted pursuant to the Plan. 
 (y) “Option Agreement” means a written agreement between the
Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 

(z) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. 
 (aa) “Other Stock Award” means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c). 
 (bb)
“Other Stock Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be
subject to the terms and conditions of the Plan. 
 (cc) “Own,” “Owned,”
“Owner,” “Ownership” A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if
such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(dd) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Stock Award. 
 (ee) “Plan” means this 2019 Equity Incentive Plan. 

(ff) “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms
and conditions of Section 6(a). 
 (gg) “Restricted Stock Award Agreement” means a written agreement
between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(hh) “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is
granted pursuant to the terms and conditions of Section 6(b). 

  
 20. 

 (ii) “Restricted Stock Unit Award Agreement”
means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms
and conditions of the Plan. 
 (jj) “Rule 405” means Rule 405 promulgated under the Securities Act. 

(kk) “Rule 701” means Rule 701 promulgated under the Securities Act. 

(ll) “Securities Act” means the Securities Act of 1933, as amended. 

(mm) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section 5. 
 (nn) “Stock Appreciation Right
Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the
terms and conditions of the Plan. 
 (oo) “Stock Award” means any right to receive Common Stock granted under
the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. 

(pp) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. 
 (qq)
“Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such
corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the
Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. 

(rr) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of
the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. 

  
 21. 

 TDTX, INC. 

STOCK OPTION GRANT NOTICE 

(2019 EQUITY INCENTIVE PLAN) 
 TDTx,
Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the “Plan”), has granted to Optionholder an option to purchase
the number of shares of the Common Stock set forth below (the “Option”). The Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (the “Grant Notice”) and
in the Plan, the Option Agreement, and the Notice of Exercise, all of which are attached to this Grant Notice and incorporated into this Grant Notice in their entirety. Capitalized terms not explicitly defined in this Grant Notice but defined in the
Plan or the Option Agreement shall have the meanings set forth in the Plan or the Option Agreement, as applicable. If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank or the
information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of grant) shall be deemed to come from the electronic capitalization system and is considered part of
this Grant Notice. 
  

			
	Optionholder:	  	  

	Date of Grant:	  	  

	Vesting Commencement Date:	  	  

	Number of Shares Subject to Option:	  	  

	Exercise Price (Per Share)1:	  	  

	Total Exercise Price:	  	  

	Expiration Date:	  	  

	Exercise Schedule:	  	[Same as Vesting Schedule] [Early Exercise Permitted]
		
	Type of Grant2:	  	[Incentive Stock Option] [Nonstatutory Stock Option]

  

			
	Vesting Schedule:	  	[Sample of standard vesting. 12/48ths of the total shares will vest on the one-year anniversary of the Vesting Commencement Date, and 1/48th of the total shares will vest each month
thereafter on the same day of the month as the Vesting Commencement Date (or if there is no corresponding day, on the last day of the month), subject to Optionholder’s Continuous Service as of each such date.]

  

	1 	 The exercise price may be paid by one or a combination of the methods permitted in the Option Agreement.

	2 	 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. 

 Optionholder Acknowledgements: By Optionholder’s signature below or by electronic acceptance or
authentication in a form authorized by the Company, Optionholder understands and agrees that the Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Option Agreement and the Notice of Exercise, all of which
are made a part of this document. 
 By accepting this Option, Optionholder consents to receive this Grant Notice, the Option Agreement, the Plan, and any
other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the
Company. Optionholder represents that he or she has read and is familiar with the provisions of the Plan and the Option Agreement. Optionholder acknowledges and agrees that this Grant Notice and the Option Agreement may not be modified, amended or
revised except in writing signed by Optionholder and a duly authorized officer of the Company. 
 Optionholder further acknowledges that in the event of any
conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan shall control. Optionholder further acknowledges that the Option Agreement sets forth the entire
understanding between Optionholder and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously
granted to Optionholder and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and Optionholder in each case that specifies the terms that should
govern this Option. 
 Optionholder further acknowledges that this Grant Notice has been prepared on behalf of the Company by Cooley LLP, counsel to the
Company and that Cooley LLP does not represent, and is not acting on behalf of, Optionholder in any capacity. Optionholder has been provided with an opportunity to consult with Optionholder’s own counsel with respect to this Grant Notice. 

This Grant Notice may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other
transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
  

									
	TDTx, Inc.	  		  	Optionholder:
					
	By:	  	  
	  		  	By:	  	  

		  	(Signature)	  		  		  	(Signature)
	Title:	  	  
	  		  	Email:	  	  

	Date:	  	  
	  		  	Date:	  	  

 Attachments: Option Agreement, 2019 Equity Incentive Plan and Notice of Exercise 

 TDTX, INC. 

2019 Equity Incentive Plan 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, TDTx, Inc. (the
“Company”) has granted you an option under its 2019 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise
price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and
the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. 

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. Vesting. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

 2. Number of Shares and Exercise Price. The number of shares of Common Stock subject to your option and your exercise price per
share in your Grant Notice will be adjusted for Capitalization Adjustments. 
 3. Exercise Restriction for
Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a
“Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six months of Continuous Service measured from
the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six month anniversary
in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your
“retirement” (as defined in the Company’s benefit plans). 
 4. Exercise prior to Vesting (“Early Exercise”).
If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is both (i) during the period of your
Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that: 

(a) a partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting
installment of unvested shares of Common Stock; 
 (b) any shares of Common Stock so purchased from installments that have not vested
as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

  
 1. 

 (c) you will enter into the Company’s form of Early Exercise Stock Purchase
Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and 
 (d) if your option
is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable
for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as
Nonstatutory Stock Options. 
 5. Method of Payment. You must pay the full amount of the exercise price for the shares you wish to
exercise. The permitted methods of payment are as follows: 
 (a) by cash, check, bank draft, electronic funds transfer or money order
payable to the Company; 
 (b) subject to Company and/or Board consent at the time of exercise and provided that at the time of
exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company
or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to
cover”; 
 (c) subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the
Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are
valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such
shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the
Company’s stock; 
 (d) subject to Company and/or Board consent at the time of exercise, and provided that the Option is a
Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that you must pay any
remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to
the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to you as a result of such exercise, and (C) shares are withheld to satisfy tax
withholding obligations; 
 (e) subject to the consent of the Company and/or Board at the time of exercise, according to a deferred
payment or similar arrangement with you; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and
compensation income to the Optionholder under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 

  
 2. 

 (f) in any other form of legal consideration that may be acceptable to the Board.

 6. Whole Shares. You may exercise your option only for whole shares of Common Stock. 

7. Securities Law Compliance. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then
registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must
comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any
restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

8. Term. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. Except as set
forth in your Grant Notice, the term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

(a) immediately upon the termination of your Continuous Service for Cause; 

(b) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death
(except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to
“Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; provided
further, that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six months after the Date of Grant, and (iii) you have vested in a portion of your option
at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven months after the Date of Grant, and (B) the date that is three months after the
termination of your Continuous Service, and (y) the Expiration Date; 
 (c) 12 months after the termination of your Continuous
Service due to your Disability (except as otherwise provided in Section 8(d)) below; 
 (d) 18 months after your death if you die
either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause; 

(e) the Expiration Date indicated in your Grant Notice; or 

(f) the day before the 10th anniversary of the Date of Grant. 

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or
Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate terminates. 

  
 3. 

 9. Exercise. 

(a) You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours. If required by
the Company, your exercise may be made contingent on your execution of any additional documents specified by the Company (including, without limitation, any shareholders agreement, voting agreement, right of first refusal agreement or other
agreement between the Company and some or all of its stockholders). 
 (b) By exercising your option you agree that, as a condition to
any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option,
(ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon
exercise of your option. 
 (d) By exercising your option you agree that you will not sell, dispose of, transfer, make any short sale
of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days
following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar
rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the
Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or
that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any
transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 10.
Transferability. Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your
option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements
required by the Company. 

  
 4. 

 (b) Domestic Relations Orders. Upon receiving written permission from the
Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official
marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You
are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic
relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. 
 11. Right of First Refusal. Shares of Common Stock that you
acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if there is no right of
first refusal described in the Company’s bylaws at such time, the right of first refusal described below will apply. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or
approved for listing) upon notice of issuance on a national securities exchange or quotation system (the “Listing Date”). 

(a) Prior to the Listing Date, you may not validly Transfer (as defined below) any shares of Common Stock acquired upon exercise of your
option, or any interest in such shares, unless such Transfer is made in compliance with the following provisions: 
 (i) Before there
can be a valid Transfer of any shares of Common Stock or any interest therein, the record holder of the shares of Common Stock to be transferred (the “Offered Shares”) will give written notice (by registered or certified
mail) to the Company. Such notice will specify the identity of the proposed transferee, the cash price offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not receive cash, such as
an involuntary transfer, gift, donation or pledge, the holder will state that no purchase price is being proposed), and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter referred to as the
“Notice Date” and the record holder of the Offered Shares will be hereinafter referred to as the “Offeror.” If, from time to time, there is any stock dividend, stock split or other change in the
character or amount of any of the outstanding Common Stock which is subject to the provisions of your option, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the
shares of Common Stock acquired upon exercise of your option will be immediately subject to the Company’s Right of First Refusal (as defined below) with the same force and effect as the shares subject to the Right of First Refusal immediately
before such event. 
 (ii) For a period of 30 calendar days after the Notice Date, or such longer period as may be required to avoid
the classification of your option as a liability for financial accounting purposes, the Company will have the option to purchase all (but not less than all) of the Offered Shares at the purchase price and on the terms set forth in
Section 11(a)(iii) (the Company’s “Right of First  

  
 5. 

 
Refusal”). In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be the Fair Market Value of the Offered
Shares as determined in good faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First Refusal to the Offeror prior to the
end of said 30 days (including any extension required to avoid classification of the option as a liability for financial accounting purposes). 

(iii) The price at which the Company may purchase the Offered Shares pursuant to the exercise of its Right of First Refusal will be the
cash price offered for the Offered Shares by the proposed transferee (as set forth in the notice required under Section 11(a)(i)), or the Fair Market Value as determined by the Board in the event no purchase price is involved. To the extent
consideration other than cash is offered by the proposed transferee, the Company will not be required to pay any additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if applicable). The Company’s notice
of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon such payment by the Company, the Company will acquire full right, title and interest to all of the Offered Shares. 

(iv) If, and only if, the option given pursuant to Section 11(a)(ii) is not exercised, the Transfer proposed in the notice given
pursuant to Section 11(a)(i) may take place; provided, however, that such Transfer must, in all respects, be exactly as proposed in said notice except that such Transfer may not take place either before the 10th calendar day after the expiration of the 30 day option exercise period or after the ninetieth 90th calendar day after the expiration of the 30
day option exercise period, and if such Transfer has not taken place prior to said 90th day, such Transfer may not take place without once again complying with this Section 11(a). The option
exercise periods in this Section 11(a)(iv) will be adjusted to include any extension required to avoid the classification of your option as a liability for financial accounting purposes. 

(b) As used in this Section 11, the term “Transfer” means any sale, encumbrance, pledge, gift or other form
of disposition or transfer of shares of Common Stock or any legal or equitable interest therein; provided, however, that the term Transfer does not include a transfer of such shares or interests by will or intestacy to your Immediate Family
(as defined below). In such case, the transferee or other recipient will receive and hold the shares of Common Stock so transferred subject to the provisions of this Section, and there will be no further transfer of such shares except in accordance
with the terms of this Section 11. As used herein, the term “Immediate Family” will mean your spouse, the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child, grandchild or adopted
grandchild of you or your spouse, or the spouse of any child, adopted child, grandchild or adopted grandchild of you or your spouse. 

(c) None of the shares of Common Stock purchased on exercise of your option will be transferred on the Company’s books nor will the
Company recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this Section 11 have been complied with in all respects. The certificates of stock evidencing shares of Common Stock
purchased on exercise of your option will bear an appropriate legend referring to the transfer restrictions imposed by this Section 11. 

(d) To ensure that the shares subject to the Company’s Right of First Refusal will be available for repurchase by the Company, the
Company may require you to deposit the certificates evidencing the shares that you purchase upon exercise of your option with an escrow agent designated by the Company under the terms and conditions of an escrow agreement approved by the Company. If
the Company does not require such deposit as a condition of exercise of your option, the Company reserves the right at any time to require you to so deposit the certificates in escrow. As soon as practicable after

  
 6. 

 
the expiration of the Company’s Right of First Refusal, the agent will deliver to you the shares and any other property no longer subject to such restriction. In the event the shares and any
other property held in escrow are subject to the Company’s exercise of its Right of First Refusal, the notices required to be given to you will be given to the escrow agent, and any payment required to be given to you will be given to the
escrow agent. Within 30 days after payment by the Company for the Offered Shares, the escrow agent will deliver the Offered Shares that the Company has repurchased to the Company and will deliver the payment received from the Company to you. 

12. Option not a Service Contract. Your option is not an employment or service contract, and nothing in your option will be deemed to
create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an
Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

13. Withholding Obligations. 

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
option. 
 (b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and
compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair
Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for
financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence will not be permitted unless
you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the
determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock will be withheld solely from fully vested shares of Common Stock determined as of the date
of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure will be your sole responsibility. 

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. 

  
 7. 

 14. Tax Consequences. You hereby agree that the Company does not have a duty to
design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities
arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair
market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an established securities market, the Fair
Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by
the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the “fair
market value” as subsequently determined by the Internal Revenue Service. 
 15. Notices. Any notices provided for in your option
or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid,
addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to
participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system
established and maintained by the Company or another third party designated by the Company. 
 16. Governing Plan Document. Your
option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and
adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. 

  
 8. 

 TDTX, INC. 

NOTICE OF EXERCISE 
 This constitutes
notice to TDTx, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.
Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan. If the Company uses an electronic capitalization table system (such as Carta or Shareworks)
and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise. 
  

			
	 Option Information
	  	
		
	 Type of option (check one):
	  	Incentive  ☐ Nonstatutory  ☐
		  	  

	 Stock option dated:
	  	
		  	  

	 Number of Shares as to which option is exercised:
	  	
		  	  

	 Certificates to be issued in name
of:3
	  	
		  	  

		
	Exercise Information	  	
		
	 Date of Exercise:
	  	
		  	  

	 Total exercise price:
	  	
		  	  

	 Cash:4
	  	
		  	  

	 Regulation T Program (cashless
exercise):5
	  	
		  	  

	 Value of _________ Shares delivered with this
notice:6
	  	
		  	  

	 Value of _________ Shares pursuant to net
exercise:7
	  	
		  	  

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the 2019 Equity Incentive Plan to the Company (including, without limitation, any shareholders agreement, voting agreement, right of first refusal agreement or other agreement between the Company and some or all of its stockholders),
(ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you
in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within one year after such Shares are issued upon exercise of
this option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other
applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

I hereby make the following certifications and representations with respect to the number of Shares listed above, which are being acquired by
me for my own account upon exercise of the option as set forth above: 
  

	3 	 If left blank, will be issued in the name of the option holder. 

	4 	 Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.

	5 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. 

	6 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an
executed assignment separate from certificate. 

	7 	 Subject to Company and/or Board consent and must be a Nonstatutory Option.

 I acknowledge that the Shares have not been registered under the Securities Act of 1933, as
amended (the “Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present
intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 

I further acknowledge and agree that, except for such information as required to be delivered to me by the Company pursuant to the option or
the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the option, ownership of such shares of Common Stock, or as a
result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under Section 220 of the Delaware General Corporation Law and all such
similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become, applicable to the Company or the Company’s capital stock (the
“Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other
proceeding to pursue or exercise the Inspection Rights. 
 I further acknowledge that I will not be able to resell the Shares for at least
90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to
affiliates of the Company under Rule 144. 
 I further acknowledge that all certificates representing any of the Shares subject to the
provisions of the option will have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate of Incorporation, Bylaws and/or applicable
securities laws. 
 I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first
underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar
transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date of a registration statement of the Company filed under the
Securities Act (or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the “Lock-Up
Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In
order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. 

Very truly yours, 
  

			
		  	  

		  	(Signature)
		
		  	  

		  	Name (Please Print)
		
	Address of Record:	  	  

		  	  

		  	  

		
	Email:	  	  

 TDTX, INC. 

NOTICE OF EXERCISE 
 This constitutes
notice to TDTx, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.
Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan. If the Company uses an electronic capitalization table system (such as Carta or Shareworks)
and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise. 
  

			
	Option Information	  	
		
	 Type of option (check one):
	  	Incentive  ☐         Nonstatutory  ☐
		  	  

	 Stock option dated:
	  	
		  	  

	 Number of Shares as to which option is exercised:
	  	
		  	  

	 Certificates to be issued in name
of:1
	  	
		  	  

		
	Exercise Information	  	
		
	 Date of Exercise:
	  	
		  	  

	 Total exercise price:
	  	
		  	  

	 Cash:2
	  	
		  	  

	 Regulation T Program (cashless
exercise):3
	  	
		  	  

	 Value of _________ Shares delivered with this
notice:4
	  	
		  	  

	 Value of _________ Shares pursuant to net
exercise:5
	  	
		  	  

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the 2019 Equity Incentive Plan to the Company (including, without limitation, any shareholders agreement, voting agreement, right of first refusal agreement or other agreement between the Company and some or all of its stockholders),
(ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you
in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within one year after such Shares are issued upon exercise of
this option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other
applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

I hereby make the following certifications and representations with respect to the number of Shares listed above, which are being acquired by
me for my own account upon exercise of the option as set forth above: 
 I acknowledge that the Shares have not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the
Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 

 

	1 	 If left blank, will be issued in the name of the option holder. 

	2 	 Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.

	3 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. 

	4 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an
executed assignment separate from certificate. 

	5 	 Subject to Company and/or Board consent and must be a Nonstatutory Option.

 I further acknowledge and agree that, except for such information as required to be
delivered to me by the Company pursuant to the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the
option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under
Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become,
applicable to the Company or the Company’s capital stock (the “Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause
to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 
 I further
acknowledge that I will not be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 
 I further acknowledge that
all certificates representing any of the Shares subject to the provisions of the option will have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the
Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 
 I further agree that, if required by the Company
(or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any
option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date
of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the
“Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such period. 
 Very truly yours, 

 

			
		  	  

		  	(Signature)
		
		  	  

		  	Name (Please Print)
		
	Address of Record:	  	  

		  	  

		  	  

		
	Email:	  	  

 TDTX, INC. 

EARLY EXERCISE STOCK PURCHASE AGREEMENT 

UNDER THE 2019 EQUITY INCENTIVE PLAN 

This Agreement is made by and between TDTx, Inc., a Delaware corporation (the “Company”), and the
individual designated on the signature page hereto as a Purchaser (“Purchaser”). 
 Recitals: 

A. Purchaser holds a stock option, granted on [•], to purchase [•] shares of common
stock (“Common Stock”) of the Company (the “Option”) pursuant to the Company’s 2019 Equity Incentive Plan (as amended and/or restated, the “Plan”). 

B. The Option consists of a Stock Option Grant Notice and a Stock Option Agreement. 

C. Purchaser desires to exercise the Option on the terms and conditions contained herein. 

D. Purchaser wishes to take advantage of the early exercise provision of Purchaser’s Option and therefore to enter into this
Agreement. 
 The parties agree as follows: 

1. Incorporation of Plan and Option by Reference. This Agreement is subject to all of the terms and conditions as set forth in
the Plan and the Option. If there is a conflict between the terms of this Agreement and/or the Option and the terms of the Plan, the terms of the Plan will control. If there is a conflict between the terms of this Agreement and the terms of the
Option, the terms of the Option will control. Defined terms not explicitly defined in this Agreement but defined in the Plan will have the same definitions as in the Plan. Defined terms not explicitly defined in this Agreement or the Plan but
defined in the Option will have the same definitions as in the Option. 
 2. Purchase and Sale of Common Stock. 

(a) Agreement to purchase and sell Common Stock. Purchaser hereby agrees to purchase from the Company, and the Company hereby
agrees to sell to Purchaser, shares of the Common Stock of the Company in accordance with the Notice of Exercise duly executed by Purchaser and attached hereto as Exhibit A. 

(b) Closing. The closing hereunder, including payment for and delivery of the Common Stock, will occur at the offices of the Company
immediately following the execution of this Agreement, or at such other time and place as the parties may mutually agree; provided, however, that if stockholder approval of the Plan is required before the Option may be exercised, then the
Option may not be exercised, and the closing will be delayed, until such stockholder approval is obtained. If such stockholder approval is not obtained within the time limit specified in the Plan, then this Agreement is null and void. 

3. Unvested Share Repurchase Option. 

(a) Repurchase Option. In the event Purchaser’s Continuous Service terminates, then the Company has an irrevocable option (the
“Repurchase Option”) for a period of six months after said termination (or in the case of shares issued upon exercise of the Option after such date of termination, within six months after the date of the exercise), or such
longer period as may be agreed to by the 

 Company and Purchaser (the “Repurchase Period”), to repurchase from Purchaser or
Purchaser’s personal representative, as the case may be, those shares that Purchaser received pursuant to the exercise of the Option that have not as yet vested as of such termination date in accordance with the Vesting Schedule indicated on
Purchaser’s Stock Option Grant Notice (the “Unvested Shares”). 
 (b) Share Repurchase
Price. The Company may repurchase all or any of the Unvested Shares at the lower of (i) the Fair Market Value of the such shares (as determined under the Plan) on the date of repurchase, or (ii) the price equal to
Purchaser’s Exercise Price for such shares as indicated on Purchaser’s Stock Option Grant Notice. 
 4. Exercise of
Repurchase Option. The Repurchase Option will be exercised by written notice signed by such person as designated by the Company, and delivered or mailed as provided herein. Such notice will identify the number of shares of Common Stock to be
purchased and will notify Purchaser of the time, place and date for settlement of such purchase, which will be scheduled by the Company within the term of the Repurchase Option set forth above. In addition, the Company will be deemed to have
exercised the Repurchase Option as of the last day of the Repurchase Period, unless an officer of the Company notifies the holder of the Unvested Shares during the Repurchase Period in writing (delivered or mailed as provided herein) that the
Company expressly declines to exercise its Repurchase Option for some or all of the Unvested Shares. The Company will be entitled to pay for any shares of Common Stock purchased pursuant to its Repurchase Option at the Company’s option in cash
or by offset against any indebtedness owing to the Company by Purchaser (including without limitation any Promissory Note given in payment for the Common Stock), or by a combination of both. Upon exercise of the Repurchase Option and payment of the
purchase price in any of the ways described above, the Company will become the legal and beneficial owner of the Common Stock being repurchased and all rights and interest therein or related thereto, and the Company will have the right to transfer
to its own name the Common Stock being repurchased by the Company, without further action by Purchaser. 
 5. Capitalization Adjustments
to Common Stock. In the event of a Capitalization Adjustment, then any and all new, substituted or additional securities or other property to which Purchaser is entitled by reason of Purchaser’s ownership of Common Stock will
be immediately subject to the Repurchase Option and be included in the word “Common Stock” for all purposes of the Repurchase Option with the same force and effect as the shares of the Common Stock presently subject to the Repurchase
Option, but only to the extent the Common Stock is, at the time, covered by such Repurchase Option. While the total Option Price will remain the same after each such event, the Option Price per share of Common Stock upon exercise of the Repurchase
Option will be appropriately adjusted. 
 6. Corporate Transactions. In the event of a Corporate Transaction, then the
Repurchase Option may be assigned by the Company to the successor of the Company (or such successor’s parent company), if any, in connection with such Corporate Transaction. To the extent the Repurchase Option remains in effect following such
Corporate Transaction, it will apply to the new capital stock or other property received in exchange for the Common Stock in consummation of the Corporate Transaction, but only to the extent the Common Stock was at the time covered by such right.
Appropriate adjustments will be made to the price per share payable upon exercise of the Repurchase Option to reflect the Corporate Transaction upon the Company’s capital structure; provided, however, that the aggregate price payable
upon exercise of the Repurchase Option remains the same. 
 7. Escrow of Unvested Common Stock. As security for Purchaser’s
faithful performance of the terms of this Agreement and to insure the availability for delivery of Purchaser’s Common Stock upon exercise of the Repurchase Option herein provided for, Purchaser agrees, at the closing hereunder, to deliver to
and deposit with the Secretary of the Company or the Secretary’s designee (“Escrow Agent”), as Escrow Agent in this transaction, three stock assignments duly endorsed (with date and number of

  
 2. 

 
shares blank) in the form attached hereto as Exhibit B, together with a certificate or certificates evidencing all of the Common Stock subject to the Repurchase Option; said documents are to be
held by the Escrow Agent and delivered by said Escrow Agent pursuant to the Joint Escrow Instructions of the Company and Purchaser set forth in Exhibit C, attached hereto and incorporated by this reference, which instructions also will be delivered
to the Escrow Agent at the closing hereunder. 
 8. Rights of Purchaser. Subject to the provisions of the Option, Purchaser will
exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow. Purchaser will be deemed to be the holder of the shares for purposes of receiving any dividends that may be paid with respect to such
shares and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company’s Repurchase Option. 

9. Limitations on Transfer. In addition to any other limitation on transfer created by applicable securities laws, Purchaser will not
sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Stock while the Common Stock is subject to the Repurchase Option. After any Common Stock has been released from the Repurchase Option, Purchaser will not
sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Stock except in compliance with the provisions herein and applicable securities laws. Furthermore, the Common Stock is subject to any right of first
refusal in favor of the Company or its assignees or other transfer restrictions that may be contained in the Company’s Bylaws. 
 10.
Restrictive Legends. All certificates representing the Common Stock will have endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties hereto):

 (a) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE
REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN
CONSENT OF THE COMPANY.” 
 (b) “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933 AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED.” 
 (c) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL
OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AS PROVIDED IN THE BYLAWS OF THE COMPANY AND IN AN AGREEMENT WITH THE COMPANY.” 

(d) “THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED PURSUANT TO THE EXERCISE OF [AN INCENTIVE STOCK OPTION/ A
NONSTATUTORY STOCK OPTION].” 
 (e) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A TRANSFER RESTRICTION,
AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

  
 3. 

 (f) Any legend required by appropriate blue sky officials. 

11. Investment Representations. In connection with the purchase of the Common Stock, Purchaser represents to the Company the
following: 
 (a) Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Common Stock. Purchaser is acquiring the Common Stock for investment for Purchaser’s own account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act. 
 (b) Purchaser understands that the
Common Stock has not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser’s investment intent as expressed herein. 

(c) Purchaser further acknowledges and understands that the Common Stock must be held indefinitely unless the Common Stock is
subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser further acknowledges and understands that the Company is under no obligation to register the Common Stock. Purchaser understands that the
certificate evidencing the Common Stock will be imprinted with a legend that prohibits the transfer of the Common Stock unless the Common Stock is registered or such registration is not required in the opinion of counsel for the Company. 

(d) Purchaser is familiar with the provisions of Rules 144 and 701, under the Securities Act, as in effect from time to time,
which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering
subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of issuance of the securities, such issuance will be exempt from registration under the Securities Act. In the event the
Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the securities exempt under Rule 701 may be sold by Purchaser 90 days thereafter, subject to the satisfaction of certain
of the conditions specified by Rule 144 and the market stand-off provision described in Purchaser’s Stock Option Agreement. 

(e) In the event that the sale of the Common Stock does not qualify under Rule 701 at the time of purchase, then the Common Stock
may be resold by Purchaser in certain limited circumstances subject to the provisions of Rule 144, which requires, among other things: (i) the availability of certain public information about the Company, and (ii) the resale occurring
following the required holding period under Rule 144 after Purchaser has purchased, and made full payment of (within the meaning of Rule 144), the securities to be sold. 

(f) Purchaser further understands that at the time Purchaser wishes to sell the Common Stock there may be no public market upon which to
make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public current information requirements of Rule 144 or 701, and that, in such event, Purchaser would be precluded from selling the
Common Stock under Rule 144 or 701 even if the minimum holding period requirement had been satisfied. 

  
 4. 

 (g) Purchaser further warrants and represents that Purchaser has either
(i) preexisting personal or business relationships, with the Company or any of its officers, directors or controlling persons, or (ii) the capacity to protect his own interests in connection with the purchase of the Common Stock by virtue
of the business or financial expertise of Purchaser or of professional advisors to Purchaser who are unaffiliated with and who are not compensated by the Company or any of its affiliates, directly or indirectly. Purchaser further warrants and
represents that Purchaser’s purchase the Common Stock was not accomplished by the publication of any advertisement. 
 12.
Section 83(b) Election. Purchaser understands that Section 83(a) of the Code taxes as ordinary income the difference between the amount paid for the Common Stock and the fair market value of the Common Stock as of
the date any restrictions on the Common Stock lapse. In this context, “restriction” includes the right of the Company to buy back the Common Stock pursuant to the Repurchase Option set forth above. Purchaser understands that Purchaser may
elect to be taxed at the time the Common Stock is purchased, rather than when and as the Repurchase Option expires, by filing an election under Section 83(b) (an “83(b) Election”) of the Code with the Internal Revenue
Service within 30 days of the date of purchase, a copy of which is included as Exhibit D. Even if the fair market value of the Common Stock at the time of the execution of this Agreement equals the amount paid for the Common Stock, the 83(b)
Election must be made to avoid income under Section 83(a) in the future. Purchaser understands that failure to file such an 83(b) Election in a timely manner may result in adverse tax consequences for Purchaser. Purchaser further understands
that Purchaser must file an additional copy of such 83(b) Election with his or her federal income tax return for the calendar year in which the date of this Agreement falls. Purchaser acknowledges that the foregoing is only a summary of the effect
of United States federal income taxation with respect to purchase of the Common Stock hereunder, and does not purport to be complete. Purchaser further acknowledges that the Company has directed Purchaser to seek independent advice regarding the
applicable provisions of the Code, the income tax laws of any municipality, state or foreign country in which Purchaser may reside, and the tax consequences of Purchaser’s death. Purchaser assumes all responsibility for filing an 83(b) Election
and paying all taxes resulting from such election or the lapse of the restrictions on the Common Stock. 
 13. Refusal to Transfer.
The Company is not required (a) to transfer on its books any shares of Common Stock of the Company which have been transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such shares
or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares have been so transferred. 
 14. No
Employment Rights. This Agreement is not an employment contract and nothing in this Agreement affects in any manner whatsoever the right or power of the Company or its Affiliates to terminate Purchaser’s employment for any reason at any
time, with or without cause and with or without notice. 
 15. Miscellaneous. 

(a) Notices. All notices required or permitted hereunder will be in writing and will be deemed effectively given: (i) upon personal
delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, and if not during normal business hours of the recipient, then on the next business day, (iii) five calendar
days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications will be sent to the other party hereto at such party’s address hereinafter set forth on the signature page hereof, or at such other address as such party may designate by 10 days advance written
notice to the other party hereto. 

  
 5. 

 (b) Successors and Assigns. This Agreement will inure to the benefit of the
successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser, Purchaser’s successors, and assigns. The Company may assign the Repurchase Option hereunder at any time or from time
to time, in whole or in part. 
 (c) Attorneys’ Fees; Specific Performance. Purchaser will reimburse the Company for all costs
incurred by the Company in enforcing the performance of, or protecting its rights under, any part of this Agreement, including reasonable costs of investigation and attorneys’ fees. It is the intention of the parties that the Company, upon
exercise of the Repurchase Option and payment for the shares repurchased, pursuant to the terms of this Agreement, will be entitled to receive the Common Stock, in specie, in order to have such Common Stock available for future issuance
without dilution of the holdings of other stockholders. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate the Company for the Common Stock and that the Company will, upon proper exercise of the
Repurchase Option, be entitled to specific enforcement of its rights to purchase and receive said Common Stock. 
 (d) Governing Law;
Venue. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware. The parties agree that any action brought by either party to interpret or enforce any provision of this Agreement will be brought in,
and each party agrees to, and does hereby, submit to the jurisdiction and venue of, the appropriate state or federal court for the district encompassing the Company’s principal place of business. 

(e) Further Execution. The parties agree to take all such further action(s) as may reasonably be necessary to carry out and consummate
this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject of this Agreement. 

(f) Independent Counsel. Purchaser acknowledges that this Agreement has been prepared on behalf of the Company by Cooley LLP, counsel to
the Company and that Cooley LLP does not represent, and is not acting on behalf of, Purchaser in any capacity. Purchaser has been provided with an opportunity to consult with Purchaser’s own counsel with respect to this Agreement. 

(g) Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the parties with respect to the subject matter
hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part, except by an agreement in writing signed by each of the parties hereto.

 (h) Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree
to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision will be excluded from this Agreement, (ii) the balance of
the Agreement will be interpreted as if such provision were so excluded and (iii) the balance of the Agreement will be enforceable in accordance with its terms. 

(i) Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or
other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

  
 6. 

 [Remainder of page intentionally left blank] 

The parties hereto have executed this Agreement as of _______________. 

 

			
	COMPANY:
	
	TDTX, INC.
		
	By:	 	  

		 	Name:                                     
                                        
            
		 	Title:                                     
                                         
           
		
	Email:	 	  

	
	PURCHASER:
	  

	(Signature)
	  

	Name (Please Print)
	  

	Email

 ATTACHMENTS: 
  

			
	Exhibit A	  	Notice of Exercise
	Exhibit B	  	Assignment Separate from Certificate
	Exhibit C	  	Joint Escrow Instructions
	Exhibit D	  	Form of 83(b) Election

 [Signature Page to Early Exercise Stock Purchase Agreement] 

 EXHIBIT A 

NOTICE OF EXERCISE 

 TDTX, INC. 

NOTICE OF EXERCISE 
 This constitutes
notice to TDTx, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.
Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan. If the Company uses an electronic capitalization table system (such as Carta or Shareworks)
and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise. 
  

			
	 Option Information
	  	
		
	 Type of option (check one):
	  	Incentive  ☐         Nonstatutory  ☐
		  	  

	 Stock option dated:
	  	
		  	  

	 Number of Shares as to which option is exercised:
	  	
		  	  

	 Certificates to be issued in name
of:1
	  	
		  	  

		
	Exercise Information	  	
		
	 Date of Exercise:
	  	
		  	  

	 Total exercise price:
	  	
		  	  

	 Cash:2
	  	
		  	  

	 Regulation T Program (cashless
exercise):3
	  	
		  	  

	 Value of _________ Shares delivered with this
notice:4
	  	
		  	  

	 Value of _________ Shares pursuant to net
exercise:5
	  	
		  	  

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the 2019 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to
an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within one year
after such Shares are issued upon exercise of this option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

I hereby make the following certifications and representations with respect to the number of Shares listed above, which are being acquired by
me for my own account upon exercise of the option as set forth above: 
 I acknowledge that the Shares have not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the
Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 

 

	1 	 If left blank, will be issued in the name of the option holder. 

	2 	 Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.

	3 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. 

	4 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an
executed assignment separate from certificate. 

	5 	 Subject to Company and/or Board consent and must be a Nonstatutory Option.

 I further acknowledge and agree that, except for such information as required to be
delivered to me by the Company pursuant to the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the
option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under
Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become,
applicable to the Company or the Company’s capital stock (the “Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause
to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 
 I further
acknowledge that I will not be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 
 I further acknowledge that
all certificates representing any of the Shares subject to the provisions of the option will have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the
Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 
 I further agree that, if required by the Company
(or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any
option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date
of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the
“Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such period. 
 Very truly yours, 

 

			
		  	  

		  	(Signature)
		
		  	  

		  	Name (Please Print)
		
	Address of Record:	  	  

		  	  

		  	  

		
	Email:	  	  

  
 2. 

 EXHIBIT B 

STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 

For Value Received, the undersigned hereby sells, assigns and transfers unto TDTx, Inc., a Delaware corporation (the
“Company”), pursuant to the Repurchase Option under that certain Early Exercise Stock Purchase Agreement, dated [______________], by and between the undersigned and the Company (the “Agreement”)
__________________ shares of Common Stock of the Company standing in the undersigned’s name on the books of the Company represented by Certificate No[s] ________________ and does hereby irrevocably constitute and appoint both the Company’s
Secretary and the Company’s attorney, or either of them, to transfer said stock on the books of the Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and
conditions of the Agreement, in connection with the repurchase of shares of Common Stock issued to the undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Repurchase Option under the
Agreement. 
  

					
	 Dated: __________________________
	 		  	
	(leave
blank)                                        
        	 		  	  

		 		  	(Signature)
		 		  	  

		 		  	Name (Please Print)

 Instruction: Please do not fill in any blanks other than the signature line. Do not fill in the date
line. The purpose of this Assignment is to enable the Company to exercise its Repurchase Option set forth in the Agreement without requiring additional signatures on the part of Purchaser. 

 EXHIBIT C 

JOINT ESCROW INSTRUCTIONS 

 JOINT ESCROW INSTRUCTIONS 

________, 20__ 
 Secretary 

TDTx, Inc. 
 One Broadway, 14th Floor 

Kendall Square 
 Cambridge, Massachusetts 02142 

Ladies and Gentlemen: 
 As Escrow Agent for both TDTx,
Inc., a Delaware corporation (“Company”) and the purchaser listed on the signature page hereto (“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant
to the terms of that certain Early Exercise Stock Purchase Agreement dated as of _______________ (“Agreement”), to which a copy of these Joint Escrow Instructions is attached as an Exhibit, in accordance with the following
instructions: 
 1. In the event Company or an assignee elects to exercise the Repurchase Option set forth in the Agreement, the
Company or its assignee will give to Purchaser and you a written notice specifying the number of shares of stock to be acquired and the time for a closing thereunder at the principal office of the Company. Purchaser and the Company hereby
irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 

2. At the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in
the number of shares being transferred, and (c) to deliver the same, together with the certificate evidencing the shares of stock to be transferred, to the Company. 

3. Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you
hereunder and any additions and substitutions to said shares as specified in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as his
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities
negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the provisions of this paragraph 3, Purchaser will exercise all rights
and privileges of a stockholder of the Company while the stock is held by you. 
 4. This escrow terminates and the shares of stock
held hereunder are released in full upon the exercise or expiration in full of the Repurchase Option, whichever occurs first. 
 5. If
at the time of termination of this escrow under Section 4 herein you should have in your possession any documents, securities, or other property belonging to Purchaser, you will deliver all of the same to Purchaser and will be discharged of all
further obligations hereunder; provided, however, that if at the time of termination of this escrow you are advised by the Company that any property subject to this escrow is the subject of a pledge or other security agreement, you will deliver all
such property to the pledgeholder or other person designated by the Company. 
 6. Except as otherwise provided in these Joint Escrow
Instructions, your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 

 7. You are obligated only for the performance of such duties as are specifically set
forth herein and may rely and are protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You are not personally liable for any
act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith and in the exercise of your own good judgment, and
any act done or omitted by you pursuant to the advice of your own attorneys is conclusive evidence of such good faith. 
 8. You are
hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or entity, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders,
judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree of any court, you are not liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance,
notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction. 

9. You are not liable in any respect on account of the identity, authorities or rights of the parties executing or delivering or
purporting to execute or deliver these Joint Escrow Instructions documents or papers deposited or called for hereunder. 
 10. You are
not liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you. 

11. Your responsibilities as Escrow Agent hereunder terminate if you cease to be Secretary of the Company or if you resign by written
notice to the Company. In the event of any such termination, the Secretary of the Company will automatically become the successor Escrow Agent unless the Company appoints another successor Escrow Agent, and Purchaser hereby confirms the appointment
of such successor as Purchaser’s attorney-in-fact and agent to the full extent of your appointment. 

12. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect
hereto, the necessary parties hereto will join in furnishing such instruments. 
 13. It is understood and agreed that should any
dispute arise with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities
until such dispute has been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but
you will be under no duty whatsoever to institute or defend any such proceedings. 
 14. All notices required or permitted hereunder
will be in writing and will be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, and if not during normal
business hours of the recipient, then on the next business day, (c) five (5) calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications will be sent to the other party hereto at such party’s address set forth below, or at such other address as such
party may designate by ten (10) days advance written notice to the other party hereto. 

  
 2. 

 
			
	Company:	  	TDTx, Inc.
		
		  	 One Broadway, 14th Floor
 Kendall
Square

		  	 Cambridge, Massachusetts 02142
 Attn: Chief
Executive Officer

		
	Purchaser:	  	                                      
                      
		  	                                      
                      
		  	                                      
                      
		
	Escrow Agent:	  	TDTx, Inc.
		  	 One Broadway, 14th Floor
 Kendall
Square

		  	 Cambridge, Massachusetts 02142
 Attn:
Secretary

 15. By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of
said Joint Escrow Instructions; you do not become a party to the Agreement. 
 16. You are entitled to employ such legal counsel and
other experts (including, without limitation, the firm of Cooley LLP) as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and you may pay such counsel
reasonable compensation therefor. The Company is responsible for all fees generated by such legal counsel in connection with your obligations hereunder. 

17. This instrument is binding upon and inures to the benefit of the parties hereto and their respective successors and permitted
assigns. It is understood and agreed that references to “you” and “your” herein refer to the original Escrow Agents and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from
time to time assign its rights under the Agreement and these Joint Escrow Instructions in whole or in part. 
 [Remainder of page
intentionally left blank] 

  
 3. 

 18. These Joint Escrow Instructions are governed by and interpreted and determined in
accordance with the laws of the State of Delaware, as such laws are applied by Delaware courts to contracts made and to be performed entirely in Delaware by residents of that state. The parties hereby expressly consent to the personal jurisdiction
of the state and federal courts located in the county in which the Company has its principal offices for any lawsuit arising from or related to this Agreement. 

Very truly yours, 
  

			
	COMPANY:
	
	TDTx, Inc.
		
	By:	 	  

		 	Name:                                     
                                    
		 	Title:
                                         
                               
	
	PURCHASER:
	
	  

	(Signature)
	
	  

	Name (Please Print)

  

	
	Escrow Agent:
	  

	Artur Adib, Secretary

 [Signature Page to Joint Escrow Instructions] 

 EXHIBIT D 

83(b) ELECTION 

 [This Form is designed for Individual purchasers. Corporate or Trust purchasers should
contact their Tax Professional to review before submitting.] 
 Instructions for Filing Section 83(b) Election 

Attached is a form of election under Section 83(b) of the Internal Revenue Code and an accompanying IRS cover letter. Please fill in your
[social security number][taxpayer identification number] and sign the election and cover letter, then proceed as follows: 
 (a) Make
three copies of the completed election form and one copy of the IRS cover letter. 
 (b) Send the original signed election
form and cover letter, the copy of the cover letter, and a self-addressed stamped return envelope to the Internal Revenue Service Center where you would otherwise file your tax return6. Even if an
address for an Internal Revenue Service Center is already included in the forms below, it is your obligation to verify such address. This can be done by searching for the term “where to file” on www.irs.gov or by calling 1 (800) 829-1040. 
 Sending the election via certified mail, requesting a return receipt, with the certified mail
number written on the cover letter is also recommended. 
 (c) Deliver one copy of the completed election form to the Company. 

(d) Applicable state law may require that you attach a copy of the completed election form to your 201[_] state personal income tax return(s) when you
file it for the year (assuming you file a state personal income tax return).7 
 Please
consult your personal tax advisor(s) to determine whether or not a copy of this Section 83(b) election should be filed with your state personal income tax return(s). 

(e) Retain one copy of the completed election form for your personal permanent records. 

Note: An additional copy of the completed election form must be delivered to the transferee (recipient) of the property if the service provider
and the transferee are not the same person. 
 Please note that the election must be filed with the IRS within 30 days of the date of your restricted
stock grant. Failure to file within that time will render the election void and you may recognize ordinary taxable income as your vesting restrictions lapse. The Company and its counsel cannot assume responsibility for failure to file the election
in a timely manner under any circumstances. 
  

	6 	 Note: Per Treasury Regulation § 1.83-2(c), the
Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. As of October 2016, if you live in a foreign country or are a dual status alien (foreigners that will have lived both in their home
country and the United States during the year in which they make the election) you should send the 83(b) election to Austin, TX 73301-0215. You can verify this is still the correct address at: http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. 

	7 	 Note: Pursuant to Treasury Regulations finalized in July 2016 (Treas. Reg. § 1.83-2(c); T.D. 9779), taxpayers are no longer required to submit a copy of a Code Sec. 83(b) election with their federal personal income tax returns for the year in which the property subject to the
election was transferred. However, you are strongly encouraged to retain a copy of the completed election form and the IRS filed-stamped copy of your cover letter along with a copy of the federal personal income tax return for the year in which the
property subject to the election was transferred for your personal permanent records in case you ever need to demonstrate proper and timely filing (a common requirement imposed by acquirers in M&A transactions).

 SECTION 83(b) ELECTION 

____________, 201_ 
 Department of the Treasury

 Internal Revenue Service 
 [City, State Zip]8[Austin, TX 73301-0215 
 USA]9 

 

	Re:	 Election Under Section 83(b) 

Ladies and Gentlemen: 
 The undersigned taxpayer hereby elects,
pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those
shares. The following information is supplied in accordance with Treasury Regulation § 1.83-2: 
  

	1.	 The name, [social security number][taxpayer identification number], address of the undersigned, and the
taxable year for which this election is being made are: 

Name:                       
  ____________ 
 [Social Security Number][Tax Identification Number]:     ____________ 10 

Address:                ____________ 

                        
                               

Taxable year: Calendar year 201_.11 

 

	2.	 The property that is the subject of this election: [#] shares of common stock of [Company], a
[State] corporation (the “Company”). 

  

	3.	 The property was transferred on: [•], 201_. 

 

	8 	 Note: Per Treasury Regulation § 1.83-2(c),
the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. Assuming these are individual taxpayers who would file a Form 1040, see http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. Use the address in the row which includes the state in which the service provider lives and in the column entitled “And you ARE NOT enclosing a payment”.

	9 	 Note: Per Treasury Regulation § 1.83-2(c),
the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. As of October 2016, if you live in a foreign country or are a dual status alien (foreigners that will have lived both in their
home country and the United States during the year in which they make the election) you should send the 83(b) election to Austin, TX 73301-0215. You can verify this is still the correct address at: http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. 

	10 	 Note: If you do not have a taxpayer ID number (TIN), put “None –non-US taxpayer” and include in the cover letter to the IRS a statement explaining that the Section 83(b) election is being filed because the individual may become a US taxpayer before the stock
vests. If the individual is applying for a TIN, instead include “applied for” and enclose a copy of the W-7 application. Note that there may be important factors to consider before applying for a
TIN, including immigration status, etc. 

	11 	 Note: If an entity is the service provider, instead use “Fiscal year ending ___.”

	4.	 The property is subject to the following restrictions: Some or all of the shares are subject to
forfeiture or repurchase at less than their fair market value if the undersigned does not continue to provide services for the Company for a designated period of time. The risk of forfeiture or repurchase lapses over a specified vesting period.

  

	5.	 The fair market value of the property at the time of transfer (determined without regard to any restriction
other than a nonlapse restriction as defined in Treasury Regulation § 1.83-3(h)): $[•] per share x [#] shares = $[•]. 

 

	6.	 For the property transferred, the undersigned paid: $[•] per share x [#] shares = $[•].

  

	7.	 The amount to include in gross income is:
$[•].12 

 The undersigned taxpayer will file this election with the Internal
Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the election also will be furnished to the person for whom the services were performed
and the transferee of the property. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable year in which the property is transferred. The undersigned is the person performing the services
in connection with which the property was transferred. 
  

	
	Very truly yours,
	
	  

	[Name]

  

	12 	 Note: This should equal the amount in Item 5 minus the amount in Item 6, and in many cases will
be $0.00. 

 RETURN SERVICE REQUESTED 

Department of the Treasury 
 Internal Revenue Service 

[City, State, ZIP][Austin, TX 73301-0215 
 USA] 

 

	Re:	 Election Under Section 83(b) of the Internal Revenue Code

 Dear Sir or Madam: 

Enclosed please find an executed form of election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with respect
to an interest in TDTx, Inc. 
 [Please note, the undersigned does not currently have a Tax Identification Number because the undersigned is
not a U.S. taxpayer, but may become a U.S. resident before the stock vests. ] 
 Also enclosed is a copy of the signed form of election
under Section 83(b). Please acknowledge receipt of these materials by marking the copy when received and returning it in the enclosed stamped, self-addressed envelope. 

Thank you very much for your assistance. 
  

	
	Very truly yours,
	
	  

	[Name]

 Enclosures 

 TDTX INC. 

RESTRICTED STOCK AWARD GRANT NOTICE 

(2019 EQUITY INCENTIVE PLAN) 
 TDTx
Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant, in consideration for Participant’s past or future services actually or to be
rendered to the Company, the number of shares of Common Stock (the “Shares”) set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock
Award Grant Notice (the “Grant Notice”) and the attached Restricted Stock Award Terms and Conditions (together with the Grant Notice, the “Award Agreement”), and the Plan, all of which are attached to
this Grant Notice and incorporated into this Grant Notice in their entirety. Capitalized terms not explicitly defined in the Award Agreement but defined in the Plan will have the meanings provided in the Plan. If the Company uses an electronic
capitalization table system (such as Carta or Shareworks) and the fields below are blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of
grant) shall be deemed to come from the electronic capitalization system and is considered part of this Grant Notice. 
  

			
	Participant:	  	                                     
                       
	Date of Grant:	  	                                     
                       
	Vesting Commencement Date:	  	                                     
                       
	Number of Shares Subject to Award:	  	                                     
                       
	Consideration:	  	[Participant’s services]

  

			
	Vesting Schedule:	  	[Sample of standard vesting. 12/48ths of the total shares will vest on the one-year anniversary of the Vesting Commencement Date, and 1/48th of the total shares will vest each month
thereafter on the same day of the month as the Vesting Commencement Date (or if there is no corresponding day, on the last day of the month), subject to Participant’s Continuous Service as of each such date].

 Additional Terms/Acknowledgements: Participant acknowledges receipt of a copy of the Plan and represents that he or she
is familiar with the terms and provisions thereof, and hereby accepts this Award subject to all of the terms and provisions of the Plan and this Award Agreement (including all attachments and exhibits) and has had an opportunity to obtain the advice
of counsel prior to executing and accepting the Award. By accepting this Award, Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board upon any questions arising under the Plan or this
Award. 
 Participant further consents to receive any documents related to the Plan by electronic delivery and to participate in the Plan through an online
or electronic system established and maintained by the Company or a third party designated by the Company. 
 Participant further acknowledges that as of
the Date of Grant, this Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements on that subject, with
the exception of (i) options, restricted stock awards or other compensatory stock awards previously granted and delivered to Participant, and (ii) any written employment or severance arrangement that would provide for vesting acceleration
of this Award upon the terms and conditions set forth therein. 

 Participant further acknowledges that this Award Agreement has been prepared on behalf of the Company by
Cooley LLP, counsel to the Company and that Cooley LLP does not represent, and is not acting on behalf of, Participant in any capacity. Participant has been provided with an opportunity to consult with Participant’s own counsel with respect to
this Award Agreement. 
 This Award may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other
applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

 

							
	TDTx Inc.	 		  	Participant:
				
	By:	 	  
	 		  	  

		 	Signature	 		  	Signature
	Title:	 	  
	 		  	Date:
                                         
       
	Date:	 	  
	 		  	

 Attachments: 
  

			
	Attachment I:	    	Restricted Stock Award Terms and Conditions
	Exhibit A:	    	Assignment Separate from Certificate
	Exhibit B :	    	Joint Escrow Instructions
		
	Attachment II:	    	2019 Equity Incentive Plan
	Attachment III:	    	Section 83(b) Election

 ATTACHMENT I 

RESTRICTED STOCK AWARD TERMS AND CONDITIONS 

 TDTX INC. 

(2019 EQUITY INCENTIVE PLAN) 

RESTRICTED STOCK AWARD TERMS AND CONDITIONS 

TDTx Inc. (the “Company”) has awarded you, in exchange for your services to the Company, the number of Shares
indicated in the Grant Notice (the “Award”) pursuant to its 2019 Equity Incentive Plan (the “Plan”). The Grant Notice and these Restricted Stock Award Terms and Conditions are collectively referred to
as the “Award Agreement”. Capitalized terms not explicitly defined in this Agreement but defined in the Plan will have the same meanings given to them in the Plan. 

The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. Escrow of Shares. As security for your faithful performance of the terms of this Award Agreement and to ensure the availability for
delivery of the Unvested Shares upon exercise of the Reacquisition Right, you agree that the Shares will be held in escrow pursuant to the terms of the Joint Escrow Instructions attached to this Agreement as Exhibit B. You agree to execute
and deliver to the individual designated as the escrow agent in the Joint Escrow Instructions or person’s designee (the “Escrow Agent”), (i) the Joint Escrow Instructions and (ii) two Assignment Separate From
Certificate forms duly endorsed (with date and number of shares blank) substantially in the form attached to this Agreement as Exhibit A and deliver the same, along with the certificate or certificates evidencing the Unvested Shares, which
will be held and used by the Escrow Agent pursuant to the terms of the Joint Escrow Instructions. 
 2. Vesting. Subject to the
limitations contained herein, the Shares will vest pursuant to the Vesting Schedule in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. “Vested Shares” will mean Shares that
have vested in accordance with the Vesting Schedule, and “Unvested Shares” will mean Shares that have not vested in accordance with the Vesting Schedule. 

3. Number of Shares; Capitalization Adjustments. The number of Shares subject to your Award may be adjusted from time to time for
Capitalization Adjustments. In the event of any such Capitalization Adjustments, new, substituted or additional securities or other property to which you are entitled by reason of your ownership of the Unvested Shares will be immediately subject to
the same vesting requirements and vesting schedule that is applicable to the Shares with respect to which such additional Shares relate, as well as all transfer restrictions contained in this Award Agreement, including the Reacquisition Right, the
Right of First Refusal and the Lock-Up Period (each as defined below). No fractional shares or rights for fractional shares will be created pursuant to this Section. Any fraction of a share will be rounded
down to the nearest whole share. 
 4. Securities Law Compliance. The Shares are not registered under the Securities Act. At this
time, the Company has determined that the issuance of the Shares under this Award is exempt from the registration requirements of the Securities Act. If the Company determines at any time that an exemption from the registration requirements of the
Securities Act was not available or that the issuance of the Shares otherwise would not comply with any other applicable laws and regulations, then the Company will not be obligated to issue the Shares or may rescind the award to you. 

  
 1 

 5. Transfer Restrictions. In addition to any other limitation on transfer
created by the Company’s bylaws and applicable securities laws, you may not Transfer all or any part of the Unvested Shares or any interest in the Unvested Shares while such shares are subject to the Reacquisition Right (as defined below) or
continue to be held by the Escrow Agent (as defined below) or by the Company’s transfer agent in restricted book entry form. In the case of Vested Shares, you may not Transfer the Vested Shares or any interest in the Vested Shares except in
compliance with this Award Agreement, including without limitation the Right of First Refusal (as defined below), the Company’s bylaws and applicable securities laws. As used in this Award Agreement, the term “Transfer”
means any sale, encumbrance, pledge, gift or other form of disposition or transfer of shares of Common Stock or any legal or equitable interest therein; provided, however, that the term Transfer does not include a transfer of such shares or
interests by will or intestacy to your Immediate Family. In such case, the transferee or other recipient will receive and hold the Shares so transferred subject to the provisions of this Award Agreement, and there will be no further transfer of such
shares except in accordance with the terms of this Award Agreement. The term “Immediate Family” will mean your spouse, the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child, grandchild
or adopted grandchild of you or your spouse, or the spouse of any child, adopted child, grandchild or adopted grandchild of you or your spouse. 

6. Unvested Share Reacquisition Right. 

(a) Reacquisition Right. In the event your Continuous Service terminates, the Company will automatically reacquire (the
“Reacquisition Right”) on the date that is 90 days after the termination of your Continuous Service (the “Reacquisition Date”) all Unvested Shares as of the date of your termination of Continuous
Service without any payment to you (that is, for zero dollars ($0)) and without any required action or notice to you. You hereby agree to take whatever action the Company deems necessary to effectuate the Company’s reacquisition of the Unvested
Shares. Following such reacquisition, the Company will become the legal and beneficial owner of the Unvested Shares being reacquired and all rights and interests in and related to such shares, and the Company will have the right to transfer to its
own name the Unvested Shares being reacquired by the Company without further action by you. Notwithstanding anything to the contrary in this Section or in this Award Agreement, the Company may elect to waive, in its sole discretion, its
Reacquisition Right in whole or in part by providing written notice to you (with a copy to the Escrow Agent, as defined below), at any time prior to or on the Reacquisition Date, and the Escrow Agent may then release to you the number of Shares not
being reacquired by the Company. 
 (b) Corporate Transactions. To the extent the Reacquisition Right remains in effect following a
Corporate Transaction or Change in Control, unless otherwise provided by the Board pursuant to the terms of the Plan, it will apply to the new capital stock, cash or other property received in exchange for the Unvested Shares in consummation of the
Corporate Transaction or Change in Control, as applicable, but only to the extent the Unvested Shares were at the time covered by such right. 

(c) Termination of Reacquisition Right. The Company’s Reacquisition Right will terminate upon the earlier of (i) the
Company’s reacquisition in full of the Unvested Shares (or waiver of the Reacquisition Right) and (ii) the expiration of the Company’s Reacquisition Right. 

7. Right of First Refusal. Shares that are received under your Award are subject to any right of first refusal that may be
described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if there is no right of first refusal described in the Company’s bylaws at such time, the right of first
refusal described below (the “Right of First Refusal”) will apply. The Right of First Refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on
a national securities exchange or quotation system (the “Listing Date”). 

  
 2 

 (a) Prior to the Listing Date, you may not validly Transfer any Shares received under
the Award, or any interest in such shares, unless such Transfer is made in compliance with the following provisions: 
 (i) Before
there can be a valid Transfer of any Shares or any interest therein, the record holder of the Shares to be transferred (the “Offered Shares”) will give written notice (by registered or certified mail) to the Company (the
“ROFR Notice”). Such notice will specify the identity of the proposed transferee, the cash price offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not
receive cash, such as an involuntary transfer, gift, donation or pledge, the holder will state that no purchase price is being proposed), and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter
referred to as the “Notice Date” and the record holder of the Offered Shares will be hereinafter referred to as the “Offeror.” 

(ii) For a period of 30 calendar days after the Notice Date, the Company will have the option to exercise its Right of First Refusal
and purchase all or any portion of the Offered Shares at the purchase price and on the terms set forth in this Section. In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be
the Fair Market Value of the Offered Shares as determined in good faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First
Refusal to the Offeror prior to the end of said 30 days. 
 (iii) The price at which the Company may purchase the Offered Shares
pursuant to the exercise of its Right of First Refusal will be the cash price offered for the Offered Shares by the proposed transferee (as set forth in the ROFR Notice), or the Fair Market Value as determined by the Board in the event no purchase
price is involved. To the extent consideration other than cash is offered by the proposed transferee, the Company will not be required to pay any additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if
applicable). The Company’s notice of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon such payment by the Company, the Company will acquire full right, title and interest to all of the
Offered Shares. 
 (iv) If, and only if, the Company elects not to exercise its Right of First Refusal as to the Offered Shares, the
Transfer proposed in the ROFR Notice may take place; provided, however, that such Transfer must, in all respects, be exactly as proposed in said notice except that such Transfer may not take place either before the 10th calendar day after the expiration of the 30 day option exercise period or after the 90th calendar day after the expiration of the 30 day option
exercise period, and if such Transfer has not taken place prior to said 90th day, such Transfer may not take place without once again complying with this Section. 

(b) None of the shares of Common Stock received under the Award will be transferred on the Company’s books nor will the Company
recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this Section have been complied with in all respects. The certificates of stock evidencing Shares received under the Award will bear
an appropriate legend referring to the transfer restrictions imposed by this Section. 
 8.
Lock-Up Period. By accepting your Award, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or
similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days following the effective date of a registration statement of the Company
filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules (the “Lock-Up Period”);

  
 3 

 
provided, however, that nothing contained in this Section will prevent the exercise of a reacquisition or repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give
further effect to the foregoing covenant. You also agree that any transferee of any other shares of Common Stock (or other securities) of the Company held by you will be bound by this Section. To enforce the foregoing covenant, the Company may
impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section and will have the right, power and
authority to enforce the provisions of this Section as though they were a party to this Award Agreement. You further agree that the obligations contained in this Section 8 shall also, if so determined by the Company’s Board of Directors,
apply in the Company’s initial listing of its Common Stock on a national securities exchange by means of a registration statement on Form S-1 under the Securities Act (or any successor registration form
under the Securities Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale (a “Direct
Listing”) (and, for avoidance of doubt, the Lock-Up Period shall be deemed to include the period following the Direct Listing during which the restrictions under this Section 8 apply)
provided that all holders of at least 5% of the Company’s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding Preferred Stock of the Company) are subject to substantially similar obligations with
respect to such Direct Listing. 
 9. Rights as Stockholder. 

(a) General. Subject to the provisions of this Award Agreement, you will exercise all rights and privileges of a stockholder of the
Company with respect to the Shares, including for purposes of exercising any voting rights relating to any Unvested Shares. 
 (b)
Dividends. You will be deemed to be the holder of the Unvested Shares for purposes of receiving any dividends that may be paid with respect to such Shares; provided, however, that any dividends or other distributions paid with respect to
the Unvested Shares shall be subject to all of the terms and conditions applicable under this Award Agreement to the same extent as the Unvested Shares. For clarity, cash dividends made prior to the vesting of any Unvested Shares will be withheld
and paid to you (without interest) only if, when and to the extent, such Shares become Vested Shares. 
 10. Waiver of
Information Rights. You hereby acknowledge and agree that, except for such information as required to be delivered to you by the Company pursuant to any other agreement by and between you and the Company, you shall have no right to receive any
information from the Company by virtue of your purchase of the Shares, ownership of the Shares, or as a result of you being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, you
hereby waive your inspection rights under Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign
regulation, that are, or may become, applicable to the Company, the Company’s capital stock or the Shares (the “Inspection Rights”). You hereby covenant and agree never to directly or indirectly commence,
voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 

  
 4 

 11. Restrictive Legends. All certificates representing the Common Stock
issued under your Award will be endorsed with appropriate legends determined by the Company in substantially the following forms (in addition to any other legend that may be required by other agreements between you and the Company): 

(a) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A REACQUISITION RIGHT AND OTHER RESTRICTIONS AND CONDITIONS SET
FORTH IN A RESTRICTED STOCK AWARD AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE COMPANY’S PRINCIPAL CORPORATE OFFICES. ANY TRANSFER OR ATTEMPTED
TRANSFER OF ANY SHARES SUBJECT TO SUCH RIGHT IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 
 (b) “THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES
UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 (c) “THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RIGHTS OF REFUSAL GRANTED TO THE COMPANY AND/OR ITS ASSIGNEE(S) AND ACCORDINGLY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF EXCEPT IN CONFORMITY WITH
THE TERMS OF THE BYLAWS OF THE COMPANY AND/OR A RESTRICTED STOCK AWARD AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE COMPANY’S PRINCIPAL CORPORATE
OFFICES.” 
 (d) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE
BYLAWS OF THE COMPANY.” 
 (e) Any legend required by appropriate blue sky officials. 

12. Investment Representations. In connection with your acquisition of the Common Stock under your Award, you represent to
the Company the following: 
 (a) You are aware of the Company’s business affairs and financial condition and have acquired
sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Shares. You are acquiring the Shares for investment for your own account only and not with a view to, or for resale in connection with, any
“distribution” thereof within the meaning of the Securities Act. 
 (b) You understand that the Shares have not been
registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of your investment intent as expressed in this Award Agreement. 

(c) You further acknowledge and understand that the Shares must be held indefinitely unless the Shares are subsequently registered under
the Securities Act or an exemption from such registration is available. You further acknowledge and understand that the Company is under no obligation to register the Common Stock. You understand that the certificate evidencing the Common Stock will
be imprinted with a legend that prohibits the transfer of the Common Stock unless the Common Stock is registered or such registration is not required in the opinion of counsel for the Company. 

  
 5 

 (d) You are familiar with the provisions of Rule 701 and Rule 144 promulgated
under the Securities Act (“Rule 144”), as in effect from time to time, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from
an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of issuance of the
securities, such issuance will be exempt from registration under the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the securities exempt under Rule 701
may be sold by you 90 days thereafter, subject to the satisfaction of certain of the conditions specified by Rule 144 and by the agreement(s) relating to the Lock-Up Period. 

(e) In the event that the sale of the Shares does not qualify under Rule 701 at the time of issuance, then the Shares may be resold
by you in certain limited circumstances subject to the provisions of Rule 144, which requires, among other things: (i) the availability of certain public information about the Company; and (ii) the resale occurring following the required
holding period under Rule 144 after you have purchased, and made full payment of (within the meaning of Rule 144), the securities to be sold. 

(f) You further understand that at the time you wish to sell the Shares, there may be no public market upon which to make such a sale,
and that, even if such a public market then exists, the Company may not be satisfying the current public current information requirements of Rule 144 or 701, and that, in such event, you would be precluded from selling the Shares under Rule 144 or
701 even if the minimum holding period requirement had been satisfied. 
 13. Withholding Obligations. 

(a) At the time your Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll
and any other amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection
with your Award (the “Withholding Taxes”). The Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of
such means: (i) withholding from any amounts otherwise payable to you by the Company; (ii) causing you to tender a cash payment; or (iii) withholding Shares issued or otherwise issuable to you in connection with the Award with a Fair
Market Value equal to the amount of such Withholding Taxes; provided, however, that the number of such Shares withheld may not exceed the amount necessary to satisfy the Company’s required tax withholding obligations using the minimum
statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income. 

(b) Unless the tax withholding obligations of the Company and any Affiliate are satisfied, the Company will have no obligation to issue
a certificate for such Shares or release such Shares from any escrow provided for in this Award Agreement. 
 14. Tax Consequences.
You agree to review with your own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Award. You will rely solely on such advisors and not on any statements or
representations of the Company or any of its agents. You understand that you (and not the Company) will be responsible for your own tax liability that may arise as a result of this investment or the transactions contemplated by this Award. You
understand that Section 83 of the Code taxes as ordinary income to you the fair market value of the Shares issued to you pursuant to the Award as of the date any restrictions on such shares lapse (that is, as of the date on which part or all of
such shares vest). In this context, “restriction” includes the right of the Company to reacquire the Shares pursuant to the Reacquisition Right set forth above. You understand that you may elect to be taxed at the time the Shares are
issued to you pursuant to your Award, rather than when and as the Reacquisition Right expires, by filing an election under Section 83(b) of the Code (an “83(b) Election”)

  
 6 

 
with the Internal Revenue Service within 30 days after the date your acquire Shares pursuant to your Award. Even if the fair market value of the Common Stock at the time of grant of your Award
equals the amount paid for the Shares (if anything), the 83(b) Election must be made to avoid income under Section 83(a) in the future. You understand that failure to file such an 83(b) Election in a timely manner may result in adverse tax
consequences for you. You acknowledge that the foregoing is only a summary of the effect of U.S. federal income taxation with respect to issuance of the Shares pursuant to your Award, and does not purport to be complete. You further acknowledge that
the Company has directed you to seek independent advice regarding the applicable provisions of the Code, the income tax laws of any municipality, state or foreign country in which you may reside, and the tax consequences of your death. You assume
all responsibility for filing an 83(b) Election and paying all taxes resulting from such election or the lapse of the restrictions on the Shares. YOU ACKNOWLEDGE THAT IT IS YOUR OWN RESPONSIBILITY, AND NOT THE COMPANY’S, TO FILE A TIMELY
83(b) ELECTION. THE COMPANY AND ITS LEGAL COUNSEL CANNOT ASSUME RESPONSIBILITY FOR FAILURE TO FILE THE 83(b) ELECTION IN A TIMELY MANNER UNDER ANY CIRCUMSTANCES. 

15. Severability. If all or any part of this Award Agreement or the Plan is declared by any court or governmental authority to be
unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Award Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Award Agreement (or part of such a Section) so declared to be
unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. 

16. Governing Law. The interpretation, performance and enforcement of this Award Agreement shall be governed by the law of the State of
Delaware without regard to that state’s conflicts of laws rules. 
 17. Notices. Any notice or request required or
permitted hereunder will be given in writing to each of the other parties hereto and will be deemed effectively given on the earlier of (i) the date of personal delivery, including delivery by express courier, or delivery via electronic means,
or (ii) the date that is five days after deposit in the United States Post Office (whether or not actually received by the addressee), by registered or certified mail with postage and fees prepaid, addressed to the Company at its primary
executive offices, attention: Stock Plan Administrator, and addressed to you at your address as on file with the Company at the time notice is given. 

18. Imposition of Other Requirements. As a condition to the grant of your Award or to the Company’s the issuance of any
Shares under this Award, the Company may require you to execute further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award. In addition, you may be required to
execute certain customary agreements entered into with the holders of capital stock of the Company, including without limitation a right of first refusal and co-sale agreement, stockholders agreement and a
voting agreement. 

  
 7 

 EXHIBIT A TO 

RESTRICTED STOCK AWARD TERMS AND CONDITIONS 

ASSIGNMENT SEPARATE FROM CERTIFICATE 

For Value Received and pursuant to that certain Restricted Stock Award Grant Notice dated ____________ (the
“Award”), [Participant’s Name] hereby sells, assigns and transfers unto TDTx Inc., a Delaware corporation (the “Company”) _______________ shares of the Common Stock of the
Company, standing in the undersigned’s name on the books of the Company represented by Certificate No(s). _____ and does hereby irrevocably constitute and appoint the Company’s Secretary as attorney-in-fact to transfer the said Common Stock on the books of the Company with full power of substitution in the premises. This Assignment Separate From Certificate may be used only in accordance
with and subject to the terms and conditions of the Award, in connection with the reacquisition of shares of Common Stock of the Company issued to the undersigned pursuant to the Award, and only to the extent that such shares remain subject to
the Company’s Reacquisition Right under the Award. 
 Dated:
                     
  

	
	  

	(Signature)
	
	  

	(Print Name)

 Instructions: Please do not fill in any blanks other than the “Signature” line and the “Print
Name” line. 

 EXHIBIT B TO 

RESTRICTED STOCK AWARD TERMS AND CONDITIONS 

JOINT ESCROW INSTRUCTIONS 
 Secretary 

TDTx Inc. 
  

 
  

Dear Sir or Madam: 
 As Escrow Agent for both
TDTx Inc., a Delaware corporation (the “Company”), and the undersigned recipient (“Recipient”) of Common Stock of the Company (the “Common Stock”), you are hereby
authorized and directed to hold the documents delivered to you pursuant to the terms of the Restricted Stock Award Grant Notice (including all attachments and exhibits) dated ___________________ (the “Award”), to which a copy
of these Joint Escrow Instructions is attached as Exhibit B to the Restricted Stock Award Terms and Conditions (the “Agreement”, in accordance with the following instructions: 

1. In the event Recipient ceases to render services to the Company or an affiliate of the Company during the vesting period set forth in
the Grant Notice, the Company or its affiliate or assignee, as applicable, will give to Recipient and you a written notice specifying the number of shares of Common Stock that will be transferred to the Company. Recipient and the Company hereby
irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 

2. At the closing you are directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in
the number of shares of Common Stock being transferred, and (c) to deliver the same, together with the certificate evidencing the shares of Common Stock to be transferred, to the Company. 

3. Recipient irrevocably authorizes the Company to deposit with you any certificates evidencing shares of Common Stock to be held by you
hereunder and any additions and substitutions to said shares of Common Stock as specified in the Grant Notice and the Agreement. Recipient does hereby irrevocably constitute and appoint you as Recipient’s attorney-in-fact and agent for the term of this escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock certificates necessary or
appropriate to make all securities negotiable and complete any transaction herein contemplated. 
 4. This escrow will terminate and
the shares of Common Stock held hereunder will be released in full upon the full vesting of the shares of Common Stock in accordance with the vesting schedule set forth in the Grant Notice or upon the earlier return of the shares of Common Stock to
the Company pursuant to the Company’s Reacquisition Right (as defined in the Agreement) or other forfeiture condition under the Company’s 2019 Equity Incentive Plan. 

5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property
belonging to Recipient, you will deliver all of same to Recipient and will be discharged of all further obligations hereunder; provided, however, that if at the time of termination of this escrow you are advised by the Company that the
property subject to this escrow is the subject of a pledge or other security agreement, you will deliver all such property to the pledgeholder or other person designated by the Company. 

 6. Except as otherwise provided in these Joint Escrow Instructions, your duties
hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 
 7. You will be
obligated only for the performance of such duties as are specifically set forth herein and may rely and will be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or
presented by the proper party or parties or their assignees. You will not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as
attorney-in-fact for Recipient while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys will be conclusive evidence of
such good faith. 
 8. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by
any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or
decree of any court, you will not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled,
set aside, vacated or found to have been entered without jurisdiction. 
 9. You will not be liable in any respect on account of the
identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Grant Notice, the Agreement or any documents or papers deposited or called for hereunder. 

10. You will not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow
Instructions or any documents deposited with you. 
 11. Your responsibilities as Escrow Agent hereunder will terminate if you cease
to be Secretary of the Company or if you resign by written notice to the Company. In the event of any such termination, the Secretary of the Company will automatically become the successor Escrow Agent unless the Company appoints another successor
Escrow Agent and Recipient hereby confirms the appointment of such successor as Recipient’s attorney-in-fact and agent to the full extent of your appointment. 

12. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect
hereto, the necessary parties hereto will join in furnishing such instruments. 
 13. It is understood and agreed that should any
dispute arise with respect to the delivery and/or ownership or right of possession of the securities, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute has
been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you will be under no
duty whatsoever to institute or defend any such proceedings. 
 14. Any notice or request required or permitted hereunder will be
given in writing to each of the other parties hereto and will be deemed effectively given on the earlier of (i) the date of personal delivery, including delivery by express courier, or delivery via electronic means, or (ii) the date that
is five days after deposit in the United States Post Office (whether or not actually received by the addressee), by registered or certified mail with postage and fees prepaid, addressed to each of the other parties hereunto entitled at the following
addresses, or at such other addresses as a party may designate by 10 days’ advance written notice to each of the other parties hereto: 

 
			
	Company:	  	 TDTx Inc.

		  	
                   
                                 

		  	
                   
                                 

		  	
                   
                                 

		  	 Attn: General Counsel / Chief Financial Officer

		
	Recipient:	  	
                   
                                 

		  	
                   
                                 

		  	
                   
                                 

		  	
                   
                                 

		
	Escrow Agent:	  	 TDTx Inc.

		  	
                   
                                 

		  	
                   
                                 

		  	
                   
                                 

		  	 Attn: Corporate Secretary

 15. By signing these Joint Escrow Instructions you become a party hereto only for the purpose of
said Joint Escrow Instructions; you do not become a party to the Grant Notice or the Agreement. 
 16. You are entitled to employ such
legal counsel, including without limitation Cooley LLP, and other experts as you may deem necessary to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and may pay such counsel reasonable
compensation therefor. The Company will be responsible for all fees generated by such legal counsel in connection with your obligations hereunder. 

17. This instrument will be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted
assigns. It is understood and agreed that references to “you” or “your” herein refer to the original Escrow Agent and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from
time to time assign its rights under the Grant Notice, the Agreement and these Joint Escrow Instructions in whole or in part. 

[Remainder of page intentionally left blank] 

 18. These Joint Escrow Instructions will be governed by and interpreted and determined in
accordance with the laws of the State of Delaware without regard to that state’s conflicts of laws rules. The parties hereby expressly consent to the personal jurisdiction of the state and federal courts located in the county in which the
Company has its principal offices for any lawsuit arising from or related to this Agreement. 
  

			
	Very truly yours,
	
	TDTx Inc.
		
	By	 	  

	Title	 	  

	
	Recipient
	
	  

	(Signature)
	
	  

	(Print Name)

  

	
	Escrow Agent:
	
	  

	(Signature)
	
	  

 (Print Name) 

 ATTACHMENT II 

2019 EQUITY INCENTIVE PLAN 

 ATTACHMENT III 

SECTION 83(B) ELECTION 

 [This Form is designed for Individual purchasers. Corporate or Trust purchasers should
contact their Tax Professional to review before submitting.] 
 Instructions for Filing Section 83(b) Election 

Attached is a form of election under Section 83(b) of the Internal Revenue Code and an accompanying IRS cover letter. Please complete and
sign the election and cover letter, then proceed as follows: 
  

	 	a)	 Make three copies of the completed election form and one copy of the IRS cover letter.

  

	 	b)	 Send the original signed election form and cover letter, the copy of the cover letter, and
a self-addressed stamped return envelope to the Internal Revenue Service Center where you would otherwise file your tax return.1 Even if an address for an Internal Revenue Service Center is
already included in the forms below, it is your obligation to verify such address. This can be done by searching for the term “where to file” on www.irs.gov or by calling 1 (800) 829-1040.

 Sending the election via certified mail, requesting a return receipt, with the certified mail number written on the
cover letter is also recommended. 
  

	 	c)	 Deliver one copy of the completed election form to the Company. 

 

	 	d)	 Applicable state law may require that you attach a copy of the completed election form to your state
personal income tax return(s) when you file it for the year (assuming you file a state personal income tax return).2 

Please consult your personal tax advisor(s) to determine whether or not a copy of this Section 83(b) election should be filed with your
state personal income tax return(s). 
  

	 	e)	 Retain one copy of the completed election form for your personal permanent records.

 Note: An additional copy of the completed election form must be delivered to the transferee (recipient) of the property if the service
provider and the transferee are not the same person. 
 Please note that the election must be filed with the IRS within 30 days of the date of
purchase/grant of the shares. Failure to file within that time will render the election void and you may recognize ordinary taxable income as your vesting restrictions lapse. The Company and its counsel cannot assume responsibility for failure
to file the election in a timely manner under any circumstances. 
  

	1 	 Note: Per Treasury Regulation § 1.83-2(c), the
Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. As of September 2018 if you live in a foreign country or are a dual status alien (foreigners that will have lived both in their
home country and the United States during the year in which they make the election) you should send the 83(b) election to Austin, TX 73301-0215. You can verify this is still the correct address at: http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. 

	2 	 Note: Pursuant to Treasury Regulations finalized in July 2016 (Treas. Reg. § 1.83-2(c); T.D. 9779), taxpayers are no longer required to submit a copy of a Code Sec. 83(b) election with their federal personal income tax returns for the year in which the property subject to the
election was transferred. However, you are strongly encouraged to retain a copy of the completed election form and the IRS filed-stamped copy of your cover letter along with a copy of the federal personal income tax return for the year in which the
property subject to the election was transferred for your personal permanent records in case you ever need to demonstrate proper and timely filing (a common requirement imposed by acquirers in M&A transactions).

 SECTION 83(b) ELECTION 

____________, 20_ 
 Department of the Treasury

 Internal Revenue Service 
 [City, State Zip]3[Austin, TX 73301-0215 
 USA]4 

Re: Election Under Section 83(b) 
 Ladies and Gentlemen:

 The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as
compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares. The following information is supplied in accordance with Treasury Regulation § 1.83-2: 
  

	1.	 The name, [social security number][taxpayer identification number], address of the undersigned, and the
taxable year for which this election is being made are: 

Name:                       
  ____________ 
 [Social Security Number][Tax Identification Number]: ____________
5 

Address:                ____________ 

                        
                                   

Taxable year: Calendar year ______.6 

 

	2.	 The property that is the subject of this election: [#] shares of common stock of TDTx Inc., a
Delaware corporation (the “Company”). 

  

	3.	 The property was transferred on: [•]. 

 

	4.	 The property is subject to the following restrictions: Some or all of the shares are subject to
forfeiture or repurchase at less than their fair market value if the undersigned does not continue to provide services for the Company for a designated period of time. The risk of forfeiture or repurchase lapses over a specified vesting period.

  

	3 	 Note: Per Treasury Regulation § 1.83-2(c),
the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. Assuming these are individual taxpayers who would file a Form 1040, see http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. Use the address in the row which includes the state in which the service provider lives and in the column entitled “And you ARE NOT enclosing a payment”.

	4 	 Note: Per Treasury Regulation § 1.83-2(c),
the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. As of December 2018, if you live in a foreign country or are a dual status alien (foreigners that will have lived both in their
home country and the United States during the year in which they make the election) you should send the 83(b) election to Austin, TX 73301-0215. You can verify this is still the correct address at: http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040
. 

	5 	 Note: If you are not a US taxpayer and do not have a taxpayer ID number (TIN), put “None –non-US taxpayer” and include in the cover letter to the IRS a statement explaining that the Section 83(b) election is being filed because the individual may become a US taxpayer before the stock
vests. If the individual is applying for a TIN, instead include “applied for” and enclose a copy of the W-7 application. Note that there may be important factors to consider before applying for a
TIN, including immigration status, etc. 

	6 	 Note: If an entity is the service provider, instead use “Fiscal year ending ___.”

	5.	 The fair market value of the property at the time of transfer (determined without regard to any restriction
other than a nonlapse restriction as defined in Treasury Regulation § 1.83-3(h)): $[•] per share x [#] shares = $[•]. 

 

	6.	 For the property transferred, the undersigned paid: $[•] per share x [#] shares = $[•].

  

	7.	 The amount to include in gross income is:
$[•].7 

 The undersigned taxpayer will file this election with the Internal
Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the election also will be furnished to the person for whom the services were performed
and the transferee of the property. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable year in which the property is transferred. The undersigned is the person performing the services
in connection with which the property was transferred. 
  

	
	Very truly yours,
	
	  

	[Name]

  

	7 	 Note: This should equal the amount in Item 5 minus the amount in Item 6, and in many cases will
be $0.00. 

 RETURN SERVICE REQUESTED 

Department of the Treasury 
 Internal Revenue Service 

[City, State, ZIP][Austin, TX 73301-0215 
 USA] 

 

	Re:	 Election Under Section 83(b) of the Internal Revenue Code

 Dear Sir or Madam: 

Enclosed please find an executed form of election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with respect
to an interest in TDTx Inc. 
 [Please note, the undersigned does not currently have a Tax Identification Number because the undersigned is
not a U.S. taxpayer, but may become a U.S. resident before the stock vests.] 
 Also enclosed is a copy of the signed form of election under
Section 83(b). Please acknowledge receipt of these materials by marking the copy when received and returning it in the enclosed stamped, self-addressed envelope. 

Thank you very much for your assistance. 
  

	
	Very truly yours,
	
	  

	[Name]

 Enclosures 

 FIRST AMENDMENT TO THE

 AFFINIA THERAPEUTICS INC. 

2019 EQUITY INCENTIVE PLAN 

A. Affinia Therapeutics Inc. (f/k/a TDTx Inc.), a Delaware corporation (the “Company”)
established the Company’s 2019 Equity Incentive Plan by an original instrument adopted by the Company on November 25, 2019 (the “Plan”); 

B. The Plan currently provides for 1,200,000 shares (after giving effect to the stock split effected by the Amended and
Restated Certificate of Incorporation of the Company filed with the Secretary of State of the State of Delaware on the date hereof (the “Stock Split”)) of Common Stock to be reserved for issuance under the Plan; and 

C. The Company now wishes to amend the Plan to increase the number of shares of Common Stock reserved under the plan to
7,062,006 shares. 
 Effective immediately following the Stock Split, the Plan is amended as follows: 

 

	 	1.	 Section 3(a)(i) the Plan is hereby amended and restated in its entirety as follows: 

“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued
pursuant to Stock Awards from and after the Effective Date will not exceed 7,062,006 shares (the “Share Reserve”).” 
  

	 	2.	 In all other respects, the Plan remains the same. 

[SIGNATURE PAGE FOLLOWS] 

 The Company has caused this First Amendment to the Company’s 2019 Equity Incentive Plan
to be executed this 12th day of March, 2020. 
  

			
	AFFINIA THERAPEUTICS INC.
		
	By:	 	 /s/ Rick Modi

		 	Rick Modi
		 	Chief Executive Officer

 SECOND AMENDMENT TO THE

 AFFINIA THERAPEUTICS INC. 

2019 EQUITY INCENTIVE PLAN 

A. Affinia Therapeutics Inc., a Delaware corporation (the “Company”) established the
Company’s 2019 Equity Incentive Plan by an original instrument adopted by the Company on November 25, 2019 (the “Plan”), as amended on March 12, 2020; 

B. The Plan currently provides for 7,062,006 shares of Common Stock to be reserved for issuance under the Plan; and 

C. The Company now wishes to amend the Plan to increase the number of shares of Common Stock reserved under the plan to
7,312,006 shares. 
 The Plan is amended as follows: 
  

	 	1.	 Section 3(a)(i) the Plan is hereby amended and restated in its entirety as follows: 

“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued
pursuant to Stock Awards from and after the Effective Date will not exceed 7,312,006 shares (the “Share Reserve”).” 
  

	 	2.	 In all other respects, the Plan remains the same. 

[SIGNATURE PAGE FOLLOWS] 

 The Company has caused this Second Amendment to the Company’s 2019 Equity Incentive
Plan to be executed this 6th day of October, 2020. 
  

			
	AFFINIA THERAPEUTICS INC.
		
	By:	 	 /s/ Rick Modi

		 	Rick Modi
		 	Chief Executive Officer

 THIRD AMENDMENT TO THE

 AFFINIA THERAPEUTICS INC. 

2019 EQUITY INCENTIVE PLAN 

A. Affinia Therapeutics Inc., a Delaware corporation (the “Company”) established the Company’s 2019 Equity
Incentive Plan by an original instrument adopted by the Company on November 25, 2019 (the “Plan”), as amended on March 12, 2020 and October 6, 2020; 

B. The Plan currently provides for 7,312,006 shares of Common Stock to be reserved for issuance under the Plan; and 

C. The Company now wishes to amend the Plan to increase the number of shares of Common Stock reserved under the plan to 11,312,006
shares. 
 The Plan is amended as follows: 
  

	1.	 Section 3(a)(i) the Plan is hereby amended and restated in its entirety as follows: 

“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued
pursuant to Stock Awards from and after the Effective Date will not exceed 11,312,006 shares (the “Share Reserve”).” 

 

	2.	 In all other respects, the Plan remains the same. 

[SIGNATURE PAGE FOLLOWS] 

 The Company has caused this Third Amendment to the Company’s 2019 Equity Incentive Plan
to be executed this 20th day of April, 2021. 
  

			
	AFFINIA THERAPEUTICS INC. 
		
	By:	 	 /s/ Rick Modi

		 	Rick Modi
		 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]